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Abstract 
This thesis describes the design of a convenient format of solid phase 
microextraction (SPME) for bioanalysis in pharmaceutical industry and the validation of 
the approach to the application. An automated in-tip SPME technique coupled with liquid 
chromatography (LC) and tandem mass spectrometry (MS/MS) for high throughout drug 
analysis has been developed and applied to the quantitative determination of various drug 
compounds in different biological fluids from drug discovery to clinical development. 
The initial research in this thesis focused on a proof-of-concept study using 
manual multi-fiber approach to determine a drug compound in human plasma from a 
clinical trial. The proof-of-concept was achieved based on the validation data and a head-
to-head comparison with conventional liquid-liquid extraction (LLE) method. An in-tip 
SPME technique was then proposed to explore the feasibility of SPME automation and 
two approaches of preparing in-tip SPME fibers were developed including fiber-packed 
and sorbent-packed fiber preparation. A simple and high throughput in-tip SPME fiber 
fabricating procedure based on polymer monoliths using photo-polymerization was 
introduced to prepare 96 fibers simultaneously. The biggest advantage of the in-tip SPME 
technique is that it is simple and easy to use for automation without introducing any 
additional devices and in the meantime, the simplicity of SPME is maintained. 
Automated in-tip SPME was applied to routine drug analysis in drug discovery 
and development environment. One case study involved the determination of vitamin D3 
in human serum with derivatization and the in-tip SPME approach was compared with 
traditional LLE method using either tubes or 96-well plate extraction. Another study was 
to use hydrophilic interaction chromatography (HILIC) –MS/MS to determine three polar 
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compounds, imipenem (IMP), cliastatin (CIL) and β-lactamase inhibitor (BLI) 
simultaneously in different biological fluids including rat plasma and mouse blood. The 
results from both studies clearly demonstrated that in-tip SPME could be used as an 
alternative sample preparation method in bioanalytical analysis. Matrix effects in 
bioanalysis using automated in-tip SPME and LC-MS/MS were then thoroughly 
evaluated for the first time. Our study indicated that the assumption that SPME should 
provide sample clean up as effective as or better than solid phase extraction (SPE) with 
no or minimal matrix effects might not be always true, and matrix effects should be 
investigated in any SPME assays in bioanalysis.  
Comparisons between in-tip SPME and other automated SPME approaches such 
as blade/thin film geometries were performed, and the advantages and limitations of 
using SPME versus conventional sample preparation methods including protein 
precipitation (PPT), LLE and SPE were summarized. Strategies for in-tip SPME method 
development and validation and the potential applications and future directions of in-tip 
SPME in bioanalysis were discussed. 
 Finally, kinetic models were established to describe SPME extraction and 
desorption processes in a complex matrix with both liquid and solid fiber coatings. The 
models were successfully applied to different scenarios to estimate the boundary layer 
(BL) thickness, extraction equilibrium time and total amount of analytes extracted at a 
given time. The excellent agreements between the model prediction results and 
experimental data indicated that the SPME modeling approach had great potentials to 
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1.1 Sample Preparation in Bioanalysis 
 
Bioanalysis is the quantitative determination of drugs and their metabolites in 
biological fluids. The technique is used throughout different drug development stages 
from drug discovery to clinical development, to help understand the metabolic fate and 
pharmacokinetics of chemicals in living cells, animals and human bodies. In addition, 
knowledge of drug levels in body fluids such as plasma and urine can optimize safety and 
efficacy of new drug therapies in humans. Although bioanalysis has been performed 
using various analytical instruments, most of these instruments cannot handle the sample 
matrices directly because of the multitude of substances present in the biological samples, 
such as proteins, salts, acids, bases, and numerous organic components with chemical 
properties similar to those of the analytes, these could potentially interfere with the 
analysis.  Thus, sample preparation is usually necessary before analysis to clean up a 
sample and/or to concentrate a sample to improve its detection.  
In bioanalytical sample preparation, there are two major goals: (i) remove 
unwanted matrix components that can cause interferences upon analysis, improving 
method specificity; and (ii) concentrate an analyte to improve its limit of detection. 
Ultrafiltration, dialysis and protein precipitation can be used to remove protein from 
biological samples. In contrast, liquid-liquid partition including LLE and liquid-phase 
microextraction (LPME),1-11 SPE1-4, 8, 12-15 and SPME,2-4, 11, 13-22 including fiber SPME, 
in-tube SPME, stir bar sorptive extraction (SBSE), solid phase dynamic extraction 
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(SPDE), and microextraction in a packed syringe (MEPS), are useful sample preparation 
techniques that can efficiently produce clean extracts for analysis. In addition, 
immunoaffinity extraction,23-24 molecularly imprinted polymer (MIP)-based extraction15 
and membrane-based extraction25-26 are also specific and efficient sample preparation 
techniques. These techniques, which are based on the partition or adsorption of analytes, 
are able to remove the majority of the biological materials from the sample matrix prior 
to analysis. A reliable bioanalytical method is achieved with the successful combination 
of efficient sample preparation, adequate chromatographic separation and a sensitive 
detection technique. In the past decade, although LC-MS/MS has become a well 
established technology with regard to assay development in bioanalysis of small 
molecule drug candidates due to its high sensitivity, selectivity, and fast analysis with 
good precision and wide dynamic range, drug analysis in biological matrices using robust 
LC-MS/MS methods remains difficult, time-consuming, and sometimes quite 
challenging. Successful use of LC-MS/MS requires understanding the mechanism of 
various sample extraction processes and the underlying principles of both 
chromatography and MS.27-30  
 
1.2 Bioanalysis in Pharmaceutical Drug Development 
 
1.2.1 Roles of Bioanalysis 
 
The drug discovery process is a series of stages through which compounds must 
pass in order to qualify for being a development compound. As shown in Figure 1, these 
stages represent various in vitro and in vivo tests that are performed on a series of 
compounds in order to select those few compounds that have the correct properties to 
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achieve the desired effect. Bioanalysis plays an integral role in the whole process and can 
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Figure 1-1 Stages in new drug discovery and levels of bioanalytical assay. 
 
In the support of drug discovery and lead optimization, information about a 
molecule's absorption, distribution (including protein binding), metabolism, and 
elimination (ADME) is obtained through a list of typical experiments such as Caco-2 
cells, PgP transport, in vivo pharmacokinetic profiling, in vitro protein binding, in vivo 
tissue distribution studies, metabolic stability screening, and P450 induction and 
inhibition studies. The rules for discovery screen assay (level I) and full PK assay (level 
II) are designed less strictly under non-good laboratory practice (GLP) and can be easily 
implemented in a high throughput manner for screening and lead optimization purposes. 
Level I assay only requires a two-point calibration curve with an appropriate internal 
standard. A one order of magnitude range is preferred to cover the samples, but two 
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orders of magnitude is acceptable. QC samples are not used and the assay is not 
validated.  Since level II assays are used for lead optimization studies, assays need to be 
more rigorous than those of level I. This is because in lead optimization studies, the goal 
is to obtain enough data to calculate several PK parameters such as clearance, half-life, 
AUC and volume of distribution from about 30-60 samples for each compound. 
Normally, a multi-point standard curve ranging from 1 to10000 ng/mL is used. The 
matrix of the calibration curve should be from the same animal species and matrix type as 
the samples. Again, QC samples are not required and the assay is not validated.  
Once a drug compound reaches the preclinical development phase, its ADME 
characteristics are determined in many species of animals. At this point, a defined and 
validated assay is used repeatedly for the determination of drug concentrations from in 
vitro and in vivo samples. The major change in a level III assay is the use of QC samples. 
The addition of QC samples provides additional confidence in the results that are 
obtained with the assays. A minimum of six QCs at three concentrations (low, middle, 
high) are used and the QC standards should be frozen at the same freeze temperature as 
the samples to be analyzed. A major effort in the clinical phase of drug development is 
the determination of drug and metabolite concentrations in biological fluids after drug 
administration to humans. The pharmacokinetic data obtained is used to support drug 
development in assessing the therapeutic index, drug-drug interactions, dose regimes, etc. 
Thousands of samples are often obtained from a single clinical study and rapid sample 
turnaround is required to plan the next clinical study. Since drugs are often dosed at lower 
levels, very sensitive assays are required to detect the low levels of drugs circulating in 
biological fluids. In addition to sensitivity, selectivity and ruggedness are also very 
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important to the analytical method; therefore, the bioanalytical assays (level IV) should 
be fully validated under GLP rules and maintained during the clinical phase of drug 
development.  
 
1.2.2 Current Practice and Future Trend 
 
Drug discovery and development pharmacokinetic analysis include multiple steps, 
which need to be performed in sequence so that the PK results can be delivered to the 
discovery team. These steps are sample dosing and collection, sample transferring and 
tracking, sample preparation and analysis, and the final PK report preparation and 
distribution. It is very important to understand the potential bottlenecks of each step so 
that efforts can be made to streamline these steps so as to reduce the cycle time of the 
whole process.  
Traditionally, for preclinical studies, one animal species is dosed with one drug 
and blood samples are collected at a series of time points after the dose was administered 
in order to obtain the drug candidate's pharmacokinetics in a living system. This 
procedure is very time consuming and labor intensive because each individual sample 
must go through analysis in series. Currently, simultaneous multiple compound dosing, or 
"cassette dosing" (n-in-1), in which multiple compounds are dosed in one animal has 
greatly improved the throughput. This is achieved with the help of the selectivity of the 
mass spectrometers that can individually quantify the concentrations of each compound 
in the mixture31-33. Animal samples are collected in a 96-well plate, which can be easily 
transferred using robotic systems for further sample preparation and analysis. Although 
only a small amount of sample is normally available, sensitivity is usually not an issue 
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and rapid sample turnaround is required. There is little time available for method 
development and, therefore, protein precipitation is the preferred sample preparation 
approach. However, in clinical analysis where drugs are more potent and are dosed at low 
levels, a large amount of sampling from the participating volunteers in clinical trials is 
often required with the utilization of individual collection tubes. Depending on the phase 
of the program and the type of drug under development, the number of blood samples 
collected during a clinical study could range from a few hundred to several thousand. The 
amount of work involved in sample collection, shipment, and tracking is quite substantial 
and, to date, this process is one of the major bottlenecks in PK analysis. Attempts have 
been made to automate the sample transfer process from tubes to plates using "de-
capping/capping" robotic systems with barcode readers. Unfortunately, the approach has 
not been widely accepted due to many reasons, and, in most cases, clinical sample 
transfer is still a labor intensive, semi-automated procedure. Sample tracking for both 
preclinical and clinical is handled by Watson LIMS, a laboratory information 
management system, used by most pharmaceutical companies. With outsourcing 
activities increasing nowadays, it can be expected that developing a harmonic sample 
tracking system will be quite challenging. 
The use of LC-MS/MS with triple-quadrupole mass spectrometers and an 
atmospheric pressure ionization (API) source, operated under selected reaction 
monitoring mode, has grown exponentially in the last decade. The principle of MS is to 
produce ions from analyzed compounds that are separated or filtered based on their mass-
to-charge ratio (m/z). Tandem mass spectrometers make use of two mass analyzers: one 
for the precursor ion in the first quadrupole and the other for the product ion in the third 
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quadrupole after the collision-activated dissociation of the precursor ion in a collision 
cell. Innovative and successful research efforts on the design of an effective interface 
connection between LC (operated under atmospheric pressure) and MS  (operated under a 
high-vacuum environment) have made the LC-MS/MS the most reliable technique for 
quantitative bioanalysis in drug discovery and development. Compared to clinical 
development, in which quality and robustness of the bioanalytical methods is more 
important; drug discovery is mainly focused on speed and high throughput. Thus, the 
applications of LC-MS/MS related approaches are quite different. LC-MS/MS using 
triple-quadrupole mass spectrometers operated under the SRM mode remains the 
workhorse for both environments. However, in drug discovery, new developments such 
as automated SRM MS/MS method optimization34-35 high-speed LC separation, including 
ultra-high pressure liquid chromatography (UPLC) system with sub-2 µm columns and 
multiplexed LC-MS/MS analysis, have been actively used.36-41 In addition, other MS-
based technologies, including online SPE-MS/MS, direct analysis using alternative 
ionization techniques, and LC-MS(MS) with other mass analyzer such as time-of-flight 
(TOF) analyzer have also emerged as promising techniques.42-49  
In spite of the great success of LC-MS/MS technology that provided sensitive and 
specific detection of analytes of interest with adequate chromatographic separation, to 
obtain a clean sample extract is always the goal for bioanalytical chemists because a 
clean extract is a prerequisite for an accurate LC-MS/MS analysis. The importance of 
sample preparation cannot be over emphasized; and efforts to develop simple, fast, 
efficient, and high throughput sample preparation methods have never stopped. Table 1 
summarizes some typical choices of sample preparation techniques in bioanalysis.  
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Table 1-1 Typical Choices of Sample Preparation Techniques in Bioanalytical Analysis 
Typical sample preparation methods Comments 
o Dilution followed by injection (Dilute and shoot) 
o PPT 
o Filtration 
o Protein removal by equilibrium dialysis or 
ultrafiltration 
o LLE 
o Solid support liquid-liquid extraction 
o SPE (off line/online)  
o Turbulent flow chromatography (TFC) 
o Restricted access media (RAM) 
o Monolithic columns 
o Immunoaffinity extraction 
o Combination of the above 
o PPT, LLE and SPE are still the most 
routinely used sample preparation 
methods in drug discovery and 
development 
o Direct injection and online extraction 
become more and more popular in 
bioanalysis 
o Combination of different sample 
preparation approaches will be the 
solutions to achieve highly sensitivity 
assays in studies such as microdosing 
 
It should be pointed out that each sample preparation method has its own 
advantages and limitations. For example, protein precipitation is often used as the initial 
sample preparation scheme in the analysis of new drug substance since it does not require 
any method development. Protein precipitation is simple, universal, inexpensive, and can 
be easily automated in microplates. However, matrix components are not efficiently 
removed and these will lead to significant matrix effects, which can directly affect the 
performance of the bioanalytical methods. On the other hand, the LLE method provides 
efficient sample cleanup as well as sample enrichment, and it is widely applicable for 
many drug compounds. However, a relatively larger amount of organic solvent is 
necessary and the whole sample preparation process is very labor intensive. Over the past 
decade, SPE has gradually replaced most LLE methods as the preferred technique to 
extract drug and metabolites from biological fluids prior to quantitative analysis.50 
Benefiting from the advances in the technology of sorbent chemistry, a wide range of 
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sorbents is now commercially available in various formats from cartridge to disk to 
microplate. These provide various applications not only for most classes of drugs and 
metabolites but also for ionic and highly polar compounds that are difficult to extract by 
other methods. High throughput SPE utilizes the 96-well plate format; although even a 
384-well format has been reported.51-52 Regardless of all these great advantages, SPE 
suffers from the disadvantages of high cost compared with other techniques, long method 
development time, and the complexity and difficulty of mastering its usage. 
   Automation plays a pivotal role in allowing high-speed analysis to meet the 
ever-increasing demands in the current pharmaceutical environment. Automation results 
in greater performance consistency over time and more reliable methods of transfer from 
site to site. One of the current strategies for high throughput bioanalysis is to use well-
established instrumentation; rigorous, standardized techniques, and automation wherever 
possible to replace manual tasks. The choices for automation differ in complexity 
according to the required task, and the size and the function of automated systems can 
vary from a small bench top to a large workstation. Commonly used commercially 
available liquid handling systems include: Hamilton STAR Line liquid handling 
workstations; TECAN Genesis liquid handling workstation; JANUS automated liquid 
handling system; and Tomtec Quadra liquid handling workstation. Most of these liquid 
handling systems have eight channels with fixed or disposable tips, although some have 
96 probes that can transfer liquid to a 96-well plate simultaneously. In bioanalytical 
sample preparation, there are three major functions that involve liquid transfer: (1) 
standard curve and QC sample preparation; (2) sample transfer which includes the 
transfer of different types of samples such as standards, QCs, control blanks, internal 
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standards, study samples from different sources vials or containers to their destination 
vials, as well as organic solvent; and (3) extraction processes include protein 
precipitation, LLE and SPE. Performing a routine sample preparation procedure is one of 
the main uses for automation. However, developing some strategies on how to use 
automation effectively in bioanalytical assay development is also very important, as most 
of the automated instruments are not ideal for performing method development by using 
variable solvents and volumes. 
Two new trends in drug development will definitely have great impact to 
bioanalysis in the near future. One is Microdosing53-55 and the other is Dried Blood Spot 
(DBS).56-58 Microdosing is defined as 1/100th or less than the pharmacological dose and 
should not exceed 100 µg. The purpose of microdosing is to reduce the resources spent 
on nonviable drug candidates and the amount of testing done on animals prior to first-in-
man studies. Microdosing requires an extremely sensitive bioanalytical method to fully 
define the pharmacokinetic profile of a compound. Currently, accelerator mass 
spectrometry (AMS) is the most effective tool, which is particularly specialized, 
requiring trace amounts of a long-lived isotope in the molecule, such as 14C. A 
sophisticated AMS can measure a ratio of the trace isotope, 14C, to total carbon at parts 
per quadrillion levels. However, an AMS assay is quite expensive, as it involves a 
radiolabeled compound. In practice, this will be a complicating factor, which may cause 
delay and increase the cost of the microdosing studies. The development and validation 
of highly sensitive LC-MS/MS methods without using radiolabeled compounds will 
greatly prompt the wide application of microdosing in the early stage of drug 
development. 
 10
DBS involves the collection of blood on an absorbent storage medium prior to 
sample analysis. As the sampling technique dates back to the 1960s, DBS has very 
recently gained increasing interest in support of pharmacokinetic and toxicokinetic 
studies in small molecule drug discovery and development. The key features of DBS 
samples are the low blood volume requirement, potentially leading to decreased animal 
use, and the potential for simplified sample collection, storage, and shipment. The 
standard sample preparation approach for DBS analysis consists of punching out a disk 
from the card that contains the DBS followed by extraction of the analyte. This procedure 
is very time consuming and labor intensive. There is an emerging need for greater 
efficiency, either through automation of the sample preparation process, or alternative 
approaches that require minimal or no sample preparation.  
 
1.2.3 Bioanalytical Assay Validation 
 
There have been no clear guidelines to validate bioanalytical assays until a 
compound enters the development stage, where most of the assays are required to be fully 
validated under GLP regulations. 59-60 Development and validation of a bioanalytical 
assay is divided into two major steps: establishing a method and routine drug analysis. 
 
1.2.3.1 Establishing a Method 
 
Typical method development and establishment for a bioanalytical method 
includes determination of (1) selectivity, (2) sensitivity, (3) calibration curve, (4) intra-




The selectivity of the assay must be confirmed by processing control biological 
fluids from at least six different sources (or subjects) to demonstrate that no interfering 
compounds elute at the same retention times as the analyte(s) of interest and a suitable 
internal standard. For biological fluids with limited availability (e.g. spinal fluid or 
semen), the sensitivity of the assay may be assessed in a fluid originating from only one 
source. 
Sensitivity 
 The sensitivity of the assay corresponds to the lower limit of quantification 
(LLOQ). The LLOQ is defined as the lowest concentration on the calibration curve that 
can be measured with acceptable precision and accuracy. In principle, the signal-to-noise 
(S/N) ratio of the analyte response should be at least 5 times the blank response. 
Calibration (Standard) Curve 
 The concentration range over which the analyte will be determined must be 
defined in the method based on evaluation of stock standard solutions of analyte spiked 
into control biological fluids. At least six concentrations should define the calibration 
curve. A least-squares regression (weighted if appropriate) of response vs. concentration 
of the calibration standards should be determined. The curve fitting parameters should 
not be changed and should be used in all subsequent analysis of clinical samples. In 
addition to at least six non-zero samples, a calibration curve should also consist of a 
blank sample (matrix processed without internal standard) and a zero sample (matrix 
processed with internal standard).  
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Intra-day Variation 
 Determination of accuracy and precision should be accomplished by analysis of 
replicate sets of analyte samples of known concentration in a biological matrix.  
o Prepare and analyze replicates of six standard curves 
o Calculate the mean, standard deviation, and coefficient of variation (CV) for 
each analyte used to construct the standard curve 
o Intraday precision should not exceed 15% for each concentration on the 
calibration curve, except for LLOQ not exceed 20% 
o Assay accuracy mean values should not deviate by more than 15% of the 
nominal value at each concentration, except LLOQ where a deviation of 20% 
is acceptable 
o LLOQ is the lowest point on the calibration curve. The precision should not 
exceed 20% and accuracy should within ±20% of the nominal value. 
Recovery 
 "Recovery" is the extraction efficiency of an analytical process reported as a 
percentage of the known amount of an analyte carried through the sample extraction and 
processing steps of the method. Recovery should be determined by comparing the 
detector response obtained from an analyte added to and extracted from the biological 
matrix to the detector response of an analyte added to a biological fluid extract obtained 
from the same volume of the biological fluid as used for analyte extraction. 
 Recovery experiments should be performed at three concentrations (low, middle, 
and high), and results reported as a mean concentration at each level obtained from six 
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different lots of matrix. Recovery of the internal standard(s) should also be determined at 
the concentration used in the construction of the calibration curve. 
Stability 
 Storage stability of the analyte in each biological matrix and the influence of 
freeze-thaw cycles should be examined. A set of QC samples should be prepared by 
spiking biological fluids with analyte to yield low QC (within 3x the concentration of the 
LLOQ), middle QC (near the center) and high QC (near the upper boundary). The QC 
standard solutions in biological fluids are subdivided into suitable aliquots and stored at -
20oC or other temperatures adequate for long-term storage of clinical specimens.  
 The standard used for preparation of QCs must be weighed separately from that 
used for calibration standards. Thaw replicate (n=5) standards and assay along with the 
calibration curve. The calculated mean values of QC samples should not deviate by 
greater than 15% of the nominal value. CV for QC replicates should not exceed 15% as 
well. LQC, MQC and HQC samples should be examined for their freeze-thaw (F-T) 
stability. At least three aliquots at each concentration should be stored at the intended 
storage temperature for at least 24 h and thawed unassisted at room temperature. When 
completely thawed, the sample should be refrozen for at least 12 h under the same 
conditions and thawed a second time. The F-T cycle should be repeated and then 
analyzed on the third cycle. The mean values should not deviate by greater than 15% of 
the control values (one F-T cycle). CV of QC replicates should not exceed 15%. Long-
term stability is determined and confirmed by the analysis of frozen QC samples during 
the course of clinical studies, which could last from several months to years. Room 
temperature and auto-sampler stability can be also performed using frozen QC samples.  
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Matrix effects 
 In the case of HPLC-MS/MS based methods, matrix effects should be 
investigated to ensure that the precision, selectivity and sensitivity of the method is not 
compromised when biofluid samples from different subjects participating in different 
clinical studies are analyzed. One of the simplest ways to demonstrate the absence of the 
matrix effect in biofluids from different sources is to perform precision and accuracy 
determination in biofluids from six different sources (lots) if available rather than six 
replicates from a single source (subject). If intraday precision and accuracy values 
obtained from six different sources meet the criteria described above, matrix effect may 
be considered as not having a significant impact on assay performance. The absence of 
matrix effect needs to be demonstrated when major changes in the assay are made 
including changes in the extraction procedure, chromatography, and in the MS interface 
etc. 
Sample Dilution 
 In order to demonstrate the stability to dilute samples above the upper limit of the 
standard curve, experiments should be performed using biofluid samples at a 
concentration 10x higher than the upper limit of quantitation (ULOQ) and diluting them 
after an F-T cycle, with a control biofluid to a concentration within the standard curve 
range. The mean values should not deviate by greater than 15% of the nominal value and 





Carry-over should be assessed by injecting an extracted double blank immediately 
after an extracted high standard. If the analyte response in the double blank does not 
exceed 20% of the LLOQ, the extent of carry-over is deemed to not have a negative 
impact on assay performance; otherwise, an attempt should be made to minimize the 
carry-over. 
 
1.2.3.2 Routine Drug Analysis 
 
Calibration Curve and Integration 
 A standard curve, utilizing the model established during prestudy assay 
validation, should be generated daily and used to calculate the concentration of analyte in 
the unknown and QC samples assay in that analytical run. Seventy-five percent, or a 
minimum of six standards whichever is greater should fall within ±15%, except for 
LLOQ, when it should be ±20% of the nominal value. All samples in an analytical run, 
including standard curve and QC samples, should be integrated in a consistent manner. 
QC Samples 
 Duplicate sets (or a minimum of 5% of the unknowns) of frozen QC samples for 
at least three concentrations (low, middle, and high) should be processed along with the 
unknown clinical samples during each analytical run. The results of the analysis of QC 
samples provide the basis of accepting or rejecting the run. At least 67% of the total QC 
samples and at least 50% of QC samples at each concentration should be within ±15% of 





SPME was first introduced by Pawliszyn and co-workers in the early 1990s.61 
SPME is a solvent-free sample preparation technique that integrates sampling, isolation, 
and concentration into one step, and has been developed to address the need for rapid 
sampling and sample preparation in both laboratory and on-site. Its simplicity of use, 
relatively short sampling processing time and fiber reusability has made SPME an 
attractive choice for many analytical applications. Since its invention, SPME has been 
widely applied to environmental, food, metallic, forensic, and pharmaceutical analysis. 16, 
19, 62-63 
 
1.3.1 Introduction to SPME 
 
SPME involves the use of a fiber coated with an extracting phase, that can be a 
liquid (polymer) or a solid (sorbent), which extracts different kinds of analytes including 
both volatile and non-volatile from different kinds of media. The quantity of analyte 
extracted by the fiber is proportional to its concentration in the sample as long as 
equilibrium is reached. In case of short pre-equilibrium times, convection or agitation is 
required to accelerate the approach to equilibrium. After extraction, the SPME fiber is 
transferred to the injection port of separating instruments, such as a gas chromatography 
or liquid chromatography where desorption of the analyte takes place and analysis is 
carried out. Figure 1-2 illustrates the first commercial SPME device made by Supelco 
Inc., where a small diameter fused-silica fiber coated with a small volume of extraction 
phase is contained in a specially designed syringe, moving the plunger allow for exposure 
of the fiber during extraction and desorption and for its protection inside the needle 
during storage and penetration of the septum.  
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Figure 1-2 Commercial design of SPME device 
 
Fibers and capillary tubes coated with an appropriate extraction phase are often 
used for SPME. However, other configurations such as stir bar sorptive extraction 
(SBSE), and membrane or thin-film SPME have also been developed (Figure 1-3). Two 
types of fiber SPME techniques can be used for analyte extraction: (i) headspace and (ii) 
direction extraction. Headspace SPME is suitable for the extraction of volatile and 
semivolatile analytes from the vapor phase above gaseous, liquid or solid samples; while 
direct SPME is used for the extraction of nonvolatile analytes or those with very low 
volatility, by immersing a fiber directly into liquid samples. In direct SPME, the amount 










     Equation 1.1 
where is the initial concentration of a given analyte in the sample,  is the sample 
volume,  is the fiber coating volume, and  is the fiber/sample matrix distribution 






 When the sample volume is large (i.e.  >> ), the amount of analyte 
extracted becomes independent of sample volume and can be described as: 
sV fsK fV
       Equation 1.2 0sffs CVKn =
In this equation, the amount of analyte extracted is proportional to the volume of 
extraction phase; therefore, SPME assay sensitivity could be increased by increasing 
extraction volume. Furthermore, increasing the surface area-to-volume ratio will result in 
enhanced sensitivity and fast extraction rate.  
Recently, great efforts have been focused on developing new SPME devices to 
increase extraction recovery. 64-66 However, the simplicity of SPME technique such as 
easy to handle, little equipment, and solvent-less characteristics should not be abandoned. 
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Figure 1-3 SPME and related microextraction techniques 
 
1.3.2 Calibration in SPME 
 
Base on the understanding of fundamental principles governing the mass transfer 
of analytes in multiphase systems, several calibration approaches have been developed in 
SPME. These can be classified as traditional calibration methods; equilibrium extraction, 
exhaustive extraction, pre-equilibrium extraction, and diffusion-based calibration.67 Each 
calibration method has its own advantages and limitations. Calibration methods that are 
suitable for SPME bioanalysis are summarized and the characteristics of these methods 
are discussed. 
Calibration Curve with Internal Standard 
This traditional calibration approach involves the preparation of several standard 
solutions in a sample matrix with the addition of a compound that is different from the 
analyte. A calibration plot is developed by determining the ratio of the peak area of the 
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analyte to the internal standard for calibration solutions that contain different 
concentrations of the analyte with a fixed concentration of the internal standard. This 
ratio is subsequently used to calibrate the unknown samples. This calibration method 
does not require extensive sample preparation, but the sampling procedure and 
chromatographic conditions must remain constant for both sample and the standard 
solutions. The internal standard is used to compensate for the matrix effect, losses of 
analytes during sample preparation and irreproducibility in parameters. Analog 
compounds are often used, but stable isotope-labeled standards are highly recommended 
to achieve a satisfactory result although the compounds may not always available. 
Calibration curve with internal standard is the simplest and the most widely used 
calibration approach in SPME high throughout bioanalysis. 
Equilibrium Extraction 
In equilibrium extraction, a small amount of extraction phase is exposed to a 
sample matrix until equilibrium is reached. If only two phases are considered, the 
equilibrium conditions can be described by Equation 1.1. Equation 1.1 indicates that the 
amount of analyte extracted onto the coating is linearly proportional to the analyte 
concentration in the sample, which is the analytical basis for quantification using SPME. 
When the sample volume is very large, Equation 1.1 can be simplified to Equation 1.2 
which illustrates the advantage of equilibrium extraction where the amount of the 
extracted analyte is independent of the sample volume. This calibration approach is 
useful for in vivo SPME because at equilibrium, the amount of analyte extracted is 
independent of the agitation conditions so that the exact blood flow rate does not need to 
be known. The only requirements that must be met are (i) that equilibrium is established 
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for both in vivo sampling situation and calibration samples, and (ii) that the calibration 
matrix closely matches the system under study. The biggest limitation is that the 
approach requires very thin coatings so that equilibrium can be reached in a reasonable 
amount of time. 
Diffusion-based Calibration 
A theoretical model based on a diffusion-controlled mass transfer process to 
describe the entire kinetic process of SPME yields following equation: 68-69 






−−=    Equation 1.3 
where is a rate constant that is dependent on the extraction phase and sample volumes, 
the mass-transfer coefficients, the distribution coefficients, and the surface area of the 
extraction phase. This dynamic model suggests that a linear relationship exists between 
the absorbed analyte and its initial concentration in the sample matrix.   
a
 Based on the dynamic model of SPME, Chen et al. 70-71 demonstrated the isotropy 
of absorption and desorption in the SPME liquid coating fiber and developed a new 
calibration method so called standard-in-fiber technique. Briefly, an appropriate standard, 
either an isotopically-labeled analogue of the analyte or any compound with mass transfer 
kinetics similar to that of the ananlyte, is preloaded on the fiber coating. During 
extraction, this preloaded standard is desorbed from the coating to the system under 
study. This desorption process can be used to calibrate the process of extracting the 
analyte of interest into the coating. The amounts of analyte extracted and the desorbed 
standard depend on the degree and uniformity of agitation in the system, the composition 
of sample matrix, and the exact length of sampling time. The whole procedure 
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compensates well for any potential sources of variability and, therefore, permits accurate 








=      Equation 1.4 
where is the initial concentration of analyte, Q is the amount of standard remaining in 
the extraction phase after exposure of the extraction phase to the sample matrix for the 
sampling time, is the volume of the fiber, is the fiber coating/sample distribution 
coefficient of the analyte, and is the amount of standard that is preloaded in the 
extraction phase. Standard-in-fiber calibration is suitable for both homogenous and 
heterogeneous samples and compensates well for effects of agitation, temperature, timing 
and biofouling; however, it needs a reproducible standard preloading procedure and 






1.3.3 Recent Development and Current Status of SPME in Bioanalysis 
 
Two major recent fundamental advances in bioanalytical applications of SPME 
include the development of in vivo SPME, and the development of high throughput 
SPME using multi-well plate technology. In vivo SPME sampling relies on direct 
immersion of SPME coating into a living system in order to directly extract the analyte 
into the coating without having to remove a representative sample of biofluid or tissue 
from the living system. Therefore, this technique eliminates the need for blood 
withdrawal during pharmacokinetic studies and allows the study of biochemical 
processes directly in vivo.  The first SPME in vivo study was reported by Heather et al. in 
2003.72 A probe based on a polypyrrole extraction phase was developed and used for 
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extraction of benzodiazepines directly from a peripheral vein with subsequent LC-MSMS 
quantification. The limit of detection of the assay is 3~7 ng/mL for analysis of the 
benzodiazepines from whole blood and the method was used to monitor the PK profiles 
of diazepam and its metabolites in dogs. The results compared favorably with profiles 
determined from conventional methods. Since then, several SPME in vivo studies have 
been conducted and reported in different animal species including pigs, rats, and mice.73-
75 The biggest challenge for in vivo SPME is the limited commercial availability of 
biocompatible coatings that are suitable for a variety of biological applications. In 
addition, the lack of automation of the sample preparation processes makes in vivo SPME 
less attractive for high throughput drug discovery environment. In addition, a SPME 
method has to be developed beforehand for each compound before in vivo 
experimentation, which would  further increase total analysis time.  
Numerous applications of automated SPME-GC for the analysis of volatiles and 
semi-volatiles in clinical samples have been established over the years. The first 
automated in-tube SPME-LC method was developed by Eisert in 1997.76 The extractions 
are achieved through several draw and eject cycles of the sample over the extraction 
phase, and subsequently the mobile phase is used to desorp and transfer the analytes to 
the analytical column for chromatographic separation and analysis. Despite the advantage 
of automation of in-tube SPME and the advantage that various GC capillary columns can 
be used as extraction phases, the approach does not permit parallel extraction processes 
and, therefore, has lower sample throughput because all samples and standards must be 
analyzed in sequence. In addition, in-tube SPME normally requires sample pre-treatment 
to filter samples containing particles or dilute biological samples to avoid capillary 
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column blocking. This will substantially increase the need in human participation in the 
whole sample preparation process. O'Reilly et al. 77 first proposed the approach of 
performing high throughput parallel SPME on a 96-well plate format. Since sample 
extraction and desorption are the most time consuming steps in SPME, a parallel multi-
fiber approach is, obviously, the best way to use automated SPME to achieve high sample 
throughput. Based on this concept, the first commercially available automated SPME 
sample preparation system from Professional Analytical System (PAS) has been 
introduced using a 96-well plate format, an SPME multi-fiber device, two orbital shakers, 
and a three-arm robotic system. With the use of this system, high throughput analysis of 
benzodiazepines in human whole blood has been achieved. The method allowed the 
automated sample preparation of 96 samples in 100 minutes with a LLOQ of 4 ng/mL 
and accuracy from 87-113% with 800 µL of blood sample.78 Although the automation 
system significantly increased the extraction recovery by using SPME fibers in thin-film 
configuration, it required a large amount of the biological sample and extraction solvent 
in order to achieve satisfactory method precision and accuracy. The most dramatic 
advantages of SPME exist at the extremes of sample volumes as a solvent-less technique 
has been abandoned in the system. 
SPME claims to have many distinct advantages over traditional sample 
preparation techniques such as PPT, LLE and SPE for bioanalytical applications. SPME 
is a simple, fast, solvent-less technique with less instrumentation and easy for automation; 
SPME provides very clean sample extracts as a small amount of sorbent is used and, thus, 
limits the possibility of co-eluting interferences;  SPME has the ability to handle very 
complex, heterogeneous samples including whole blood without sample pre-treatment. 
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SPME is able to obtain free and total concentration information from a single biofluid 
sample by using appropriate calibration strategies. However, to date, the goal of using 
SPME technique as an alternative approach for quantitative determination of analytes 
especially in pharmaceutical bioanalysis has not been realized. Most of the applications 
are limited to research purposes. For example, compared with the rapid growth of SPE 
sorbents in the market, although many fiber coating techniques are now available in the 
literature79 including sol-gel coating technology, electrochemical, and chemical 
procedures, and physical deposition of biocompatible materials, the progress of 
developing commercial available new SPME coatings is not substantial. In addition, 
although it is a very promising technique in the early drug discovery stage, in vivo SPME 
has not been widely accepted and the published results are generated mainly from one 
laboratory. Furthermore, few reported SPME assays have been fully validated according 
to FDA guidelines that could be used for routine drug analysis and researchers have 
seldom investigated matrix effects, which is essential for quantitative determination of 
drug analytes in various biological fluids. Based on the current practice of bioanalysis in 
drug discovery and development, it is necessary to explore and develop different 
automated SPME approaches that can be easily adapted to common commercially 
available liquid handling systems while maintaining the simplicity of the SPME 
technique. 
 
1.3.4 SPME Modeling and Simulation 
 
In SPME, equilibrium established must be among the concentrations of an analyte 
in the sample, in the headspace above the sample, and in the polymer coating on the fused 
silica fiber. Depending on the type of SPME coating, the extraction mechanism can be 
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distinguished as absorption for liquid coatings and adsorption for solid coatings. 
Independent from the nature of the coating, analyte molecules are initially attached to the 
surface of the coating. Whether they migrate to the bulk of the coating or remain at its 
surface depends on the magnitude of the distribution coefficient of the analyte in the 
coating. The amounts of the analytes extracted at equilibrium can be determined by 
laboratory experiments or by simplified mathematical models. However, SPME 
measurements are often performed under non-equilibrium conditions, in particular, for 
more hydrophobic chemicals for which equilibration times can be very long. It would be 
very useful to have a model that can be used to analyse measured concentrations in the 
fiber coating as a function of time. In addition, in a complex sample, the presence of 
another matrix or hydrophobic phase, such as protein or humic acids, may strongly 
influence the extraction efficiency and complicate the calibration procedure. An 
understanding of the possible mechanisms of binding matrix on the uptake of kinetics of 
analytes into the SPME fiber should be very valuable.  
Several approaches have been proposed to mathematically model the kinetics of 
the absorption process to SPME liquid fibers such as PDMS. Vaes et al. 80 introduced 
"negligible depletion SPME" (nd-SPME) as a simple method to measure the free 
concentration of a compound in various matrixes. In nd-SPME, the concentration of 
analyte in the fiber coating ( ) in time is related to the freely dissolved concentration in 
the aqueous phase ( ) through a first-order kinetic, one compartment model with 








C −−=     Equation 1.5 
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This model is based on the assumptions that there must be equilibrium between the free 
and matrix bound fraction of the analyte, that the fiber should extract only a negligible 
amount of the free fraction, and that the matrix should not influence the uptake kinetics or 
adsorb to the fiber. The advantage of such an approach is its simplicity. The disadvantage 
is that the model is not explicitly based on processes like diffusion and partitioning of the 
analyte and on the experimental conditions like medium volume and fiber geometry. 
Therefore, the model hampers the development of a more fundamental understanding of 
the experimental data which can be used to optimize experimental conditions. 
In 1997, Ai68-69 proposed a dynamic SPME model based on a diffusion-controlled 
mass-transfer process. In this approach, absorption into the fiber coating is a process 
governed by intra-fiber molecular diffusion and mass transfer between the bulk medium 
and the fiber by intra-layer molecular diffusion through a stagnant layer around the fiber 
with a finite thickness. The bulk medium is considered to be well stirred. The model can 
explain the influence of stirring or agitation on the uptake kinetics and it can also be 
applied to predict kinetics based on parameters such as the fiber-water partition 
coefficient, diffusion coefficient, and diffusion layer thickness. A layer thickness for this 
model can be estimated by assuming that the flow around the SPME fiber is steady and 
laminar. However, the layer thickness estimate requires additional parameters such as the 
speed of the fluid at the fiber surface, the fluid's kinematic velocity, and the diffusion 
coefficient of the analyte in the medium. The disadvantage of the model is that for other 
agitation conditions such as ultrasound agitation, or agitation by fiber itself, the 
accelerated flow regimes do not fulfill the requirements for estimating the stagnant layer 
thickness.  
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  Instead of assuming that mass transfer from bulk medium to fiber is controlled 
by an explicitly modeled stagnant layer around fiber, others have introduced the concept 
that mass transfer is governed by the concentration difference between bulk medium and 
outer fiber surface.81-82 The model assumes that the diffusion of analyte in the fiber and in 
the boundary layer surrounding the coating is the rate limiting factor, and transport by 






),(),(      Equation 1.6 
Here the diffusion mass flux J (mol dm-2h-1) at time t and at the radial coordinate r is 
proportional to the concentration gradient and D is the diffusion coefficient.  
 Furthermore, the model includes binding of the analyte to a matrix of bovine 
serum albumin (BSA). One limitation of using SPME to determine free concentration in 
biological matrixes is that binding matrixes should not interact with the SPME fiber. 
Binding matrixes may interact by adsorbing to the fiber surface, thus, possibly blocking 
the exchange of analyte across the fiber boundary. This may also lead to an 
overestimation of the concentration in the fiber coating as the matrix-bound analyte 
adsorbed to the fiber coating is measured along with the analyte in the fiber coating. 
Understanding the mechanism of the possible influence of a binding matrix on the uptake 
kinetics of compounds into the fiber is particularly important when considering SPME 
measurements performed under non-equilibrium conditions. Figure 1-4 shows a 














Figure 1-4 Simplified schematic depiction of the model compartments in radial 
coordinates (r). 
 
 It is assumed that the unbound and bound concentrations in the medium are in 
chemical equilibrium and that, in any instant at the fiber-medium interface, the 
concentration in fiber and the unbound concentration in medium are in equilibrium. In 
addition, continuity of fluxes over both the fiber coating and boundary layer interface and 
boundary layer and bulk medium interface is assumed. In this model, since the fiber 
coating thickness and the initial concentration of the analyte are known, the model 
requires the estimation of many parameters including diffusion coefficients, boundary 
layer thickness, fiber-medium partition coefficient, and association and dissociation 
constants. These parameters are obtained by fitting the model to the experimental data, 
however, the computation times or numerical stability can become prohibitive for some 
combinations of these parameter values.   
 An understanding of the fundamentals of thermodynamics and mass transfer of 
analytes in multiphase systems will provide insight and direction when developing SPME 
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methods and identifying parameters for rigorous control and optimization. For example, 
based on the dynamic model proposed by Ai,68-69 Chen et al.70-71 demonstrated the 
isotropy of absorption and desorption in the SPME liquid coating fiber and proposed a 
new concept called "in-fiber standardization technique". Later this was termed the 
"kinetic calibration method". The method uses the desorption of the standards, which are 
preloaded in the extraction phase, to calibrate the extraction of the analytes. More 
recently, the one-calibrant kinetic calibration technique was developed to use the 
desorption of a single calibrant to calibrate all extracted analytes. The technique 
eliminates the requirement of several isotopic compounds, or high-concentration 
standards, and it simplifies the standard loading and quantitation procedures. Despite all 
the efforts and successfully applications of SPME modeling and simulation, there is still a 
need to develop simple and accurate models not only for liquid coating fibers, but for 
solid coating fibers as well. Increasing computation capabilities and advancements in the 
application of numerical techniques make it possible to include all transport steps in 
kinetic modeling and simulation. The effective use of the modeling approach will be 
helpful in SPME fiber selections and will minimize the number of experiments needed in 
SPME method development and, therefore, shorten the total cycle time. 
 
1.4 Thesis Objectives 
 
The overall objective of this thesis is to design a convenient format of SPME for 
high throughput bioanalysis in pharmaceutical industry and to validate the approach to 
the application.  
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Chapter 2 describes a proof-of-concept study of a multi-fiber SPME approach in 
96-well format using commercially available Polydimethylsiloxane (PDMS) – 
divinylbenzene (DVB) fibers with a homemade module for simultaneous multi-fiber 
extraction and desorption. For the first time, a sensitive and selective HPLC-MSMS 
method has been developed and fully validated to determine a drug compound in clinical 
development with multi-fiber SPME in 96-well format. Proof-of-concept has been 
achieved based on the validation results and a head-to-head comparison with an LLE 
method for analyzing clinical samples.  
Chapter 3 discusses the development of the in-tip SPME technique including 
preparation of fiber-packed and sorbent-packed in-tip SPME fibers. The in-tip SPME 
technique takes advantage of widely used commercially available automated liquid 
handling systems such as the Tomtec Quadra 96 workstation, and integrates the fiber 
SPME with the system in a very unique configuration. In-tip SPME is simple and easy to 
automate without introducing additional devices. 
Chapters 4 and 5 report two applications of the automated in-tip SPME in 
bioanalysis. Chapter 4 is the quantitative LC-MS/MS determination of vitamin D3 in 
human serum with derivatization. The in-tip SPME approach is compared with traditional 
LLE methods using either tubes or 96-well plate extraction. Chapter 5 reports the use of 
HILIC-MS/MS to determine three polar compounds, IMP, CIL and BLI, in biological 
fluids.  
Chapter 6 reports a comprehensive evaluation of matrix effects using the 
automated in-tip SPME approach in bioanalysis.  
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Chapter 7 compares in-tip SPME with other automated SPME approaches and 
mainly focuses on the comparison between in-tip SPME and methods using the PAS 
SPME automation system. Strategies for in-tip SPME method development validation, 
potential applications, and future directions of in-tip SPME in bioanalysis are discussed. 
Chapter 8 describes various model approaches to simulate the SPME extraction 
and desorption processes with both liquid and solid coating fibers. The simulation results 
are compared with experimental data and different applications of using SPME modeling 
and simulation are also discussed.  
Finally, Chapter 9 summarizes the overall conclusion of the research work 




Proof of Concept Study:  
Comparison of SPME and LLE in 96-well Format for the 
Determination of a Drug Compound in  
Human Plasma by LC-MS/MS 
 
 




This chapter has been published as a paper: W. Xie, J. Pawliszyn, W.M. Mullett, 
B.K. Matuszewski, "Comparison of solid-phase microextraction and liquid-liquid 
extraction in 96-well format for the determination of a drug compound in human plasma 
by liquid chromatography with tandem mass spectrometric detection", J. Pharm. Biomed. 
Anal. 2007, 45, 599-608. The figures and tables are reprinted from this manuscript with 
the permission of Elsevier (Copyright Elsevier 2007). 
 The authors would like to point out that this research work was completed and 
submitted for publication to Journal of Chromatography B in 2004. Unfortunately, the 
Journal could not publish the paper unless the structure of the compound, which was in 
the clinical trials at the time, was released. The manuscript was finally published three 
years later in Journal of Pharmaceutical and Biomedical Analysis without the compound 
structure. In 2005, O'Reilly et al.* first proposed the approach of performing high 
throughput parallel SPME on a 96-well plate format in Journal of Separation Science. 
 
* O'Reilly, J.; Wang, Q.; Setkova, L.; Hutchinson, J.P.; Chen, Y.; Lord, H.L.; Linton,  





 HPLC-MS/MS has gained widespread acceptance for the quantitative 
determination of drugs and metabolites in biological fluids because of the method’s high 
selectivity and sensitivity compared to other techniques.83-87 In spite of the high 
selectivity and sensitivity achieved by HPLC-MS/MS, a rapid and accurate determination 
of trace amounts of drugs in very complex matrices such as plasma and urine is still quite 
challenging. This is largely due to the possibility of a severe matrix effect originating 
from co-eluting matrix components that may affect ionization of analytes of interest 
leading to ion suppression or enhancements.88-91 In addition, the co-eluting metabolites of 
a drug being analyzed may give a MS/MS response in the channel used for drug 
quantification.10-12 Therefore, isolation of analytes from biological matrices using an 
effective sample clean up technique is often critical to achieve assay selectivity. 
 LLE and  SPE either on-line or off-line are two very commonly used approaches 
and are generally found to be sufficient to reduce or eliminate matrix effects and to 
provide reliable HPLC-MS/MS data.95,96 Although both LLE and SPE sometimes involve 
tedious and time-consuming extraction steps and often require evaporation and 
reconstitution steps prior to injection into the chromatographic system, up until now LLE 
and SPE are still the preferred methods for quantitative drug analysis in the 
pharmaceutical industry. With the development of new analytical instrument and 
techniques, high sensitivity of MS/MS detection may be achieved; therefore, in drug 
analysis the trend is to use a small volume of samples (usually less than 100 μL) and 
simplify sample extraction procedures to improve overall method efficiency with low 
cost. Extracting very small volumes of samples using conventional methods, such as LLE 
 35
and SPE may be challenging. As an alternative method, SPME has shown great potential 
as a highly efficient sample preparation technique. Since its invention in 1990,61 SPME 
has been widely used in biomedical and pharmaceutical analysis, and several excellent 
reviews have been published on the topic.16,19,62,63,97  The great advantage of SPME over 
other extraction methods is that SPME is a solvent free extraction technique that 
combines sampling, extraction, concentration, and sample introduction in one step. The 
method could save sample preparation time and disposal cost, and can be used with a 
very small volume of samples. Despite the advantages of this technique, SPME has never 
been reported in the literature for routine drug quantitation from biological fluids in the 
pharmaceutical industry. Ulrich62 listed some principal disadvantages of SPME in 
biomedical analysis preventing its applications in drug analysis in biological fluids. In 
addition, limited selections of commercially available SPME fibers and difficulties with 
method automation for high-throughput sample analysis are also reasons why SPME is 
not widely accepted and used in clinical sample analysis. 
 As part of a series of research studies conducted in our laboratory to explore the 
SPME technique in high-throughput drug analysis, we have developed and validated two 
extraction methods based on LLE and SPME to quantify a drug compound in human 
plasma from a clinical study. To increase sample throughput of SPME, the concept of 96-
well format was introduced into sample preparation. In order to make a direct comparison 
between LLE and SPME, the same amount of plasma sample was processed over the 
same calibration curve range. The intraday precision and accuracy, the lower limit of 
quantitation, and the matrix effects of each method were evaluated, and results obtained 
from a healthy subject after single-dose and administration of 25 mg of drug using the 
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two different extraction methods were compared. To the best of our knowledge, this is 
the first example of implementation of SPME in 96-well format and validation of the 






 A drug compound and its deuterated internal standard (d6-ISTD, Figure 2-1), were 
synthesized at Merck Research Laboratories (Rahway, NJ, USA). All solvents were 
HPLC or analytical grade and were purchased from Fisher Scientific (Fair Lawn, NJ, 
USA). Ammonium formate (HPLC grade), purchased from J.T. Baker (Phillipsburg, NJ, 
USA), formic acid (95%) and 85% o-phosphoric acid (Sigma, Milwaukee, WI, USA), 
were used as received. Deionized water was obtained by passing in-house water through 
a Millipore Milli-Q plus system (Bedford, MA, USA). Nitrogen (99.999%) was supplied 
by West Point Cryogenics (West Point, PA, USA). PDMS – DVB fibers (60 µm) were 
purchased from Supelco (Bellefonte, PA USA). 96-Well collection plates (1.2 and 2.4 
mL) and mats were purchased from Marsh Biomedical (Rochester, NY, USA). Different 
lots of drug free human plasma were obtained from Biological Specialties Corp. 



































  MK-0533    Internal Standard (d6-ISTD) 
 





 A Perkin-Elmer (Norwalk, CT, USA) LC-200 micro pump and a Shimadzu SIL-
HTC autosampler (Columbia, MD, USA) for 96-well plate were used in this work. The 
chromatographic separation of analytes was performed on a Restek BDS Hypersil C18 
column (5 × 2.1 mm, 3 μm) with a 0.5 μm in-line filter. Mobile phase consisted of 
acetonitrile (ACN) : water (80:20, v/v) and was pumped at a flow rate of 0.2 mL/min. The 
total run time was 4 minutes. ACN : water (90:10, v/v) was used as a washing solvent for 
needle and flow path cleaning of the autosampler after each injection. 
 An Applied Biosystems-Sciex API 4000 triple quadruple mass spectrometer 
(Foster City, CA, USA) equipped with a turbo ion spray (TIS) source operating in the 
negative ion ionization mode was used for all HPLC-MS/MS analysis. Multiple reaction-
monitoring (MRM) mode was utilized for quantitation. In TIS experiments, the TIS probe 
temperature was maintained at 450 oC, and the nebulizing gas (air) pressure was set at 75 
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psi. The settings for the curtain gas, gas 1, and gas 2 were 10, 40, and 50 psi, respectively, 
and the ion spray voltage was -4200 V. Source and MS parameters were optimized by 
infusing a neat solution of drug compound prepared in ACN : water (50:50, v/v)  at a flow 
rate of 20 μL/min into a mobile phase pumped at 0.2 mL/min through the TIS interface.  
Multiple reaction monitoring of the precursor → product ion pairs at m/z 526 → 440 for 
drug compound and m/z 532→ 440 for d6-ISTD was used for quantitation. 
 
2.2.3 Preparation of Standard Solutions and QC Samples 
 
 A stock solution of drug compound (100 μg/mL) was prepared in ACN : water 
(50:50, v/v). This stock solution was further diluted with ACN : water (50:50, v/v)  to 
give a series of working standards with concentrations of 5, 25, 50, 250, 500, 1,000, and 
2,500 ng/mL. The d6-ISTD was also prepared as a stock solution (100 μg/mL) in ACN : 
water (50:50, v/v). A working standard solution of 1,000 ng/mL of d6-ISTD, prepared by 
diluting stock solution with ACN : water (50:50, v/v), was used for plasma samples 
analyses. All standard solutions were stored at 4oC. Plasma standards were prepared by 
adding 50 μL of each working standard to 250 μL of acidified human control plasma (15 
µL of concentrated phosphoric acid per mL of plasma). The resulting plasma standard 
concentrations ranged from 1 to 500 ng/mL. 
 A stock solution for QC samples of drug compound was prepared separately by 
the same procedure using a separate weighing. QC samples were prepared by diluting the 
QC working solution with acidified human control plasma. QC samples at three 
concentrations (Low QC (2 ng/mL); Middle QC (100 ng/mL); High QC (400 ng/mL)) 
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were used to evaluate assay precision and accuracy.  All QC samples were divided into 1 
mL aliquots in separate cryo tubes and stored at –20 oC until analysis. 
 
2.2.4 LLE Procedure 
 
 Standards, QC, and subject plasma samples were thawed at room temperature. 
250 μL of subject plasma samples were added individually into a 2 mL deep 96-well 
plate with 50 μL of ACN : water (50:50, v/v)  into blank and QC/subject plasma samples. 
Internal standard solution (50 μL) was added to each well of the plate, except to the well 
designated for the double blank plasma. The plate containing samples was placed onto a 
Tomtec Quadra 96 workstation (Hamden, CT, USA) for liquid transfer. After transferring 
1.2 mL of hexane : isopropanol (80:20 v/v) extraction solution by Tomtec workstation, 
the plate was sealed with mat made of molded PTFE/silicone liner and was roto-mixed 20 
minutes for LLE. The plate was then centrifuged for 15 minutes at 3,000 rpm and the top 
organic layer (100 µL) was aspirated and dispensed into a 1.2 mL 96-well collection plate 
by Tomtec workstation. The organic extract was evaporated to dryness under heated N2 
stream and reconstituted in 300 μL of ACN : 10 mM ammonium formate (80:20 v/v, 
adjusted pH = 3.3 using formic acid) solution and 2 μL were injected into the HPLC-
MS/MS system. 
 
2.2.5 SPME Procedure 
 
 Standards, QC, and subject plasma samples were thawed at room temperature. 
250 μL of subject plasma samples were added individually into a 2 mL deep 96-well 
plate with 50 μL of ACN : water (50:50, v/v) into blank and QC/subject plasma samples. 
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Internal standard solution (50 μL) was added to each well of the plate, except the well 
designated for the double blank plasma. After transferring 500 µL of water to all wells on 
the plate using a Tomtec Quadra 96 workstation, the plate was sealed with mat made of 
molded PTFE/silicone line. A homemade plastic module (Figure 2-2) was used for SPME 
in 96-well format. The plastic module consists of three plates. The bottom plate was cut 
1.3 cm deep at the bottom to fit the 2 mL deep 96-well plate and to seal the mat 
completely to avoid any leaking during rotation. In addition, 96 holes were drilled 
through the bottom plate with diameter slightly larger than that of SPME needle. The 
middle plate was used for two purposes. First, 96 wells were cut on the plate with holes 
drilled through to match the holes from the bottom plate, therefore, SPME needles could 
line up easily in each well but have to be manually penetrated through the mat. The 
height of the middle and bottom plates were measured accurately so that when fibers 
were manually pushed out of the needle, they would not reach the bottom of the 96-well 
plate (Figure 2-2). Secondly, after extraction, the fibers would be first withdrawn to the 
needles individually. Then the middle plate could be pulled out and all the SPME needles 
would come out of the mat altogether. The top plate was used as a cover so that the whole 
unit could be put on a Multi-tube vortexer for roto-mixing. During extraction procedure, 
eight PDMS/DVB needles were used at the same time, and the extraction time was 
optimized at 20 minutes. The same procedure was repeated except a new collection plate 
and a new mat were used with 1 mL of acetonitrile in each well for solvent desorption. 
After desorption for 10 minutes, the fibers were put into a standard desorption chamber 
individually for cleaning, and the same eight fibers were used for another eight samples 
extraction from the original 2 mL deep 96-well plate. Until desorption of all the samples 
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was done, the collection plate was evaporated to dryness under heated N2 stream and 
reconstituted in 150 μL of the same solution as in LLE procedure, and 10 μL was injected 
into the HPLC-MS/MS system. 
 
 
Figure 2-2 A home-made plastic module for SPME in 96-well format 
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2.2.6 Precision and Accuracy 
 
 The precision of the method was determined by the replicate analysis (n = 5) of 
drug compound in five different sources of human plasma at all concentrations utilized 
for the construction of calibration curves. The linearity of each calibration curve was 
confirmed by plotting the peak area ratio of the drug to internal standard versus drug 
concentration. The unknown sample concentrations were calculated from the equation y 
= mx + b, as determined by weighted (1/x2) linear regression of the standard line. The 
accuracy of the method was determined as the percentage between the mean 
concentration observed and the nominal concentration. The precision of the method as 
measured by the CV was required to be <15% at the LLOQ and <10% at other 




 The selectivity of the method was confirmed by processing control drug-free 
human plasma samples from six different sources to determine whether endogenous 
peaks were present at the MS/MS transitions used for monitoring the analyte and/or the 
internal standard. In addition, the “cross-talk” between MS channels used for monitoring 
the analyte and the internal standard was evaluated. 
 
2.2.8 Recovery and Matrix Effects 
 
 Extraction recovery was evaluated for drug compound and its internal standard 
using standards spiked at three concentrations (5, 50, and 200 ng/mL) for drug compound, 
and for internal standard at a concentration of 200 ng/mL. Recovery was determined by 
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comparing the absolute peak areas of standards spiked into control human plasma and 
extracted to the control plasma extracted in the same manner and then spiked post-
extraction with the analytes. Since a stable isotopically labeled compound was used as an 
internal standard, the potential “relative” matrix effects on ionization should not have any 
adverse effect on the quantitation of the drug compound in different plasma lots. The 
absence of the “relative” matrix effects was illustrated by the examination of the slopes of 




 The stability of drug compound and its internal standard in the stock and working 
solutions was investigated. Storage stability of the drug compound in human plasma and 
the influence of freeze-thaw cycles were also examined by analyzing a set of QC samples 
at three concentrations. The calculated mean values should not deviate by greater than 
15% of the nominal value. 
 
2.3 Results and Discussion 
 
2.3.1 Evaluation of the Stability of the Acyl-glucuronide of Drug Compound 
 
 Due to the presence of a carboxylic group moiety in the drug compound under 
study, the formation of the acyl-glucuronide metabolite of drug in vivo was likely and 
was confirmed after dosing animal species with the drug. This acyl-glucuronide could 
potentially hydrolyze to parent compound in sodium heparinized human plasma 
following sample collection. Therefore, it was necessary to evaluate the stability of this 
metabolite in human plasma during sample extraction and handling. Hydrolysis of the 
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glucuronide was found to be dependent on the temperature and pH of the sample. The 
addition of at least 10 µL of concentrated phosphoric acid per milliliter plasma was found 
to prevent the glucuronide hydrolysis. Up to 30 µL of concentrated phosphoric acid per 
mL of plasma could be added to heparinized human control plasma without denaturing 
plasma proteins. The acyl-glucuronide was found to be stable in acidified plasma stored 
at room temperature for at least 60 minutes. However, at room temperature, hydrolysis 
was observed in non-acidified heparinized human control plasma after 30 minutes and it 
became significant after 60 minutes. The stability of acyl-glucuronide was further 
assessed by spiking 200 ng of acyl-glucuronide standard (known to be contaminated with 
drug) in 1 mL of acidified human control plasma and analyzing the resulting drug 
concentrations following F-T cycles. The determined drug concentrations in these 
samples practically did not change following up to three freeze-thaw cycles. 
 
2.3.2 Optimization of Chromatography and Extraction Conditions 
 
 Good peak shape and acceptable sensitivity were observed when initial attempts 
were made to detect drug compound by using turbo-ion spray interface in positive ion 
mode with conventionally buffered mobile such as ACN:10 mM ammonium formate 
(60:40 v/v, pH 3). However, poor reproducibility was obtained when five standard curve 
samples were extracted from acidified plasma and analyzed. It was interesting to find that 
utilization of a “buffer-free” mobile phase of ACN: water (80:20, v/v), in negative 
ionization mode using turbo-ion spray interface resulted in significant improvement in 
sensitivity and reproducibility, as long as the mobile phase used as the reconstitution 
solutions was adjusted to pH of about 3. After exploring many different kinds of reverse 
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phase columns, it was found that BDS Hypersil C18 column (5 × 2.1 mm, 3 μm) 
produced the best results in terms of peak shape and retention of analytes. The acy-
glucuronide of drug compound eluted at the solvent front and was, thus, well separated 
from the analyte under the conditions utilized. 
 Different types and various compositions of organic solvents were tested to 
achieve better recovery of analyte from plasma during LLE. Due to the acidic nature of 
the compound, it was found that for most of solvents tested, better recoveries were 
obtained at a pH of 3. However, good reproducibility was also observed when the 
extraction solvent was composed of 80% hexanes and 20% IPA. The solubility of IPA in 
aqueous media plays a critical role during the extraction, but its volume should not 
exceed 20 percent. As both control and subject plasma samples were treated with 
concentrated phosphoric acid, no other buffers were necessary for pH adjustment before 
liquid-liquid extraction. 
 The biggest advantage of SPME is that it is a solvent-free extraction technique. 
The SPME fibers were directly immersed into the plasma for extraction and all 
commercial available fibers were tested under same conditions for extraction efficiency 
and sensitivity of detection. The extraction efficiency of SPME depends on the inter-
molecular interactions between the fiber coating and the analytes. It was found that 
PDMS-DVB gave the best results compared with other types of SPME fibers. For 
analytes extraction from biological fluids, SPME fibers with solid coatings generally 
produce better extraction efficiency compared with those with liquid coatings. This is due 
to the well-defined, dense crystalline structure of solid coating which significantly 
reduces the diffusion coefficients within the structure and extraction occurring through 
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adsorption on the surface of the fiber.98-101 In order to make a direct comparison between 
SPME and LLE, attempts were focused on making SPME procedure as simple as 
possible. No salts were added to the samples and no pH adjustment of plasma samples 
were made, except the addition of 500 μL of water to each sample well in the 96-well 
plate to reduce viscosity of plasma sample caused by the presence of a concentrated acid 
and to make sure the fibers could be completely immersed in the sample solution during 
the plate rotation. Agitation was unnecessary for SPME extraction in this work as the 
whole plate was rotated consistently and the fiber position in the plate well was not 
critical, as long as the fiber was completely exposed from the protective needle. In order 
to achieve a 1 ng/mL of LLOQ, extraction time was optimized to 20 minutes and 10 
minutes for desorption. Considering 96-well format was used for SPME sample 
preparation, the whole process was relatively fast and simple. Both methanol and 
acetonitrile were tested for solvent desorption and no difference between these two 
solvents was observed. Since acetonitrile was used for sample preparation and in the 
mobile phase; this solvent was also selected as the desorption solvent. Issues with sample 
carry-over were observed in this experiment. It was found that after a single solvent 
desorption, there were still more than 10% of the analytes remaining in the SPME coating, 
and further washing was necessary to reduce carry-over to an acceptable level before the 
same fiber could be used for subsequent sample extraction. A standard desorption 
chamber from Supelco was used for fiber cleaning. Mobile phase was flushed through the 
fiber until no carry-over was observed. It took about 4 to 8 minutes to eliminate carry-
over depending on analyte concentration. Further experiments are needed to reduce the 
time and to increase the efficiency of the desorption procedure. In the work present in this 
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paper, eight commercially available PDMS-DVB fibers were used at the same time for 
96-well format extraction. The excellent precision and accuracy of the method indicated 
that the concept of 96-well format could be successfully applied to SPME using large 
number of fibers. 
 
2.3.3 Method Validation 
 
 The two methods based on LLE and SPME were validated in human plasma over 
the concentration range of 1 to 500 ng/mL of drug. Assessment of the intraday variability 
of each method was conducted in five different lots of acidified human control plasma 
spiked with drug compound. The resulting method precision and accuracy data are 
presented in Tables 1 and 2. For LLE, the intra-day precision of the method was 0.8% at 
LLOQ, and was equal to or lower than 3.3% at all other concentrations used for the 
construction of the calibration curve.  Method accuracy was found to be within ±2% of 
the nominal concentration for all the standards evaluated. For SPME, the intra-day 
precision was 6.9% at LLOQ, and was equal to or lower than 5.7% at all other 
concentrations. Method accuracy was found to be within ±5% of nominal concentrations. 
The correlation coefficient for the mean standard curves constructed from five different 










 Assessment of the selectivity of a method is critical and needs to be confirmed in 
the presence of in-vivo metabolites of an analyte. Metabolites that are 
chromatographically not separated from the analyte of interest may be converted to a 
parent drug during sample preparation and/or undergo partial fragmentation in the ion 
source at elevated temperatures giving the same molecular ion as for the parent drug. The 
major metabolites of drug compound were evaluated for the “cross-talk” in channels used 
for monitoring both drug and the internal standard. No interference or “cross-talk” from 
these metabolites was observed. In addition, the “cross-talk” between channels used for 
monitoring both drug and the internal standard was evaluated by the analysis of standard 
samples containing individual compounds separately at the concentrations of 500 and 200 
ng/mL for drug and internal standard, respectively, and monitoring the response in other 
MS/MS channel used for quantification. No response was observed in the channel of the 
other analytes at their retention times.  Figure 2-3 shows the representative extraction ion 
chromatograms obtained from human control plasma blank, human control plasma spiked 
with 200 ng/mL of internal standard, human control plasma spiked with 1 ng/mL of drug 




Figure 2-3 Representative extracted ion chromatograms of (A) double blank; (B) 
single blank, spiked with 200 ng/mL of d6-ISTD; (C) lower limit of 
quantification (LLOQ), 1 ng/mL of drug with 200 ng/mL of d6-ISTD 
using LLE; (D) LLOQ, 1 ng/mL of drug with 200 ng/mL of d6-ISTD using 
SPME; (E) 500 ng/mL of drug only using LLE 
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2.3.5 Recovery and Assessment of the Matrix Effects 
 
 In the 96-well LLE procedure, extraction recovery and the effect of the plasma 
matrix on ionization was evaluated for drug compound using standards spiked at 
concentrations of 5, 50, and 200 ng/mL and for d6-ISTD spiked at a concentration of 200 
ng/mL. Recoveries were determined by comparing the peak areas of standards spiked into 
five different lots of acidified human control plasma and extracted as per LLE procedure 
to acidified human control plasma extracted in the same manner and then spiked post-
extraction with a known amount of the drug. “Absolute” matrix enhancement/suppression 
of ionization was evaluated by comparing the peak area of acidified human control 
plasma samples extracted and then spiked with a known amount of each analyte, to neat 
standards injected directly in the same reconstitution solvent. Results are shown in Table 
2-3. Based on the intraday precision and accuracy results (Table 2-1) and the slope data 
(Table 2-4) that were obtained using five different lots of human control plasma, the use 
of a stable isotope labeled analogue as the internal standard largely compensated for any 
variation in matrix effects and/or recovery between the different lots of human control 
plasma. Therefore, “relative” matrix effects93 on ionization from five different lots of 
human control plasma were negligible. A general practice in determining the recovery in 
SPME is to compare the peak areas obtained from the extracted, spiked plasma samples 
with those obtained by direct injection of standard solutions. Due to the relatively small 
surface area of the stationary phase of the SPME fiber and the use of different extraction 
mechanisms compared with LLE, the recoveries observed in SPME are generally one 
order of magnitude lower than those obtained by LLE, which was also found to be the 
case in this work. However, special attention was given to the evaluation 
of the “relative” matrix effects. It was expected that variation in the “absolute” matrix effects in SPME would be larger than that in 
LLE, as SPME fibers were directly immersed in plasma samples. Based on the intraday precision and accuracy results (Table 2-2) and 
the slope data (Table 2-4) that were obtained using five different lots of human control plasma, it was found that the “relative” matrix 
effects were not observed, and the utilization of a stable isotope labeled analog as the internal standard played a critical role in 
compensating for any variation in “absolute” matrix effects and/or recovery between different lots of human control plasma. In cases 
when an analog rather than a stable isotope labeled internal standard are utilized, the careful assessment of the “relative” matrix effects 









2.3.6 Analyte Stability 
 
 The stability of drug stock solution was evaluated by comparing freshly prepared 
standards solutions from a new standard weighing to similarly prepared solutions stored 
for 60 days at 4 oC. The peak areas of the new standard solutions were found to be within 
98-102% of the 60 days old standard solution peak areas, confirming the stability of drug 
in stock solutions for 60 days. QC samples (n = 5 at each concentration) were subjected 
to three freeze-thaw cycles consisting of a thaw to reach room temperature and then 
refreezing at –20 oC.  These samples, together with a set (n = 5 at each concentration) of 
human QC samples that were not subjected to additional freeze-thaw cycles, were then 
defrosted and analyzed.  In all cases, the results for the samples that were subjected to 
additional freeze-thaw cycles were within ±8% of the nominal value. The results are 














2.3.7 Clinical Sample Analysis 
 
 The method using LLE approach has been implemented in a clinical study, and 
thus far, more than two thousands plasma samples have been analyzed. Inter-day 
precision and accuracy of the method for the clinical samples analysis were determined 
by analyzing QC samples at low, medium, and high concentrations. Table 2-6 
demonstrated the means, precision, and accuracy for QC samples prepared before the 
analysis of the study samples and for QC samples analyzed in replicate with the daily 
runs of the clinical samples. The precision for daily runs (n=84) was less than 4.5% with 
accuracy ranging from 97.9-99.6%.  
 In order to compare the clinical data obtained using LLE vs SPME technique, 
samples from one post-dose subject from the clinical study were reanalyzed using both 
approaches. Concentration-time profiles of drug in plasma of the same healthy subject 
after single-dose administration of 25 mg of drug obtained using LLE and SPME 
methods are presented in Figure 2-4. The two data sets obtained using two widely 
different extraction methods are in excellent agreement, clearly demonstrating that SPME 
could be used in the case under study as an alternative approach for multi-sample analysis 
in pharmacokinetic studies. 
 
 
Figure 2-4 Concentration-time profile of drug compound in plasma of a healthy 
subject after single-dose administration of 25 mg of drug using LLE and SPME 
techniques. 
 
2.3.8 Comparison between LLE and SPME 
 
 The same LLOQ of 1 ng/mL when 0.25 mL of human plasma was processed was 
achieved using both LLE and SPME methods. Both procedures were validated in the 
same concentration range of 1 - 500 ng/mL. The linearity of the calibration curves, the 
intra-day precision, and accuracy were all satisfactory in both methods. Recoveries of 
analytes using LLE were at least 10 times higher than those obtained by SPME and 
overall sensitivity of detection was much better from LLE than that from SPME. In the 
reported study, the overall sample preparation time for LLE was less than half of that 
required for SPME with the same number of clinical samples. However, the advantages 
of using SPME were also very evident. First, the procedure is simple and organic solvent 
consumption is far less than that of LLE. Secondly, evaporation and reconstitution steps 
required in LLE prior to injection to the chromatographic system could be avoided in 
SPME, which may be particularly desirable for the quantification of labile analytes that 
are stable in biological fluids, but may decompose during the evaporation process. In 
 57
addition, there is a great potential that the sample preparation time could be significantly 
reduced if the SPME process is automated. In our case, if more than eight fibers were 
used for extraction at a time, the total sample preparation time of SPME would be 
comparable or shorter than that of LLE. On the other hand, the disadvantages of SPME 
cannot be overlooked. There are only a few commercially available SPME fibers. In 
comparison with LLE, SPME is a relatively non-selective extraction method, and great 
effort is needed to increase extraction recovery and efficiency. In addition, extra clean-up 
procedures are necessary for repeat analyses using the same fiber. Quantitation is more 
prone to errors due to changes of the matrix in SPME than in other conventional 





 For the first time, highly selective and sensitive HPLC-MS/MS methods with 
LLE and SPME approaches in 96-well format were developed and validated for the 
determination of a drug compound in human plasma. Both methods achieved a LLOQ of 
1 ng/mL using 0.25 mL of plasma sample. The applicability of the method using liquid-
liquid extraction was demonstrated by analysis of a drug compound in more than two 
thousands human plasma samples from a clinical study. The potential for implementation 
of SPME approach in multi-sample drug analysis was also successfully demonstrated, 
and the results obtained from the analysis of a drug in plasma samples from a healthy 
subject after single-dose and administration of 25 mg of drug using the LLE and SPME 





Development of High Throughput In-tip SPME Fibers 
 
 
3.1 Preamble and Introduction 
3.1.1 Preamble 
Experimental results described in this chapter about fiber-packed in-tip SPME has  
been published as a paper: W. Xie, W.M. Mullett, C.M. Miller-Stein, J. Pawliszyn, 
"Automation of in-tip solid-phase microextraction in 96-well format for the 
determination of a model drug compound in human plasma by liquid chromatography 
with tandem mass spectrometric detection", J. Chromatogr. B 2009, 877, 415-420. The 
figures and tables are reprinted from this manuscript with the permission of Elsevier 
(Copyright Elservier 2009) 
 Experimental results described in this chapter about sorbent-packed in-tip SPME 
will be published in Bioanalysis in the September Special Issue on Biological Sample 
Preparation as an invited paper. 
 
3.1.2 Introduction 
Since its introduction in 1990, SPME has been widely used in many areas of 
analytical chemistry, such as food, environmental, and biological analysis as a solvent-
free extraction technique which combines sampling, sample clean-up, and pre-
concentration into a single step. The most significant advantages of SPME include the 
potential for fast methods, easy handling, automation, minimal requirements for 
necessary equipment, and low solvent usage. However, its disadvantages can limit the 
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viability of the method as much as its advantages promote it. In 2000, Ulrich gave a 
critical review62 of SPME in biomedical analysis which summarized and concluded that 
SPME was not a universal sample preparation method: as a non-exhaustive extraction 
technique, in complex matrices, the extraction time was relatively long and recoveries 
were considerably lower than those reported from other extraction methods, such as LLE 
and SPE. Therefore, it is difficult to analyze target analyte at very low concentrations due 
to interferences from endogenous substances in biological fluids. Analyte carry-over is 
also possible in SPME methods due to the repeated use of a single fiber and the 
requirements for longer desorption time decreases the advantages of the SPME methods. 
Besides these principle disadvantages, the limited range of commercially available SPME 
stationary phases and lack of high throughput capability are also major factors that 
prevents its application in routine use as an alternative approach for quantitative 
determination of analytes, especially in pharmaceutical bioanalysis. 
To solve these problems and overcome the challenges of SPME technique, 
research has been focused on the areas of new SPME coatings and devices that offer 
higher extraction efficiency and selectivity, automation for high throughput analysis, and 
new SPME method optimization and calibration approaches. Although the development 
of new coatings is one of the most active areas of SPME studies, the progress of 
developing commercially available new SPME coatings is not substantial compared with 
the rapid development of SPE sorbents in the market. Up until now, commercially 
available fibers include PDMS, poly(acrylate) (PA), carboxen/poly(dimethylsioxane) 
(CAR/PDMS), carbowax/templated resin (CW/TPR), and PDMS/DVB, all of which only 
roughly cover the scale of polarity. The existing fibers can have issues with instability 
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and swelling in organic solvent, lack of lot-to-lot reproducibility, breaking of the fibers, 
stripping of the coatings, and a relatively high expense. Several SPME coating 
procedures have been explored in the past, including sol-gel technology, in-tube 
extraction, electrochemical procedures, and physical deposition, and the most recent 
developments in SPME coatings have been summarized in some reviews.79,98,102 Many 
in-house made SPME coatings have been discovered and tested in various applications, 
such as a new type of molecularly imprinted polymers (MIPs), fibers that were directly 
synthesized using silica capillaries as molds with silica being etched away after 
polymerization and tested for the SPME of triazines from environmental and food 
samples.103  Other examples include a novel Pt fiber coated with single-walled carbon 
nanotubes prepared by electrophoretic deposition and applied to the determination of 
phenols in aqueous samples 104 and a new line of biocompatible coatings immobilized on 
the metal fiber core and consisting of a mixture of proprietary biocompatible binder and 
various types of coated silica particles with an assessment in vitro.105 An interesting trend 
of developing new SPME coatings is to use methacrylate-based monoliths, which are 
widely used as efficient stationary phases for all types of chromatography separations 
since their introduction in the early 1990s. The polymer monoliths are normally prepared 
through bulk free-radical copolymerization of a monovinyl monomer with a cross-link 
monomer in the presence of porogenic solvent and an initiator by thermal or irradiation. 
The pore properties and the surface area of the polymer monoliths could be freely 
controlled by the type and composition of the porogenic solvent and by the percentage of 
cross-linkers. The main advantages of polymer monoliths are the simplicity of 
preparation with a wide range of chemistries for reactions and enhanced mass transfer. In 
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addition, entrapping chromatographic beads and sorbents for preparing fritless columns 
using methacrylate-based monoliths is one of the favorable features of the technique. The 
initial applications of polymer monoliths are mainly focused on protein separation and 
dedicated to use in conventional SPE; 106,107 more recent polymer monoliths are used as 
sorbent for in-tube SPME for drug analysis.108 The successful applications of these in-
tube SPME methods using polymer monoliths demonstrated the feasibility of this new 
coating approach, however, due to the limitations of high throughput in in-tube SPME, as 
each sample is processed serially, it is generally agreed that parallel SPME fibers using a 
multi-well plate approach would be the best option for high throughput bioanalytical 
applications of SPME.109,110  
To accomplish SPME automation and to maintain the simplicity of the technique, 
which is the biggest advantage compared with other conventional extraction methods, we 
have developed a new approach of using pipette tip-based SPME in a 96-well plate 
format. The automation of in-tip SPME technique can be easily achieved by 
commercially available system using 96-well extraction plates and a robot without the 
need to for introducing additional devices. In this study, we aim to introduce a simple and 
high throughput in-tip SPME fiber procedure based on polymer monoliths using photo-
polymerization. Different from other reported SPE based microtips,111 the polymer 
monoliths in-tip SPME fibers are designed for non-exhaustive extraction and could be 
used as disposable tips which will completely eliminate carry-over effect encountered 
often in repeated use SPME fibers. The open configuration for extraction also better 
facilitates viscous samples as commonly encountered with bioanalysis. Besides sorbent-
 62
packed in-tip SPME, an alternative technique using SPME fiber instead of polymer 
materials has also been developed.  
To the best of our knowledge, this is the first study to use an automation device to 
prepare 96 fibers at one time. A polymerization mixture consisting of ethylene glycol 
dimethacrylate (EDMA), dimethoxy-α-phenylacetophenone (DMPA), and 1-decanol was 
used to prepare the sorbent-packed in-tip SPME fibers. The optimization procedures that 
affect polymer morphology, such as compositions of the cross-linkers and porogens, 
polymerization time and fiber thickness, and the extraction efficiency by immobilized 
extraction sorbent such as Oasis HLB particles were investigated. Also, the 
reproducibility of automated in-tip SPME fiber preparation, as well as sample processing 
parameters, such as sample extraction and desorption times and volumes, aspiration, and 
dispense speed were evaluated. Finally, the performance of the sorbent-packed and fiber-
packed in-tip SPME was assessed with model drug compounds and compared with those 




3.2.1 Materials  
 
 EDMA, DMPA, and 1-decanol were purchased from Sigma-Aldrich (Milwaukee, 
WI, USA), and were used as received. MK-0533 and MK-0974 and their deuterated 
internal standards (Figure 3-1, structures of MK-0533 and its internal standard are shown 
in Chapter 2) were synthesized at Merck Research Laboratories (Rahway, NJ, USA). 
Oasis HLB with particle size 60 µm and Oasis HLB (5 mg) µElution SPE plates were 
obtained from Waters (Milford, MA, USA). All solvents were HPLC or analytical grade 
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and were purchased from Fisher Scientific (Fair Lawn, NJ, USA). Ammonium formate 
(HPLC grade), purchased from J.T. Baker (Phillipsburg, NJ, USA), formic acid (95%) 
and 85% o-phosphoric acid (Sigma, Milwaukee, WI, USA), were used as received. 
Deionized water was obtained by passing in-house water through a Millipore Milli-Q 
plus system (Bedford, MA, USA). Nitrogen (99.999%) was supplied by West Point 
Cryogenics (West Point, PA, USA). Blank GC capillary was obtained from Restek 
(Bellefonte, PA, USA). PDMS – DVB fibers (60 µm) were purchased from Supelco 
(Bellefonte, PA USA). 96-Well collection plates (1.2 and 2.4 mL) and mats were 
purchased from Marsh Biomedical (Rochester, NY, USA). Different lots of drug free 
human plasma were obtained from Biological Specialties Corp. (Lansdale, PA, USA) and 
























































 A Tomtec Quadra 96 workstation (Hamden, CT, USA) was used in high 
throughput polymer monoliths in-tip SPME fibers preparation and the automated sample 
extraction and desorption process. Photo-polymerization was achieved using UVP 
Compact UV lamps purchased from Fisher Scientific. A LEO 1530 field emission 
scanning electron microscopy (SEM) (Carl Zeiss NTS GmbH, Oberkochen Germany) 
was used to acquire SEM images of the coating using an acceleration voltage of 15 kV. A 
Perkin-Elmer (Norwalk, CT, USA) LC-200 micro pump and a CTC PAL Leap 
autosampler (Carrboro, NC, USA) for 96-well plates was used in this work. The 
chromatographic separation of analytes was performed on a Thermo-Hypersil Keystone 
(Bellefonte, PA, USA) FluoPhase RP column (150 × 2.1 mm, 5 μm) and a Restek BDS 
Hypersil C18 column (50 × 2.1 mm, 3 μm), respectively. Mobile phase consisted of (A) 
ACN: water (60:40, v/v) with a flow rate of 0.2 mL/min in a total run time of 4.5-min 
was used for MK-0974; and (B) ACN: water (80:20, v/v), flow rate 0.2 mL/min, total run 
time 3-min for MK-0533. 50% ACN with 0.1% formic acid and a "cocktail" of 
ACN/IPA/acetone (50:40:10, v/v/v) were used as washing solvents for the autosampler. 
An Applied Biosystems-Sciex API 3000 triple quadruple mass spectrometer (Foster City, 
CA, USA) equipped with a TIS source operating in the positive ion ionization mode was 
used for all HPLC-MS/MS analysis. MRM mode was utilized for quantitation. The 
transitions monitored were m/z 567 → m/z 219 and m/z 528 → m/z 135 for MK-0974 
and MK-0533, respectively; m/z 572 → m/z 224 and m/z 534 → m/z 135 for the their 
internal standards, respectively. In TIS experiments, the turbo ion spray probe 
temperature was maintained at 450 oC and the ion spray voltage was at 5000 V. Source 
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and MS parameters were optimized by infusing a neat solution of drug compound 
prepared in ACN:water (50:50, v/v) at a flow rate of 20 μL/min into a mobile phase 
pumped at 0.2 mL/min through the turbo ion spray interface. 
 
3.2.3 Preparation of Sorbent-packed In-tip SPME Fibers 
 
 Polymer monolith in-tip SPME fibers were prepared in two steps. First, in-tip 
SPME fiber modules were prepared for photopolymerization (Figure 3-2A). Polyethylene 
(PE) frits (25 µM, 6.3 mm in diameter) purchased from Innovative Microplate (Chicopee 
MA, USA), and non sterilized polypropylene pipette tips purchased from Tomtec Inc 
were used to prepare the modules. A piece of GC capillary tubing (0.01”-0.03” outer 
diameter) was cut into pieces (about 6.5 cm) and punctured into the middle of the PE frit 
to ensure a secure fit of the tubing. The PE frit with the capillary tubing was carefully 
inserted into the pipette tip so that the PE frit sat tightly at the top of the pipette tip with 
the capillary exposed by 2-3 mm outside the tip. The distance from the PE frit to the top 
of the pipette tip was about 11 mm to avoid extrusion from tip loading. Up to 96 tips 
were prepared in the same way and were loaded on a Tomtec Quadra 96 Workstation. 
The whole process took about 60 minutes and the PE frits with capillaries were reusable 
for future in-tip fibers preparation. 
 Secondly, the 96 tips were filled with a polymerization mixture for 
photopolymerization. A mixture of cross-linker (EDMA, 0.8 g), initiator (DMPA, 0.008 
g), and porogen (1-decanol, 1.2 g) was prepared in a 4 mL glass vial, vortex-mixed 
thoroughly, and ultrasonicated for 10 s. About 100 µL of the mixture was transferred to 
each well in a 96-well plate with 600 µL 12×8 removable tube strips from ArcticWhite 
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LLC (Bethlehem, PA, USA). For Oasis HLB in-tip fibers, the polymerization mixture 
was mixed thoroughly with Oasis HLB particles in a ratio of 1 mg of particle / 4 µL of 
mixture. The plate was placed at one position on the deck of the Tomtec Workstation and 
UV light lamps were placed at another position for photopolymerization. The Tomtec 
Workstation was programmed as such so that the tips with capillaries exposed were 
lowered to the bottom of the wells, but ensured no contact. 10 µL of polymerization 
mixture solution was aspirated simultaneously from the 96-well plate to 96 pipette tips 
and then moved to the UV lamps position, the 96 tips were photo-illuminated at 365-nm 
for 10 minutes. After photopolymerization, the 96 tips were un-loaded from the 
workstation , the capillary tubing was manually removed from the bottom of each tip, and 
all the tips were immersed into a reservoir with methanol overnight and dried under 
vacuum. The whole photopolymerization process was performed at room temperature. 
The freshly prepared tips were ready for SPME experiments (Figure 3-2B).  
 
3.2.4 Preparation of Fiber-packed In-tip SPME Fibers 
 
Polyethylene (PE) frits (25 µM, 6.3 mm in diameter) purchased from Innovative 
Microplate (Chicopee MA, USA), and non-sterilized polypropylene pipette tips 
purchased from Tomtec Inc (Hamden, CT, USA) were used to prepare the in-tip SPME 
fibers. A hole was drilled in the middle of the PE frit with a needle of the same diameter 
as the protective needle of a SPME fiber; ensuring a secure fit of the fiber by the PE frit. 
The SPME fiber was carefully exposed just outside the protective needle and cut 
precisely to remove the sealing septum and the hub from the SPME fiber. The distance 
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from the end of the fiber to the bottom of the pipette tip should be 11 mm, as well as the 
distance from the PE frit to the top of the pipette tip.    
 
3.2.5 SPME Automation 
 
 In-tip SPME extraction and desorption process for all experiments was fully 
automated using a Tomtec Quadra 96 workstation (Figure 3-2C). In summary, 96-well 
sample extraction and desorption plates, as well as tip washing plate, waste plate, and 
reservoirs containing desorption solvent were placed on the deck of the Tomtec Quadra 
96 workstation. The Tomtec Quadra 96 workstation was programmed as such so that the 
whole process ran in a sequence of tip loading, extraction, washing, and desorption. The 
sample extraction and desorption process was accomplished through repeated aspirating 
and dispensing of sample solution and desorption solvent, respectively (Figure 3-2D). 
After sample extraction and desorption, the plate was either directly injected to the 














Figure 3-2 (A) In-tip SPME fiber module of 96 tips with capillary tubing inside each 
pipette tip; (B) In-tip SPME fibers coated with Oasis HLB poly(EDMA) monoliths in 96 




3.2.6 Standards and Sample Preparation  
 
 Stock standard solutions for MK-0974 and d5-ISTD were prepared at 
concentrations of 200 µM. A series of MK-0974 working standard solutions at 
concentrations of 5, 10, 20, 200, 800, 2000, 4000, and 5000 nM were diluted from the 
stock standard. A working d5-ISTD standard solution was prepared similarly by diluting 
the 200 µM stock solution to 800 nM. A solvent of ACN/water (50:50, v/v) was used for 
standard preparation and dilution. The standards were prepared and used at room 
temperature and were stored at 4oC. A stock solution for QC samples of MK-0974 was 
prepared separately by the same procedure using a separate weighing. QC samples were 
prepared by diluting the QC working solution with human control plasma to obtain the 
corresponding QC samples containing 15, 400, and 4000 nM of MK-0974. The QC 
samples were divided into 500µL aliquots in 12×75mm conical polypropylene tubes with 
caps (Sarstedt, NC, USA) and stored at -70 oC; clinical samples were stored under 
identical conditions.  
 For MK-0974 in-tip SPME preparation, 200 µL of 0.1 M acetic acid was added to 
50 µL of control plasma, QC, and clinical samples in a 2-mL 96-well plate. 50 µL of 
working standard was added to control plasma and 50 μL of 50% ACN/water to the 
single blank, QC, and plasma samples, or 100 μL to the double blank to balance the total 
volume with 50 μL of internal standard working solution in each well, except double 
blank.  The plate was sealed with mat and vortex-mixed 10 minutes before in-tip SPME 
processing on Tomtec Quadra 96 Workstation. The steps in the sample extraction 
procedure are:  Precondition Oasis HLB polymer monolith in-tip SPME fibers with 2×50 
µL of ACN followed by 2×50 µL of water; aspirate and dispense 100 µL of plasma 
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sample 20 times for extraction; wash in-tip SPME fibers with 2×50 µL water followed by 
aspirate and dispense 10 times in a 1.2 mL 96-well collection plate with 100 µL of ACN 
for desportion; Dry the collection plate completely under nitrogen at 20 to 40oC and 
reconstituted the residue into 120 µL of 50% ACN and injected 15 µL to LC-MS/MS 
system.  
 Standards and sample preparation for MK-0533 as well as in-tip SPME 
procedures have been described previously in Chapter 2. 
 
3.3 Results and Discussion 
 
3.3.1 Preparation of Polymer Monolith In-tip SPME Fibers 
 
 The focus of this work was to develop a simple, flexible, low-cost, and 
reproducible procedure for the preparation of in-tip SPME fibers with polymer monoliths 
using photo-polymerization technique. A model system based on published research 
work112-114 has been selected and modified with EDMA as a cross-linker, DMPA as an 
initiator, and 1-decanol as a porogenic solvent. The optimization procedures that affect 
polymer morphology, such as compositions of the cross-linkers and the types of porogens, 
as well as polymerization time were evaluated. Factors that could impact extraction 
efficiency such as fiber thickness and coating volumes, as well as chromatographic beads 
or sorbents immobilized by the polymer monoliths were also investigated. 
   Unlike polymer monoliths in chromatographic applications where the monoliths 
must have low flow resistance, engineering pressure drop is not a major concern in 
developing polymer monolith in-tip SPME fibers when capillary tubing is applied to form 
a flow channel through the monolithic materials. This unique way of preparing in-tip 
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SPME fibers distinguishes themselves from other tip-based micro extraction devices in 
such that extraction is non-exhaustive and the mechanism of extraction is based on the 
adsorption of analyte to the surface of the polymer monoliths. An extraction phase with 
large surface area to volume ratio will greatly enhance the sensitivity of SPME method 
and thus becomes one of the main objectives in in-tip SPME fibers preparation. Based on 
many previous studies on polymer monoliths, it has been found that the character of the 
porogenic solvent, the concentration of cross-linkers, and the ratio between total 
monomer to total porogen have a direct impact on the porous properties of the polymer 
monoliths, and the percentage of initiator should not exceed 1 wt% of the total 
polymerization mixture.115  
Porogens play a critical role in obtaining the desirable porous structure without   
changing the rigidity of the polymer monoliths. The mechanism of pore formation using 
porogens is based on the solubility of the porogenic solvents to the final polymer. During 
the polymerization process, the polymer chains are formed initially in a homogenous 
solution and precipitated immediately when they become insoluble in the reaction 
medium depending on the types of porogenic solvents used. If the porogenic solvent is a 
thermodynamically "good" solvent for the final polymer, then the phase separation occurs 
later and the pores will be smaller.116-118 A variety of solvents including methanol, 
propanol-2, 1-decanol, ethyl ether, and THF were evaluated to prepare in-tip polymer 
monoliths with same amount of cross-linker and 1wt% initiator. For EDMA, all solvents 
yielded a white solid porous monolith except that THF formed a transparent solid, which 
indicated the formation of an extremely small pore structure and, as a result, the capillary 
tubing was difficult to withdraw from the pipette tips without breaking the final polymer. 
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The percentage of EDMA was adjusted from 30% to 70% in order to evaluate its impact 
to porous properties and chemical composition of the monoliths. Because of the early 
formation of highly cross-linked microglobules, an increase in percentage of cross-linker 
could result in decrease in average pore size,116 Therefore, it was expected that the 
extraction efficiency would be increased due to increase of the surface area. As shown in 
Figure 3-3, the analyte relative abundance increased slightly when the percentage of 
EDMA increased from 30 to 60 %, and the relative abundance increased dramatically 
when the EDMA reached 70%. However, the biggest challenge at such a high 
concentration of EDMA was to pull out the capillary tubing from the pipette tips. This 
problem was encountered as before when THF was used as the porogenic solvent. The 
final compositions of the polymer mixture (EDMA : 1-decanol, 40:60 w/w) were selected 
based on the formation of rigid monoliths with large surface areas and, in the meantime, 
the capillary tubing could be easily withdrawn from the pipette tips without breaking the 
final monolithic materials. SEM images in Figures 3-4A, 3-4B and 3-4C illustrate the 


















Figure 3-3  Dependence of cross-linker (EDMA) percentage on extraction efficiency 
using MK-0974 as a model compound at a concentration of 2000 nM spiked in human 
control plasma. SPME procedure is described in the experimental section. Error bars 
represent %RSD of five extractions using five different fibers. 
 
 
Both thermal and UV-initiated polymerization can be used for polymer monoliths. 
Typically, thermally-initiated polymerization uses AIBN as initiator and the 
polymerization takes a longer time, about 24 h.119 In contrast, the UV-initiated 
polymerization process is usually performed at room temperature and can be 
accomplished within a few minutes.120 As a commonly used initiator, DMPA was 
selected in the current study. It was found that the polymerization conversion was 
achieved within 5 minutes by observation of the polymerization mixture in pipette tips 
changing from clear solution to dense liquid and, finally, to white solid; complete 
conversion was achieved in 10 minutes. Photo-polymerization time from 10 to 30 
minutes was tested (Figure 3-5A) and resulted in comparable analyte recoveries. This 
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indicated that longer photo-polymerization time did not impact the porous properties of 
the monoliths and the polymerization conversion was complete.  Thus, 10 minutes was 
applied throughout all future experiments. The thickness of polymer monoliths could be 
adjusted by using capillary tubing with different diameters. Three different sizes of 
capillary tubing with diameters of 0.01", 0.02", and 0.03" were tested during polymer 
monoliths preparation. As shown in Figure 3-5B, there was an apparent linear 
relationship between the observed analyte recovery and the size of the capillary tubing, 
with about 20% on average. However, because of the limited dimensions of the pipette 
tips, it was not feasible to use capillary tubing with a diameter larger than 0.03". The 
increased extraction recovery was mainly due to the larger surface area obtained from 
using the larger diameter capillary tubing when same amount of polymerization mixture 
was aspirated to the pipette tips, although the in-tip SPME fiber thickness was larger with 
0.01" than with 0.03" capillary tubing. The capillary tubing with diameter of 0.02" was 
selected for in-tip SPME fibers preparation because the inter-fiber reproducibility was 
much better than that using 0.03" and it was much easier to handle when the capillary 
tubing was withdrawn from the pipette tips. The loading volume of the polymerization 
mixture was also evaluated and the extraction recovery increased substantially when the 
volume of the polymerization mixture aspirated to the pipette tips increased from 5 µL to 
15 µL (Figure 3-5C), which provided an alternative option to increase assay sensitivity, if 
needed. One of the favorable features of polymer monoliths is that they could be used as 
a medium to entrap chromatographic beads or sorbents in the photo-polymerization 
process for analyte separation and extraction. Oasis HLB sorbent with a particle size of 
60 µm was thoroughly blended with EDMA/DMPA/1-decanol mixture and the extraction 
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recovery was evaluated at different ratios between the volume of polymerization mixture 
and the amount of Oasis HLB particles. Figure 3-5D demonstrates that the extraction 
recovery almost doubled when Oasis HLB particles were immobilized within the 
polymer monoliths in a ratio of 1 mg of particle / 4 µL of mixture. Oasis HLB in-tip 
SPME fibers were used in MK-0974 assay validation and sample analysis in order to 
make a direct comparison between in-tip SPME and SPE approaches as the clinical assay 
was developed using Oasis HLB (5 mg) µElution SPE plates.121 
 
  
Figure 3-4  SEM images of in-tip SPME fiber coated with poly(EDMA) monoliths 
with surface morphology using magnification = 4000 × in (A) EDMA (40%); (B) EDMA 













































































Figure 3-5 Evaluation of polymerization time (A): 10, 20, and 30 minutes; capillary 
size (B): 0.01', 0.02', and 0.03'; polymer mixture loading size (C): 5, 10, and 15 µL; and 
Oasis HLB amount (D): 0, 0.5, and 1 mg on extraction efficiency for MK-0974 at 2000 
nM spiked in human control plasma. SPME procedure is described in the experimental 
section. Error bars represent %RSD of five extractions using five different fibers. 
 
During polymer monolith in-tip SPME fibers preparation, it was important that 
the 96 pipette tips with polymerization mixture aspirated to the sharp end of the tips  and 
received uniform illumination from the UV lamps; therefore, the lamps were placed right 
below the sharp ends of the pipette tips at a distance about 5 cm without any angle.  It 
was very difficult to line up the capillary tubing right in the middle of each tip; this is 
illustrated in Figure 3-6 where capillary tubing was withdrawn from the pipette tips after 
photo-polymerization. It is seen very clearly that the positions of the flow channels 
created from the capillary tubing were random. However, the relative standard deviations 
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(R.S.D.) from each measurement using the five different in-tip SPME fibers shown in 
Figures 3-3 and 3-5 ranged from 8 to 16%, which demonstrated that the position factor 
might contribute to the variations of the measurements, but did not affect the overall 
performance of the fibers. This was further verified from the inter-fiber reproducibility 
experiments. The flexibility of the capillary tubing positions in pipette tips made the 
whole preparation process quick and easy. Compared with the preparation procedure for 
polymer monolith in-tip SPME fibers using homogeneous polymerization mixture of 
EDMA/DMPA/1-decanol, it was a big challenge to prepare fibers with a slurry mixture 
such as Oasis HLB particles blended with EDMA/DMPA/1-decanol. The sample plate 
containing the slurry polymerization mixture needs to be vortex-mixed thoroughly before 
aspirating to the pipette tips and this mixture transfer step must be performed very 
quickly so that the Oasis HLB particles are distributed homogeneously across the 




Figure 3-6 SEM images of cross-sections of three different in-tip SPME fibers coated 
with poly(EDMA) monoliths using magnification 40 ×. 
 
 
3.3.2 Performance of Polymer Monolith In-tip SPME Fibers 
 
The evaluation of the performance of the polymer monolith in-tip SPME fibers 
mainly focused on fiber to fiber reproducibility, extraction efficiency, and matrix effects, 
fiber carry-over, and pre-treatment. 
 Considering the small volume of the extraction phase in SPME, obtaining high 
fiber to fiber reproducibility is challenging for in-house tailor-made and commercial 
devices. It would be ideal to ensure excellent fiber reproducibility as many factors can 
contribute to the extraction variability using SPME. Fiber to fiber reproducibility 
becomes less of an issue during quantitative SPME method development when an 
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internal standard compensates for differences between individual fibers. 96 polymer 
monolith in-tip SPME fibers were simultaneously evaluated by performing an extraction 
of the test compound (MK-0974) at 2000 nM in human plasma with 5 aspiration/dispense 
cycles. The absolute analyte response and the accuracy of each measurement are shown 
in Figure 3-7. The relative standard deviation (R.S.D.) of the absolute peak areas from 96 
fibers was 15.4%, but the accuracy results were excellent with a R.S.D. of 5.6% when 
isotopic labeled internal standard was applied. The utilization of automation to prepare 
polymer monolith in-tip SPME fibers greatly improved the inter-fiber reproducibility as 
well as sample throughput since the Tomtec Workstation could aspirate equal amounts of 
polymerization mixture to the 96 pipette tips at the same time with good precision. 
According to previous studies,112, 122 similar tip-based micro-extraction devices were 
made based on capillary force and, therefore, it was difficult to control the total volume 
of polymerization mixture in each individual pipette tip. The major contributing factor to 
the variability of the in-tip SPME fibers was the thickness differences of the monolith 
coatings due to the variable positions of the capillary tubing in the pipette tips, although a 
number of other factors could have contributed to this variability as well.  
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Figure 3-7 Distributions of absolute peak area and accuracy of MK-0974 extracted 
from 96 Oasis HLB polymer monolith in-tip SPME fibers at concentration of 2000 nM 
spiked in human control plasma.  
 
 
One of the disadvantages of the SPME technique is the relatively low extraction 
efficiency compared with other types of extraction methods such as LLE and SPE. In 
most cases, the absolute recovery is normally less than 1% and this could be problematic 
in SPME assay development if sensitivity is an issue. According to SPME fundamental 
principles, the amount of analyte extracted by SPME is proportional to the volume of the 
extraction phase, and sensitivity of the SPME methods could be improved by an increase 
in the volume of the extraction phase. In this study, the absolute extraction recovery for 
MK-0974 was about 20% determined at three different concentrations. Although it was 
impossible to make direct comparisons of fiber coatings between polymer monolith in-tip 
SPME fibers and other traditional fibers with coating dimensions of 1 cm coating length 
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and 10-100 µm coating thickness, it was believed that the total surface area of polymer 
monoliths was much larger than those of traditional fibers due to the inner surface area of 
the flow channel as well as outer surface area of the polymer monoliths because the 
polymer materials were physically attached to the surface of the pipette tips allowing 
sample solutions to flow through both sides during aspiration/dispense procedure. In 
addition, the homogeneous distribution of Oasis HLB particles in polymer monolithic 
materials enhanced the weak intermolecular interactions and hydrophobic interactions 
between analytes and extraction sorbent, which improved extraction efficiency of in-tip 
SPME fibers over other traditional SPME fibers.   
 Matrix effects must be considered during any SPME quantitative bioanalytical 
assays development and validation especially when the fibers are directly immersed into 
biological matrix for sample extraction. The matrix effects, which are defined as 
interference from matrix components that are unrelated to the analyte, could cause 
significant errors in precision and accuracy of the SPME-LC-MS/MS assays. Because of 
the equilibrium extraction characteristics of the much smaller volume of sorbent, SPME 
is often considered as a sample preparation technique which provides sample clean-up as 
effective or better than SPE with no or minimal matrix effects because the absolute 
amounts of analytes of interests as well as potential interferences extracted by SPME are 
much smaller. However, this conception was not supported in the evaluation of matrix 
effects using different SPME coatings including Oasis HLB polymer monolith, PDMS-
DVB, C18, and C30 phase coated SPME fibers in our other study [unpublished data]. It 
was found that SPME was less effective at removing phospholipids, a major cause of 
matrix effects, than LLE and SPE regardless of the types of coatings when SPME was 
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performed at equilibrium in biological fluids. The explanation to this phenomenon was 
that, unlike LLE and SPE methods, SPME combines sampling, sample clean-up, and pre-
concentration into a single step, such that SPME fibers are not "washed" to remove the 
loosely bound species such as phospholipids co-extracted in the sample preparation 
process. In MK-0974 in-tip SPME method validation, matrix enhancement/suppression 
of ionization was evaluated by comparing the absolute peak areas (n=5 at each 
concentration) of post-spiked plasma samples to that of neat standard at the same 
concentration, and the absolute matrix effects90 were about 89%. In contrast, in a 
different method using Oasis HLB (5 mg) µElution SPE plate, no ion 
suppression/enhancement was observed with absolute matrix effect values close to 100%.  
 Compared with other extraction methods, SPME is relatively simple and can be 
done at a low cost mainly because SPME fibers could be used many times. However, the 
advantage has, also, its limitations as carry-over effects occur very easily in SPME 
methods because of the repeated use of one single fiber. Additional efforts are often 
necessary to handle this problem, which will reduce the speed of the whole sample 
preparation process. A detailed investigation of carry-over effects was performed to 
evaluate if the fibers could be used repeatedly during method development. It should be 
pointed out that carry-over is also compound dependent. In the current study when MK-
0974 was used as the model compound, it was found that carry-over effects could be 
controlled within 2% by using a high percentage of organic solvent such as ACN (>90%) 
in the desorption solvent (1 mL) and increasing desorption time (>40 cycles of 
aspiration/dispense); fibers could be used repeatedly at least five times without any loss 
in fiber performance. To eliminate carry-over effects in high throughput quantitative 
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biological analysis using SPME, fibers should be used only once. Fiber pre-conditioning 
is a necessary step in most SPME assays in order to ensure the best performance of the 
fibers, in general, this essential step will add up approximately 30 minutes to sample 
extraction and may not be acceptable for routine sample analysis. For polymer monolith 
in-tip SPME fibers, pre-conditioning could be achieved in less than one minute by 2 
aspiration/dispense cycles with 50 µL of 50% ACN or methanol.  
   
3.3.3 In-tip SPME Procedures 
 
Analyte extraction using automated in-tip SPME was accomplished by repeatedly 
aspirating and dispensing sample solution through pipette tips utilizing an automation 
system such as Tomtec Workstation, and equilibrium could be established between the 
SPME phase and the analyte extracted after a certain number of aspirate/dispense cycles. 
During in-tip SPME procedures, several important factors need to be considered 
including extraction and desorption time, sample and desorption volume, extraction speed, 
as well as tip positions, which could all impact the outcome of the automation process.  
  It is desirable to perform extraction at equilibrium in SPME to reach maximum 
sensitivity. The types of fibers and the thickness of the coatings, the properties of the 
analytes, and the agitation speed could all contribute to the time to reach equilibrium and, 
in many cases, this process could be extremely long. In this study, it was found that the 
extraction equilibrium was reached after nearly 60-min (720 cycles) for MK-0533 in 
plasma samples, while for MK-0974, although equilibrium was achieved under the tested 
conditions, the extraction recovery was increased from 7% to 38% when 
aspiration/dispense cycles changed from 5 to 320 cycles. Results from this and recent 
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studies in our laboratory both demonstrate that automated SPME could be used without 
impacting precision with pre-equilibrium extraction time as long as sufficient time was 
allowed to establish uniform agitation.78  Unlike exhaustive sample preparation methods, 
the amount of analyte extracted at equilibrium using SPME is dependent on sample 
volume, and an increase in sample volume will lead to a non-linear increase in the 
amount extracted. However, this trend was not obvious in the extraction of MK-0974 
using polymer monolith in-tip SPME when sample volume was tested at 25, 50, and 100 
µL, respectively. The relative recovery of the analyte was approximately constant and 
independent of the sample volume; this was properly due to the short pre-equilibrium 
sampling times. The utilization of different volumes of desorption solvent did not make 
any differences to the release of the analyte from the polymer monolith sorbent and, 
therefore, it was better to use as little organic solvent as possible. Because it was difficult 
to handle very small volumes using instruments such as the Tomtec workstation, it was 
recommended to use a volume above 50 µL during aspirate and dispense cycles for in-tip 
SPME approach. 
 Besides the aspiration/dispense volume and cycle, the aspiration and dispense 
speed is another parameter that can be evaluated and optimized with the Tomtec Quadra 
96 workstation. Three aspiration and dispense speeds are available, from low (speed 1), 
to medium (speed 2), to high (speed 3). Three different PDMS-DVB fibers were used at 
three different well locations for each speed while other parameters were constant such as 
aspiration volume and cycles. In this experiment, aspiration and dispense speed was 
maintained equally and no combinations were tested, such as aspiration at speed 1 and 
dispense at speed 2, etc. It was found that there were no major differences between the 
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different speeds, with % C.V. from 10.4 to 13.1% (Figure 3-8). Since high speed is 
relatively faster than medium and low speed in terms of shortened extraction and 
desorption time, high speed is selected for future experiments.  In addition, higher flow 
velocities generated during rapid draw/eject cycles facilitates more rapid diffusion of the 
analytes into the fiber coating; thereby reducing equilibration time.   
 
 
Figure 3-8 In-tip SPME extraction speed profile. Conditions: in-tip SPME was 
performed in accordance to the method outlined in the experimental section. Three in-tip 
SPME fibers were extracted simultaneously at three different wells with 




The tip position of in-tip SPME fibers within wells of a 96-well plate was not as 
critical as that reported in the literature when different extraction phase geometries of 
SPME were applied in parallel fiber automation.65,78 This was very obvious as in either 
the thin film or blade approach, the SPME fibers had to be immersed completely into the 
sample solution to make sure uniform contact between the coating surface and sample 
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solution while the sample plate was agitated at a moderate speed, normally 850 rpm to 
avoid a splashed solution. In in-tip SPME, extraction was accomplished by repeated 
aspirating and dispensing of sample solution through pipette tips, and the tip position was 
very flexible as long as sample solution could be completely aspirated and dispensed. The 
relative standard deviation in analyte extraction and desorption was largely based on the 
performance of the automation system. However, because of the viscosity of blood and 
plasma sample, in addition to diluting the biological sample with water, it is suggested 
that the tips be lowered to the bottom of the well during aspiration and raised to the top of 
the well after aspiration so that the sample solution could be completely dispensed into 
the well plate before the next cycle. It might be helpful to aspirate an air gap of 50 µL 
before and after sample solutions, to expel all sample residues from the pipette tips.  
 
3.3.4 Applications of Drug Analysis 
 
A sensitive and selective SPME-LC-MS/MS method using Oasis HLB polymer 
monolith in-tip SPME fibers was developed and validated to determine MK-0974 in 
human plasma over the concentration range of 5-5000 nM. Assessment of the intraday 
variability of the method was conducted in five different lots of human control plasma 
spiked with MK-0974. The resulting method precision and accuracy data are presented in 
Table 3-1. The intraday precisions (%C.V.) was 13.0% at LLOQ, and was equal to or 
lower than 7.2% at all other concentrations used for the construction of the calibration 
curve. Method accuracy was found to be within ±4.3% of the nominal concentration for 
all the standards evaluated. The correlation coefficient for the mean standard curves 
constructed from five different lots of human plasma was 0.9996. The selectivity of the 
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assay was assessed in six different lots of human control plasma and no interfering peak 
was observed in the retention time window of MK-0974 and the internal standard at the 
conditions specified in the experimental section. In addition, no “cross-talk” was 
observed between MS channels used for monitoring MK-0974 and the internal standard.  
Extraction recovery and matrix effects were evaluated at nominal concentrations of 5, 
200, and 5000 nM for MK-0974 and working concentration of 800 nM for internal 
standard and the results are listed in Table 3-2. Recovery of the extraction was 
determined by comparing the absolute peak areas (n= 5 at each concentration) of pre-
spiked analyte to that of post-spiked analyte, and the mean recoveries were 20.2% and 
17.5% for MK-0974 and internal standard, respectively. Although slight ion-suppression 
was observed in "absolute" matrix effects determination, the precision of standard line 
slopes in five different lots of human plasma expressed as coefficient of variation C.V.% 
did not exceed 3%, which indicated that the in-tip SPME method could be considered 
practically free from the "relative" matrix effect liability.123 The stability of MK-0974 and 
its internal standard was also investigated in human plasma and the influence of freeze-
thaw cycles were examined by processing a set of QC samples at concentrations of 15, 
400, and 4000 nM. The results are shown in Table 3-3. In all cases, the results for the 
samples that were subjected to additional freeze-thaw cycles were within ± 4% of the 
nominal value. 
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Table 3-1 Intraday Precision and Accuracy Data for the Determination of MK-0974 in 














5 4.99 13.0 99.8 
10 9.82 5.3 98.2 
20 20.86 7.2 104.3 
200 202.72 4.0 101.4 
800 790.32 5.6 98.8 
2000 1950.14 3.0 97.5 
4000 3975.98 3.7 99.4 
5000 5030.71 3.4 100.6 
 
a  Mean concentrations calculated from the weighted linear least-squares regression 
 curve constructed using all five replicate values at each concentration. 
b  Expressed as coefficient of variation (C.V.%) of peak height ratios. 
c  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100%. 
  
 
Table 3-2  Extraction Recovery and Assessment of the “Absolute” Matrix Effects During 




Concentration  (nM) 
% Extraction 
Recovery b % Matrix Effects 
c 
5 19.2 (12.0) 94.8 (5.9) 
200 19.7 (10.7) 84.9 (2.1) 
5000 21.6 (5.5) 88.0 (7.4) 
Mean 20.2 (6.3) 89.2 (5.7) 
d5-ISTD 






a Determined in 5 different lots of control human serum 
b Extraction recovery was calculated by dividing the mean peak area of 
analyte spiked before extraction by the respective mean peak area of  analyte 
spiked after extraction and multiplying by 100. 
  c Matrix effect was calculated by dividing the mean peak area of an analyte  
  spiked after extraction by the mean peak area of the neat analyte standard  
  and multiplying by 100. 
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Mean Determined  
Conc. (nM)  





After 3 F/T (n=5) 
Accuracyb 
(%) 
15 14.4 (3.7) 96.2     15.6 (4.7) 103.7 
400 398.8 (2.8) 99.7   410.3 (3.1) 102.6 
4000 3736.6 (1.6) 93.4 3848.3 (4.7) 96.2 
a Numbers in parentheses are coefficients of variation (%CV). 
b Expressed as [(mean determined concentration)/(nominal concentration)] × 100%. 
 
 
Since an assay validation has been performed in Chapter 2 for MK-0533 using 
PDMS-DVB SPME fibers, assessment of the intraday variability of the automated in-tip 
SPME approach was only conducted in three different lots of acidified human control 
plasma over the concentration range of 5 to 2000 ng/mL of MK-0533. The resulting 
method precision and accuracy data is presented in Table 3-4. The intra-day precision 
was 13.7% at LLOQ, and was equal to or lower than 9.1% at all other concentrations 
used for the construction of the calibration curve.  Method accuracy was found to be 
within ±8% of the nominal concentration for all the standards evaluated. The correlation 
coefficient for the mean standard curves constructed from three different lots of acidified 
human plasma was 0.9957. 
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Table 3-4 Intraday Precision and Accuracy Data for the Determination of MK-0533 














5 4.73 13.7 94.5 
10 10.72 9.1 107.2 
50 52.78 1.0 105.6 
100 97.13 5.1 97.1 
200 211.75 4.2 105.9 
500 510.50 3.5 102.2 
1000 948.25 2.4 94.8 
2000 1825.00 2.0 91.3 
 
a  Mean concentrations calculated from the weighted linear least-squares regression 
 curve constructed using all three triplicate values at each concentration. 
b  Expressed as coefficient of variation (C.V.%) of peak area ratios. 




A LC-MS/MS assay using Oasis HLB (5 mg) µElution plates was originally 
developed and validated for the determination of MK-0974 in human plasma. A detailed 
comparison of sample preparation procedure between SPE and in-tip SPME methods was 
illustrated in Figure 3-9. In-tip SPME clearly demonstrated its advantages of simple, fast 
and utilization of less organic solvent, let alone the extreme low cost compared with 
µElution SPE plates. In addition, in-tip SPME approach using Oasis HLB polymer 
monolith achieved similar intraday precision and accuracy as that from SPE method, and 
this was shown in Figure 3-10 where the relative deviations from nominal concentrations 
obtained from the five-curve validation of two different methods were overlapped across 
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Figure 3-9 Comparison of SPE assay using Oasis HLB µPlate and in-tip SPME assay 



























Figure 3-10 Comparison of in-tip SPME and SPE methods with relative deviations 
from nominal concentrations in five curve validations and QC samples using different 
lots of plasma. 
 
 
The SPE method has been implemented in sample analysis up to phase three 
clinical studies with several thousands of samples already  analyzed. In order to compare 
the clinical data obtained using SPE versus in-tip SPME technique; clinical samples from 
several post-dose subjects were pooled and re-analyzed using both approaches. Individual 
and mean concentration-time profiles from three different subjects after oral 
administrated of 400 mg of MK-0974 obtained from two methods are presented in Figure 
3-11, and individual and mean pharmacokinetic parameters such as AUC0-∞, AUC0-last, 
Cmax, Tmax and apparent half-life (t1/2) are reported in Table 3-5. The two data sets 
obtained from two different sample preparation methods are in good agreement, clearly 
demonstrating that in-SPME could be used as an alterative approach for multiple sample 




























































































Figure 3-11 Individual and mean plasma concentration-time profiles of MK-0974 
following oral administration of 400 mg MK-0974 in healthy subjects obtained from SPE 




It is important and challenging to develop a simple, low-cost, and reproducible 
procedure to prepare SPME coatings that could be used for high throughput drug analysis. 
The overall data from this study demonstrated that using in-tip SPME coated with 
polymer monoliths through photo-polymerization was a feasible approach with variation 
of the absolute peak areas from 96 fibers at 15.4%, and accuracy of 5.6% when 
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isotopic labeled internal standard was applied for the extraction of a drug compound from human plasma. Many factors, such as the 
compositions of the cross-linkers and porogens, polymerization time, and fiber thickness could impact the performance of the polymer 
monolith in-tip SPME fibers. The advantages of polymer monoliths fibers are: (i) simple and easy to fabricate at a low-cost, (ii) 
enhanced extraction recovery and (iii) no carry-over effects if used as disposable fibers. In addition, the SPME method selectivity 




Table 3-5 Individual and Mean MK-0974 Plasma Pharmacokinetic Parameters Following Administration of Single Oral Doses of 400 


























1 15581 15899 15483 15807 5560 5410 1.0 1.0 6.7 6.3 0.98 0.98 1.03 
2 14201 12981 14089 12809 6105 4745 1.3 1.0 10.5 15.0 1.09 1.10 1.29 
3 24317 21018 24121 20960 8107 6310 0.7 1.3 10.2 7.2 1.16 1.15 1.28 
AM 18033 16633 17898 16525 6591 5488 1.0 1.1 8.8 8.2 1.08 1.08 1.20 
SD 5486 4068 5434 4123 1341 786 0.3 0.2 2.6 3.1 0.09 0.09 0.15 




Applications of In-tip SPME (Part I):  
Quantitative LC-MS/MS Determination of Vitamin D3 in Human 
Serum with Derivatization: A Comparison of In-tube LLE,  
96-well Plate LLE and In-tip SPME 
 
 
4.1 Preamble and Introduction 
4.1.1 Preamble 
 This chapter has been accepted for publication in Journal of Chromatography B 




 It is well known that vitamin D plays a critical role in the control of calcium and 
phosphate metabolism in the human body by increasing calcium absorption in the 
intestines, mobilizing calcium from bone, and decreasing its renal excretion. In humans, 
there are two sources of vitamin D: dietary ergocalciferol (vitamin D2), derived from 
ergosterol in plants, and cholecalciferol (vitamin D3, I) generated in the skin from 7-
dehydrocholesterol by the action of ultraviolet irradiation. Vitamin D3 has no biological 
activity, but is converted to the biologically active metabolite, 25-hydroxyvitamin D3 
(calcifediol) by oxidation in the liver, and this metabolite then is further converted to a 
series of other metabolites of varying activity in the kidney, the most of which is 1α,25-
dihydroxyvitamin D3 (calcitriol). The biosynthesis of vitamin D is illustrated in Figure 4-
1. 
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 Determinations of vitamin D3 and its metabolites at relatively high concentrations 
(≥ 2 ng/mL) have been reported in the literature.124-129 These methods were mostly based 
on HPLC with ultraviolet (UV) detection, a highly complex sample preparation 
procedure, and were all potentially non-selective in the presence of metabolites and 
related compounds present in serum samples. For example, Holick et al. 130,131 used a 
LLE followed by SPE and HPLC with UV detection to quantitate vitamin D3 in human 
serum following oral doses of 12.5 mg or greater. The precision of this method was 19% 
at the claimed LLOQ of 2 ng/mL, with poor and variable recovery (50-70%). 
        The development and validation of reliable quantification methods for vitamin D3 in 
clinical samples at low sub-nanogram concentrations (0.1 – 1 ng/mL) using a small 
volume of serum is difficult and has not been described in the literature. Concentrations 
of vitamin D3 after microgram (μg) doses to human subjects are very low (≤0.5 – 5 
ng/mL), and the determination of I in the presence of a number of metabolites circulating 
in human biofluids exhibiting similar chemical and HPLC behavior as the parent 
compound may be highly non-selective. In addition, both I and metabolites are 
potentially unstable in the presence of UV light and elevated temperatures.132  
         Similarly to the determination of the majority of drugs, metabolites, and variety of 
other analytes in complex matrices, the HPLC with MS/MS detection has proven to be a 
powerful tool for the analysis of vitamin D related compounds in biological samples. 
Atmospheric pressure ionization methods, such as electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI) were used for structural identification 
by tandem mass spectrometry of vitamin D metabolites in biological fluids at relatively 
low concentrations and facilitated their quantification.133-136 However, because vitamin 
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D3 and its metabolites have no easily ionizable polar functional groups in their molecules, 
the ionization efficiency of these compounds using either ESI or APCI is very limited, 
and the required sensitivity for trace determination of these compounds in biological 
fluids is difficult to achieve.  
       In recent years, a variety of analogs and metabolites of I have been derivatized with 
dienophiles to form a Diels-Alder cycloaddition products.137,138 Higashi et al., 139-141 for 
example, described the determination of vitamin D3 metabolites in plasma based on 
chemical derivatization. When reacted with 4-substituted 1,2,4-triazoline-3,5-dione 
(TAD) type compounds (dienophiles, Cookson reagents)), the s-cis-diene moiety of  the 
hydroxyvitamin D3 analogs rapidly and quantitatively reacts with the derivatizing reagent 
to form Diels-Alder cyclo-addition products. The sensitivity of detection of metabolites 
of I increased dramatically after the introduction of the high proton-affinity atoms from 
these dienophilic reagents. For example, the derivatives of 25-(OH)D3 with 4-(4-
nitrophenyl)-1,2,4-triazoline-3,5-dione (NP-TAD) provided 30-fold higher sensitivity of 
detection compared to an underivatized compound in the negative ionization mode using 
APCI. Although many applications have focused on identification and determination of 
vitamin D3 metabolites, quantitative and selective analytical methods for the 
determination of vitamin D3 by HPLC-MS/MS after derivatization with dienophiles 
directly in human plasma or serum at sub-nanogram/mL concentrations were not 
developed and described in the literature. The development of new, more sensitive, 
selective, reliable, and high throughput methods for the quantitative determination of 
vitamin D3  was required to meet the high demand for pharmacokinetic (PK) data in 
support of clinical studies at very low (μg) oral doses of vitamin D3.  For this purpose, in 
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our studies, the reaction between I and a dienophile, 4-phenyl-1,2,4-triazoline-3,5-dione 
(P-TAD), was utilized. This reaction was never used for the development of quantitative 
methods for I in plasma or serum.  
 In order to map out the concentration-time profile following a single low oral 
dose of 70 µg of vitamin D3 to human subjects, a method (method A) based on chemical 
derivatization of I with P-TAD after conventional tube LLE, and HPLC with MS/MS 
detection has been initially developed and validated in our laboratory. This method 
required processing 1 mL of serum and achieved the LLOQ of 0.5 ng/mL. However, the 
method had a relatively low sample throughput due to the labor intensive and time-
consuming sample preparation steps required. Later, a higher throughput, highly sensitive 
and selective HPLC-MS/MS method B was also developed. In method B, both the LLE 
and derivatization of vitamin D3 and its stable isotope-labeled internal standard (D6-I, IS, 
II) were both performed in the 96-well plate format. This method required only 0.4 mL 
of serum for processing and achieved the same LLOQ (0.5 ng/mL) as in method A. As 
part of a series of studies conducted in our laboratory to explore the SPME technique in 
high throughput drug analysis, we developed a new approach of using in-tip SPME19 in 
96-well format for determination of various drugs in biofluids. Compared with traditional 
extraction methods such as LLE and SPE, SPME has the advantage because of its 
simplicity and solvent-less characteristic. In order to further demonstrate the feasibility of 
using the in-tip SPME approach in high throughput clinical sample analysis and to 
explore the potential advantages and limitations of SPME technique in routine 
bioanalysis, we developed another method for the quantification of vitamin D3 in human 
serum using in-tip SPME (method C) followed by chemical derivatization of I and the IS 
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(II) with P-TAD requiring only 0.1 mL of human serum, but with a higher LLOQ of 5 
ng/mL. In all three methods, the derivatives formed (III and IV, respectively) were 
determined using HPLC-MS/MS in the positive ionization mode. Head-to-head 
comparisons were made among three different methods including precision and accuracy, 
sample throughput, recovery, and matrix effects, and the advantages and limitations of 


















































4.2.1 Materials  
 
  Vitamin D3 (I) was purchased from Sigma Chemical Company (St. Louis, MO, 
USA), and its deuterated internal standard (D6-I, II) was synthesized at Merck Research 
Laboratories (Rahway, NJ, USA). A reference compound V and its deuterated internal 
standard (D8-V) were also synthesized at Merck Research Laboratories. All solvents were 
HPLC or analytical grade and were purchased from Fisher Scientific (Fair Lawn, NJ, 
USA). The derivatizing reagent (4-phenyl-1,2,4-triazoline-3,5-dione; P-TAD), EDMA 
and DMPA  were purchased from Aldrich Chemical Company (Milwaukee, WI, USA). 
Ammonium acetate (HPLC grade) purchased from J.T. Baker (Phillipsburg, NJ, USA), 
formic acid (95%) and 1-decanol obtained from Sigma (Milwaukee, WI, USA) was used 
as received. Oasis HLB with particle size 60 µm was obtained from Waters (Milford, MA, 
USA). Deionized water was obtained by passing in-house water through a Millipore 
Milli-Q plus system (Bedford, MA, USA). Nitrogen (99.999%) was supplied by West 
Point Cryogenics (West Point, PA, USA). 96-Well collection plates (1.2 and 2.4 mL) and 
mats were purchased from Marsh Biomedical (Rochester, NY, USA). Different lots of 
human control serum were obtained from Biological Specialties Corp. (Lansdale, PA, 




 A Perkin-Elmer (Norwalk, CT, USA) binary 250 pump and a Varian (Palo Alto, 
CA, USA) ProStar 96-well plate autosampler were used in this work. The 
chromatographic separation of analytes was performed on a Phenomenex Synergi Polar-
 101
RP column (50 × 2 mm, 4 μm) with a 0.5 μm in-line filter. Mobile phase consisted of 
methanol (MeOH):10 mM ammonium acetate (88:12, v/v) and was pumped at a flow rate 
of 0.3 mL/min. The total run time was 5 minutes. Two mL of MeOH was used as a 
washing solvent for needle and flow path cleaning of the autosampler after each injection. 
 An Applied Biosystems-Sciex API 3000 triple quadruple mass spectrometer 
(Foster City, CA, USA) equipped with a heated nebulizer (HN) source operating in the 
positive ionization mode was used for all HPLC-MS/MS analysis. MRM was utilized for 
quantification. In HN experiments, the heated nebulizer probe temperature was 
maintained at 400 oC, and the nebulizing gas (air) pressure was set at 80 psi. The settings 
for the curtain and collision gases were 8 and 4 psi on the API 3000 mass spectrometer, 
respectively. 
 
4.2.3 Preparation of Standard Solutions and QC Samples 
 
 A stock solution of I (100 μg/mL) was prepared in methanol. This stock solution 
was further diluted with methanol to give a series of working standards with 
concentrations of 0.005, 0.01, 0.025, 0.05, 0.1, 0.15, and 0.25 μg/mL. The internal 
standard (II) was also prepared as a stock solution (100 μg/mL) in methanol. A working 
standard solution of 0.1 μg/mL of II, prepared by diluting stock solution with methanol, 
was used for serum samples analyses. All standard solutions were stored at 4oC.  
 A stock solution for QC samples of I was prepared separately by the same 
procedure using a separate weighing. QC samples were prepared by diluting the QC 
working solution with human control serum. QC samples at three concentrations (Low 
QC, Middle QC, and High QC) were used to evaluate assay precision and accuracy.  All 
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QC samples were divided into 1.25 mL aliquots in separate cryo tubes and stored at –20 
oC until analysis. 
A stock solution of reference compound V (10 μg/mL) was prepared in 50% ACN 
in water (v/v). Working standards were obtained by further dilution of the stock solution 
of V with 20% ACN in water (v/v). The internal standard (D8-V) was also prepared as a 
stock solution (10 μg/mL) in 50% ACN in water (v/v). A working standard solution of 
100 ng/mL of D8-V, prepared by diluting stock solution with 50% ACN in water (v/v), 
was used for all measurements. All standard solutions were stored at 4oC.  The purpose of 
preparing standard solution V and D8-V was to determine Cσ  and α in an empirical 
model to evaluate the effect of an ion-current ratio on measurement precision.  
Because of light sensitivity, all standard preparation and sample extractions were 
performed under yellow light.  
 
4.2.4 Sample Processing 
 
4.2.4.1 In-tube LLE (Method A) 
 
 Standards, QC, and subject serum samples were thawed at room temperature. One 
mL serum samples were basified with pH 9.8 (1 mL) carbonate buffer, then extracted 
twice with 7 mL MTBE using 15 mL conical disposable glass tubes. The tubes were 
placed in a dry ice/acetone bath until the aqueous layer froze. The organic extracts were 
manually transferred to a clean 15 mL centrifuge tube and were evaporated to dryness 
under heated N2 stream. The dried residue was reacted with 0.2 mL of derivatizing agent, 
P-TAD (0.25 mg/mL in ACN) for 30 minutes. Upon completion of the reaction, the 
excess of P-TAD was reacted with 0.5 mL of methanol. The mixture was dried under 
 103
heated N2 stream and reconstituted in 150 μL of mobile phase. Fifteen μL of this solution 
was injected into the HPLC-MS/MS system. Serum standards were prepared the same 
way as serum samples by adding 100 μL of each working standard and 100 μL internal 
standard to 1 mL of human control serum. The resulting serum standard concentrations 
ranged from 0.5 to 25 ng/mL. 
 
4.2.4.2 96-well Plate LLE (Method B) 
 
 Standards and QC serum samples were thawed at room temperature. A 400 μL 
aliquots of subject or control serum samples were added individually into a 2 mL deep 
96-well plate followed by 40 μL of 50 % of methanol in water (v/v). 40 μL of the internal 
standard solution was added to each well, except to the well designated for the double 
blank serum. The plate containing samples was placed onto a Tomtec Quadra 96 
workstation (Hamden, CT, USA) for liquid transfer. After transferring 50 μL of 0.2 M 
sodium carbonate buffer solution (pH = 11) and 1.28 mL of MTBE by Tomtec 
workstation, the plate was sealed with mat made of molded PTFE/silicone liner and was 
roto-mixed for LLE. The plate was then centrifuged and the top organic layer was 
aspirated and dispensed by Tomtec workstation into a 1.2 mL 96-well collection plate. 
The serum samples were extracted again with 1.28 mL of MTBE. The organic extract 
was evaporated to dryness under heated N2 stream. The dried residue was reacted with 
0.2 mL of derivatizing agent, P-TAD (0.125 mg/mL in ACN) for 30 minutes. Upon 
completion of the reaction, the excess of P-TAD was reacted with 0.2 mL of methanol. 
The mixture was dried under heated N2 stream and reconstituted in 150 μL of mobile 
phase. Fifteen 15 μL of this solution was injected into the HPLC-MS/MS system. 
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4.2.4.3 In-tip SPME (Method C) 
 
Preparation of In-tip SPME Fibers 
 
 A detailed preparation procedure has been described previously.142 
SPME Conditions 
 
 Standard and QC serum samples were thawed at room temperature. 100 μL of 
subject serum samples were added individually into a 2.4 mL deep 96-well plate spiked 
with 100 μL of methanol:water (50:50, v/v). Standard curve samples were prepared by 
spiking 100 μL of appropriate standard into 100 μL of human control serum. Internal 
standard solution (100 μL) was added to each well of the plate. After adding 50 µL of 0.2 
M sodium carbonate buffer solution (pH = 11) to all wells on the plate, the plate was 
sealed with mat made of molded PTFE/silicone line and vortex-mixed thoroughly on a 
VWR multi-tube vortexer for 2 minutes. In-tip SPME extraction and desorption process 
was fully automated on a Tomtec Quadra 96 workstation (Hamden, CT, USA). Briefly, 
in-tip SPME fibers in 96-well format were loaded at position 1 (tip plate) on the deck of 
the Tomtec Quadra 96 workstation. Washing solvent, water, and 5% methanol (5% 
methanol : 95% water, v:v) reservoirs were placed at position 2 and 3, and eluting solvent 
methanol was at position 4, respectively. An empty 1.2 mL deep 96-well plate was placed 
at position 5 for desorption. The mat was carefully removed from the 2.4mL sample plate 
and the plate was placed at position 6 for extraction. The Tomtec Quadra 96 workstation 
was programmed as follows: after tips were picked up and washed subsequently with 50 
µL of methanol and 50 µL of water, 300 µL of the solution containing serum was 
repeatedly aspirated and dispensed for 40 minutes from extraction plate at position 6. 
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When extraction was completed, in-tip SPME fibers were washed once with 50 µL of  
water and 10% methanol, respectively, then 50 µL (twice) of methanol was aspirated 
from methanol reservoir with 50 µL air gap and dispensed into the empty 1.2 mL 
desorption plate. The 1.2 mL deep 96-well plate was evaporated to dryness under heated 
N2 stream and the dried residue was reacted with 0.2 mL of derivatizing agent, P-TAD 
(0.125 mg/mL in ACN) for 30 minutes. Upon completion of the reaction, the excess of P-
TAD was reacted with 0.2 mL of methanol. The mixture was dried under heated N2 
stream, reconstituted in 150 μL of mobile phase and 15 μL was injected into the HPLC-
MS/MS system. 
 
4.2.5 Validation Procedures 
 
4.2.5.1 Precision and Accuracy 
 
 The precision of the method was determined by the replicate analysis (n = 5) of I 
in five different sources of human serum at all concentrations utilized for the construction 
of calibration curves. The linearity of each calibration curve was confirmed by plotting 
the peak height ratio of the derivatized drug (III) to the derivatized internal standard (IV) 
vs. drug concentration. Calibration curve calculations were made by subtracting the mean 
peak height ratio of derivatized drug (III)/derivatized IS (IV) of triplicate analysis of the 
control blank serum samples used for the construction of standard lines from the 
respective peak height ratios of each standard concentration. The unknown sample 
concentrations were calculated from the equation y = mx + b, as determined by weighted 
(1/x) linear regression of the standard line. The accuracy of the method was determined 
as the percentage between the mean concentration observed and the nominal 
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concentration. The intra-day accuracy was required to be within ±15% at all 
concentrations. The precision, expressed by the coefficient of variation (%C.V.), was 




 The selectivity of the method was confirmed by processing control drug-free 
human serum samples from six different sources to determine whether endogenous peaks 
interfered at the mass transitions chosen for the derivatized analyte and/or the internal 
standard. In addition, the “cross-talk” between MS channels used for monitoring the 
analyte and the internal standard was evaluated.   
 
4.2.5.3 Recovery and Matrix Effects 
 
 Extraction recovery for I and II was evaluated using standards spiked at three 
concentrations of analytes. Recovery was determined by comparing the absolute peak 
heights of the standards in control human serum extracted and derivatized according to 
the described sample processing procedures to control serum extracted in the same 
manner and then spiked post extraction with the analytes and derivatized. Matrix 
enhancement/suppression of the ionization or "absolute" matrix effect was evaluated by 
comparing the absolute peak heights of the standards in post spiked extraction samples to 
neat derivatized standards injected directly in the same reconstitution solvent. Since a 
stable isotope labeled internal standard was used, a potential “relative” matrix effect on 
ionization should not have any adverse effect on the quantitation of I in different serum 
lots. This was evaluated and confirmed by the determination of slopes of the calibration 
curves in five different lots of control serum as suggested in the literature.123 
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4.3 Results and Discussion 
 
4.3.1 Derivatization of Vitamin D3 and Optimization of MS/MS Conditions 
 
Vitamin D3 (I) that is formed from cholesterol by opening the B-ring of the 
secosteroid, is generated in the skin from 7-dehydrocholesterol under UV radiation 
(Figure 4-1). Therefore, it is necessary to evaluate the potential interference from 7-
dehydrocholesterol in the determination of I in human serum. Initially, an attempt was 
made to develop a method based on the MS/MS detection of underivatized I using both 
TISP and HN interfaces. As illustrated in Figure 4-2A, an intense MS/MS response for a 
neat standard of I was observed when precursor and product ion pair at m/z 385  367 
was monitored. However, this response was significantly higher (~5x) when the same 
amount of I was extracted from the control serum. Two additional peaks, which were 
separated from I, were also detected in the same MS/MS channel as for I (Figure 4-2B). 
To separate the interference peak which caused the enhancement of I as well as other 
endogenous serum impurities, further experiments were conducted using more selective 
chromatographic conditions.  Under these HPLC conditions, I was separated from a large 
interference peak (Figure 4-3) and other interferences detected at the same MS/MS 
channel as I.  However, due to a long (10.5 min.) retention time of I (k’=25) a significant 
peak broadening was observed decreasing the sensitivity of detection. The interference 
peak was further identified as 7-dehydrocholesterol, which had the same molecular 
weight as vitamin D3 and fragmented to the same product ion (m/z 367).  
The MS/MS detection of underivatized I was also attempted using APPI interface.  
Similarly as in the case of TISP and HN interfaces, a strong MS/MS response for neat 
standard (Figure 4-4A) of I was observed.  However, when serum extracts containing I 
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were analyzed under the same conditions, a large number of interfering peaks were 
observed at the same MS/MS channel as used for monitoring I. The chromatograms of 
serum extract presented in Figures 4-4B and 4-4C illustrate how non-selective MS/MS 
detection can be. In spite of the utilization of the MS/MS detection, a large number of 
interfering compounds possessing the same MS/MS ions as the compound of interest are 
present. The need for an efficient chromatographic separation in such cases cannot be 
overemphasized. In order to improve the sensitivity and selectivity of detection and 
potentially produce a precursor → product ion pair that was distinguishable from 7-
dehydrocholesterol, it was decided to evaluate derivatization of I. 
 As reported in the literature, because a cisoid diene system is a feature common to 
most vitamin D related compounds; all these compounds may react with dienophilic 
reagents such as triazolinediones to form Diels-Alder cycloaddition products at room 
temperature. These derivatized products will greatly enhance the sensitivity of their 
MS/MS detection. At the same time, these derivatives may also distinguish themselves 
from other interferences due to a significant increase in the molecular mass and their 
detection in the higher mass range together with a different fragmentation in the ion 
source. A variety of analogs and metabolites of vitamin D compounds have been 
derivatized with different triazolinediones,143, 144 including P-TAD, and these 
derivatization reactions were used predominantly for the qualitative assessment and 
structural confirmation of the presence of metabolites and/or analogs. An analog of I was 
quantified in plasma using an electron- capture derivatization reagent PFB-TADO, a 
pentafluorobenzyl (PFB) analog of P-TAD, and the potential for derivatization of I with 
this reagent was discussed.144 However, the reaction with PFB-TAD and/or with P-TAD 
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Figure 4-2 Representative chromatograms of 20 ng/mL neat standard of I (A) and a 
human control serum extract (B) monitored at m/z 385 → 367, using MeOH:water 
































































Figure 4-3 Representative chromatograms of 40 ng/mL neat standard of I (A), a 
human control serum extract (B), and human control serum spiked with 20 ng/mL of I 
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Figure 4-4 Representative chromatograms of 0.5 ng/mL neat standard of I (A), a 
human control serum extract (B), and human control serum spiked with 10 ng/mL of I 






In MS/MS infusion experiments, MeOH-free methylene chloride was chosen as 
the reaction solvent, as P-TAD is very sensitive to air and moisture. One µg/mL of the P-
TAD-vitamin D3 derivative was prepared as follows: a P-TAD solution (0.29 M) in 
methylene chloride was reacted at room temperatue with 0.1 M of I also in methylene 
chloride at 1:1 molar ratio. The reaction was stopped by adding water and the post-
reaction mixture was extracted with methylene chloride. The organic extract was 
evaporated to dryness and the residue was reconstituted in methanol. I, II, and the 
biological precursor 7-dehydrocholestrol were successfully derivatized (Figure 4-5). The 
derivatized I was detected in the positive ionization mode using a heated nebulizer probe 
and a major product ion at m/z 298 was observed. The same experiment was performed 
using 7-dehydrocholesterol, however, a fragment ion at m/z 298 was not observed. 
Therefore, MRM transition at m/z 560  298 was selected for selective quantification of 
I (Figure 4-6). The different fragmentation pattern between the derivatized I (III) and 7-
dehydrocholesterol demonstrated that the derivatization enhanced not only sensitivity but 
also selectivity of the determination of I. Precursor – product ion at m/z 566  298 was 
chosen for the derivatized internal standard (IV). Optimization of source and MS 
parameters were obtained by infusing neat solutions of the synthesized derivatives at a 
flow rate of 20 μL/min into a mobile phase pumped at 0.5 mL/min using the heated 
nebulizer interface at 400oC. 
 It is important to note that during derivatization of the human serum extracts, an 
excess concentration of the P-TAD reagent is provided since many endogenous 
components may be co-extracted and may consume the P-TAD reagent affecting the 
derivatization yield of an analyte of interest and the sensitivity and reliability of the 
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Figure 4-5 Derivatization of vitamin-D3 (I) and D6-I (II) with P-TAD and the 
formation of P-TAD-vitamin-D3 (III) and P-TAD-D6-vitamin D3 (IV) 
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 +MS2 (560.30) CE (21): 0.251 to 0.620 min from Sample 13 (Dscan P-VitD-After Opti-MM3) of 29-... Max. 4.5e5 cps. 
































 +MS2 (566.40) CE (21): 0.419 min from Sample 3 (Dscan FIA 10 ng Ptad d6-Vit D3-1) of 17-Dec-2... Max. 1.8e6 cps.






















































Figure 4-6 The product ion mass spectra of the protonated molecules of P-TAD-
vitamin-D3 (III, chromatogram A) and P-TAD-D6-vitamin D3 (IV, chromatogram B) 
derivatives (M+H)+, m/z = 560 and 566, respectively, under the optimized MS/MS 
conditions used in the assay. 
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4.3.2 Automated In-tip SPME Method Evaluation and Optimization 
 
 As an innovative technique that allows the integration of sampling and extraction 
in a single step, SPME has the advantages of (1) less solvent used, (2) easy handling, (3) 
little equipment needed, and (4) faster speed of analysis. However, the technique has not 
yet been accepted as an alternative approach for quantitative determination of analytes in 
pharmaceutical bioanalysis for many reasons. First of all, because of the fiber and in-tube 
configurations, SPME suffers from low-throughput and lack of automation which limits 
its application in analysis of a large number of similar samples. Secondly, as pointed out 
by Ulrich,62 there are some major disadvantages of SPME that include longer desorption 
time, carry over effects due to repeated use of the same fiber, and the method being prone 
to errors due to considerably lower recovery in comparison with more classical extraction 
methods. These issues have not been completely addressed and resolved since SPME 
invention.  
 In the current study, a simple, flexible, low-cost, and reproducible procedure for 
the preparation of in-tip SPME fibers with polymer monoliths using photo-
polymerization technique was developed. The porous polymers have many advantages 
including the simplicity of their fabrication and the wide range of chemistries for 
reactions. More importantly, the relative large surface areas of polymer monolith in-tip 
SPME fibers dramatically increase the absolute extraction recoveries (up to 30%) while 
in general, the recoveries reported for SPME are considerably lower (<1%). In addition, 
in-tip SPME is very easily coupled with commercially available liquid handling systems 
for automated sample preparation without introducing any additional equipment while 
maintaining its simplicity. 
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Factors that were involved in fiber fabrication included concentration of the 
initiator, total monomer to total porogen ratio, porogen type, and optimized 
photopolymerization time. The optimized reagent composition of 40 wt% of EGDMA 
and 60 wt% of 1-decanol with 1 wt% of DPA was obtained for preparing monolith in 
terms of rigidity and homogeneity. The scanning electron microscopy (SEM) 
micrographs of the monolithic structure indicated that the UV irradiation time of 10 
minutes was sufficient of initiating monolithic polymerization of the solution in the tips.  
For the SPME automation to be successful in parallel extraction format, good 
reproducibility of the amount of analyte extracted by different fibers is necessary. In this 
study, 96 in-tip SPME fibers were fabricated at the same time by photopolymerization 
using a Tomtec Quadra 96 workstation. Fiber-to-fiber reproducibility was found to be 
within %C.V. of 15.4% using absolute peak area counts of a standard analyte. However, 
the precision increased significantly to 5.6% C.V. with the use of a stable isotope labeled 
internal standard that was extracted simultaneously with the analyte. This indicated that 
the inter fiber reproducibility is not critical in quantitative analysis in terms of accuracy 
and precision as long as an internal standard is able to compensate for the inter fiber 
variability in extraction capacity.  
 During in-tip SPME method development, parameters such fiber coating, sample 
volume, extraction conditions (pH or ionic strength), extraction and desorption time, 
desorption solvents, and calibration methods were thoroughly investigated. For in-tip 
SPME, samples were aspirated/dispensed across the solid phase media and the extraction 
equilibrium was accomplished through multiple aspirate/dispense cycles. Unlike 
conventional SPME methods, where agitation is a big issue, especially in automated 
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SPME-LC, the uniformity of agitation could be easily achieved for in-tip SPME using an 
automated liquid handling system such as the Tomtec Workstation. Extraction conditions 
were based on those from LLE and serum sample volume was chosen at 100 μL. In order 
to achieve the maximum recovery in a reasonable period of time, 480 cycles was chosen 
which required about 40 minutes. Because of the small monolithic bed volume of the in-
tip SPME fiber, extracted analytes could be released efficiently from the extraction 
sorbent with minimal elution volume. An elution scheme of 2×50 µL of solvent was 
sufficient for the quantitative release of analytes. Carryover effect was eliminated as 
polymer monolith in-tip SPME fibers were used as disposable.   
 
4.3.3 Methods Validation 
 
 Method A and B were validated in human serum in the concentration range of 0.5 
to 25 ng/mL of I, whereas the in-tip SPME method was validated in the concentration 
trange of 5 to 250 ng/mL. The assessment of the intraday variability of each method was 
conducted in five different lots of human control serum spiked with I. The resulting 
method precision and accuracy data is presented in Table 4-1. For the in-tube LLE 
method A, the intra-day precisions (%C.V.) was 2.8% at LLOQ, and was equal to or 
lower than 6.0% at all other concentrations used for the construction of the calibration 
curve. Method A accuracy was found to be within ± 2% of the nominal concentration for 
all the standards evaluated. In 96-well plate LLE method B, the intra-day precisions 
(%C.V.) was 5.9% at LLOQ, and was equal to or lower than 5.2% at all other 
concentrations used for the construction of the calibration curve. Method accuracy was 
found to be within ± 3% of the nominal concentration for all standards evaluated. In in-
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tip SPME method C, the intra-day precisions (%C.V.) was 10.9% at LLOQ, and was 
equal to or lower than 8.7% at all other concentrations used for the construction of the 
calibration curve. Method accuracy was found to be within ± 8% of the nominal 
concentration at all standards concentrations evaluated. The correlation coefficient for the 
mean standard curves constructed from five different lots of human serum was 0.9997, 
0.9996, and 0.9980 for methods A, B, and C, respectively. 
 
Table 4-1 Intraday Precision and Accuracy Data for the Determination of Vitamin 
D3 in Five Different Lots of Human Control Serum Using In-tube LLE (Method A), 96-
well Plate LLE (Method B), and In-tip SPME (Method C), respectively 
 
Accuracy (%) a  
[%C.V.] (n= 5) 
Accuracy (%) a  
[%C.V.] (n= 5) 
Accuracy (%) a  
[%C.V.] (n= 5) Nominal Conc. 





0.5 100.0 [2.8] 102.0 [5.9] 5 103.6 [10.9] 
1 100.0 [2.4] 97.3 [4.2] 10 99.2 [8.7] 
2.5 98.8 [6.0] 100.6 [5.2] 25 100.4 [5.6] 
5 101.6 [3.5] 99.8 [1.6] 50 92.8 [2.8] 
10 99.1 [0.9] 101.2 [2.3] 100 101.3 [2.2] 
15 99.7 [3.0] 98.9 [2.2] 150 104.8 [3.2] 
25 100.3 [2.0] 100..2 [3.1] 250 98.0 [6.4] 
 





 Assessment of the selectivity of the method is critical and needs to be confirmed 
in the presence of in-vivo metabolites of the analyte. Some metabolites may be converted 
to parent drug during sample preparation and/or undergo partial fragmentation in the ion 
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source at high temperatures giving the same molecular ion as for the parent drug. The 
major metabolites 25-hydroxyvitamin D3 and 1, 25-dihydroxyvitamin D3 of I were 
evaluated for the “cross-talk” in channels used for monitoring both I and the internal 
standard. No interference or “cross-talk” from these metabolites was observed. In 
addition, the “cross-talk” between channels used for monitoring both I and the internal 
standard was evaluated by the analysis of standard samples containing individual 
compounds separately at the concentrations of 25 and 10 ng/mL for I and internal 
standard, respectively, and monitoring the response in other MS/MS channel used for 
quantification. No response was observed in the channel of the other analytes at their 
retention times. Also, no interference or “cross-talk” was observed from these 
compounds in the channels used for monitoring derivatized I and the internal standard 
(III and IV, respectively). Figure 7 shows the representative extracted ion 
chromatograms obtained from human control serum blank (Figure 4-7(1a) and 4-7(1b)), 
human control serum spiked with 10 ng/mL of II (Figure 4-7(2a) and 4-7(2b)), human 
control serum spiked with 0.5 ng/mL of I and 10ng/mL of II (Figure 4-7(3a)  and 4-
7(3b)), and human control serum spiked only with 40 ng/mL of I (Figure 4-7(4a) and 4-
7(4b)). No “cross-talk” between channels used for the determination of I and II was 
observed. The small peak (<10% of the LLOQ) in the channel used for monitoring 
derivative III in blank serum sample was due to the endogenous I present in the serum 
sample. In clinical samples, when necessary and if present in pre-dose human serum in 
any quantifiable concentrations, this endogenous peak was subtracted from the total 













































































































(1a) P-TAD-Vitamin D3 (III), 0 ng/mL 
(1b) P-TAD-d6-Vitamin D3 (IV) 0 ng/mL 
(2a) P-TAD-Vitamin D3 (III) 0 ng/mL 

















































Vitamin D3  (IV) 
10 ng/mL 


















(4a) P-TAD-Vitamin D3  (III) 40 ng/mL 
 
 
Figure 4-7 Representative chromatograms of human control serum obtained by 
multiple reaction monitoring at m/z 560 → 298 for derivatized vitamin D3 and m/z 566 
→298 for derivatized D6-vitamin D3 using 96-well plate LLE 
 
 
4.3.5 Recovery and Assessment of the Matrix Effects 
 
 Extraction recovery and the effect of the serum matrix on ionization and 
derivatization efficiency was evaluated for I and the internal standard using standards 
spiked at concentrations of 0.5, 10, and 25 ng/mL for I, and at 10 ng/mL for II  in both 
methods A and B. In method C, this evaluation was performed at concentrations of 5, 100, 
and 250 ng/mL for I, and 100 ng/mL for II. Recoveries were determined by comparing 
the peak height of standards spiked into three different lots of human control serum and 
extracted as per sample preparation to human control serum extracted in the same manner, 
then spiked post-extraction with a known amount of the drug. The mean recoveries of I 
and II were 82% and 84%, respectively, in method A; 69% and 63%, respectively, in 
method B, and 29% and 24%, respectively, in method C (Table 4-2). Recovery in all 
methods was consistent over the entire range of the standard curve indicating that 
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extraction of the analytes in each method was independent on the concentration. In order 
to assess the "absolute" matrix effect on the ionization and derivatization process, the 
absolute peak heights of control human serum samples extracted and then spiked with a 
known amount of analytes and derivatized were compared to neat standards derivatized 
and injected directly in the same solvent. Results are shown in Table 4-2. Considering the 
experimental uncertainties, the "absolute" matrix effects in methods A and C were much 
less significant than those observed in method B with ion enhancement about 140%. 
However, the use of stable isotope labeled I as the internal standard fully compensated 
for any variation in matrix effect and/or recovery between different lots of human control 
serum. Therefore, an “absolute” matrix effect on ionization or any differences in 
derivatization efficiency of I and internal standard would not have any adverse effect on 
the precision and accuracy of any of the methods presented. The absence of a “relative” 
matrix effect89,90,123 on ionization and derivatization efficiency was confirmed by an 
examination of the slopes of the calibration curves that were constructed in five different 
lots of human control serum. The high precision of these slopes (1.3, 2.0, and 4.2% C.V.) 
in methods A, B, and C, respectively, confirms the absence of a “relative” matrix effect 
in all methods developed. 
 
4.3.6 Analyte Stability 
 
 Standard solution stability was confirmed for a period of 20 days when 
refrigerated. QC samples (n = 5 at each concentration) were subjected to three freeze-
thaw cycles consisting of a thaw to reach room temperature, then refreezing at –20 oC.  
These samples, together with a set (n = 5 at each concentration) of human QC samples 
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that were not subjected to additional freeze-thaw cycles, were then defrosted and 
analyzed.  In all cases, the results for the samples that were subjected to additional freeze-
thaw cycles were within ± 9% of the nominal value (Table 4-3). 
 
 
Table 4-2 Extraction Recovery and Assessment of the “Absolute” Matrix Effects 
During the Determination of Vitamin D3 and Internal Standard in Human Control Serum 










Method          A      B           C            A      B        C 
   
0.5 81    68          92   142 
5.0                                26                               121 
10.0 78    68   89   141 
25.0 88    70 89   145 
100                                31                               114 
250                                30                               110 
        Mean: 82    69           29 90   143      115 
            D6-I 
10.0 (II) 
 
84    63 
 
92   140 
        100   (II)                                24                               116 
 
a Determined in three different lots of control human serum 
b Extraction recovery was calculated by dividing the mean peak height of 
 analyte spiked before extraction by the respective mean peak height of 
 analyte spiked after extraction and multiplying by 100. 
  c Matrix effect was calculated by dividing the mean peak height of an analyte  
  spiked after extraction by the mean peak height of the neat analyte standard  




Table 4-3 Intra-day Analysis of Serum QC Samples Containing Vitamin D3   
 
In-tube LLE (Method A)  Low QC Middle QC High QC 
Nominal Conc. (ng/mL) 1.5 12.5 22.0 
Mean Calculated Conc. 
(ng/mL), n=5 
1.4 11.5 21.3 
Accuracy 
a
 (%) 96.0 92.0 96.8 
%C.V.
b  9.6 2.5 2.8 
96-well Plate LLE (Method B)  Low QC Middle QC High QC 
Nominal Conc. (ng/mL) 1.5 12.5 22.0 
Mean Calculated Conc. 
(ng/mL), n=5 
1.6 12.8 23.9 
Accuracy 
a
 (%) 103.6 102.0 108.4 
%C.V.
b  3.0 6.0 3.3 
In-tip SPME (Method C) Low QC Middle QC High QC 
Nominal Conc. (ng/mL) 15 125 220 
Mean Calculated Conc. 
(ng/mL), n=5 
16.0 132.0 237.0 
Accuracy 
a
 (%) 106.7 105.6 107.7 
%C.V.
b  4.4 7.0 5.8 
 
a  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100%. 






4.3.7 Methods Comparison 
 
The LLOQ of 0.5 ng/mL was achieved using both in-tube and 96-well plate LLE 
methods, however, in the 96-well plate LLE method, only 0.4 mL of human serum 
needed to be processed instead of 1 mL required in the in-tube LLE method. Both 
procedures were validated in the same concentration range of 0.5 - 25 ng/mL. In the in-
tip SPME method, the LLOQ was 5 ng/mL but only 0.1 mL of serum was required. The 
method C was validated in the concentration range of 5 to 250 ng/mL. The linearity of 
the calibration curves, intraday precision, and accuracy were satisfactory in all methods. 
Recoveries of analytes using in-tube LLE were above 80% compared to about 70% in the 
96-well plate LLE. The recoveries in both LLE methods were much higher than those 
from the in-tip SPME (~30%). However, the overall sample preparation time was 
decreased from 9 hours per 96 samples required in method A to about 3 hours in Method 
B and 2 hours in method C with much less labor efforts involved. The matrix effects in 
different human serum samples from the three methods were also examined. Since a 
stable isotope-labeled internal standard was used in all methods, a potential “relative” 
matrix effect on ionization was shown not to have any adverse effect on the quantitation 
of Vitamin D3 in different serum lots. Based on the excellent intra-day precision and 
accuracy results obtained in all methods that were obtained using five different lots of 
control human serum, any differences in the “absolute” matrix effect on ionization or any 
difference in derivatization efficiency did not have any significant effect on the precision, 
accuracy, and the reliability of the analysis. This was confirmed by the analysis of 
subjects’ samples using methods A and B. Both methods generated very similar 











































Figure 4-8 Concentration-time profile of vitamin D3 in serum of a healthy subject (A) 
after single-dose administration of 70 µg of vitamin D3 
 
   
Matthews et al 145 used standard models of noise to develop a method that 
evaluates ion-current ratio noise (i) that varies with the signal intensity and (ii) that is 
signal dependent. An empirical equation to predict the standard deviations of sample 



















tR σασ         (equation 1) 
where Tσ is the total variance of a mass spectrometric ion-current measurement and Cσ  
is the constant noise. R (R = Aa/Ab) is the measured ratio of two species, a and b. Aa and 
Ab are integrated peak areas for a and b, respectively, usually in arbitrary unit; ttl, ta, and tb 




normalization factor that accounts for the relationship between ions collected and the 
instrument-reported peak area. Among these terms in the above equation, Cσ and α are 
constants and can be determined from two or more points that satisfy the equation and the 
rest of the terms are either known or can be measured. Because Cσ and α are related to 
the noise contribution from signal dependent and constant noise sources, respectively, 
these constants can be applied to define the precision of an ion-current ratio measurement 
for the instrument and method used. These constants can also be used to predict the 
precision for other ratio measurements to be measured by the same system or to compare 
the performance of two different systems. 
 In order to compare the effect of signal intensity, ion-current ratio magnitude, and 
internal standard on the measurement precision in Methods A and B, a reference 
compound V and its deuterated internal standard (D8-V) were used to determine Cσ  and 
α. The ion-current integrated areas (Aa, Ab) and the ion-current ratio (R = Aa/Ab) were 
measured for the reference compound and its internal standard using the same Sciex API 
3000 mass spectrometer as used for the Vitamin D3 determination. Using equation 1, the 
following results were obtained, α = 1.02 × 104 and Cσ  = 2.88 ×10
-2. Both five 
calibration curves from validation runs in methods A and B were used to evaluate the 
effect of sample size (ion-current intensity, A) and ion-current ratio (R) on the precision 
of ion-current measurements. Representative plots from the in-tube LLE method A are 
shown in Figures 4-9 and 4-10. The values Cσ  and α obtained from the reference 
compound were used to calculate Tσ as a function of the ion-current ratio from the above 




and solid lines, respectively. If equation 1 accurately models the noise of the ion-current 
ratio measurement, then 68% of the points in Figures 6a and 6b should fall within 1 Tσ  
and 95% within 2 Tσ . Experimentally, in terms of the effect of ion-current ratio on the 
ion-current ratio precision, for method A, 71% of the data points lie within the 1 
Tσ contours and 93% lie within the 2 Tσ contours; while in method B, the corresponding 
numbers are 64% and 87%, respectively. In terms of the effect of ion-current intensity on 
the ion-current ratio precision for method A, 67% of the data points lie within the 1 
Tσ contours and 90% lie within the 2 Tσ contours while in method B, the similar numbers 
are 63% and 84%, respectively. The standard deviations predicted by the empirical 
equation are very close to standard deviations of samples measured experimentally in 
both methods during methods validation. However, in method A, relative error increases 
when R < 0.1 or R > 2.5, while in method B, the relative error increases when R < 0.25 or 
R > 2, which indicates that statistically, the possibilities of measurement errors are 
greater in the method B in comparison with method A. The lower recoveries of analytes 
and larger "absolute" matrix effect are due to relatively dirty extracts that could all make 
quantitation more prone to errors in method B than in method A. 
Although method C did not meet the assay sensitivity requirement for clinical 
sample analysis after dosing with 70 μg of I, the advantages of using SPME to support 
PK studies at higher doses of I were also evident. First of all, the procedure is simple and 
organic solvent consumption is far less than that of the two LLE, methods A and B. Less 
than 500 µL of solvent was used during the extraction and desorption process in method 
C, compared with more than 17 mL in method A and 2.56 mL in method B. Secondly, 




automated SPME process. Our studies further demonstrated that as an alternative 
approach for routine analysis of I, SPME is more suitable for PK studies when dose 
levels are relatively high and the concept of coupling the in-tip SPME with automated 
liquid handling system has proven to be a suitable direction for SPME automation in 






























Figure 4-9 Effect of ion-current ratio (R) on the ion-current ratio precision.  
The mean ratio for each sample was determined (Ravg, values displayed on the x-axis). 
The y-axis plots the relative deviation of each measurement from the mean value of each 
sample. The broken and solid lines are the theoretical 1 Tσ and 2 Tσ envelopes, 
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Figure 4-10 Effect of sample size (ion-current intensity) on the ion-current ratio 
precision. The x-axis shows the peak area of each sample. The y-axis plots the relative 
deviation of each measurement from the mean value of each sample. The broken and 





4.3.8 Clinical Sample Analysis 
 
 Both methods A and B were applied for the determination of I in more than 400 
serum samples from a clinical study in which healthy subject received single oral dose of 
70 µg of I. Inter-day precision and accuracy of the method for the clinical samples 
analysis were determined by analyzing QC samples at low, medium, and high 




for QC samples prepared before the analysis of the study samples, and for QC samples 
analyzed in replicate with the daily runs of clinical samples. The precision for daily runs 
(%C.V.) was less than 8.7% with accuracy ranging from 98.9-99.9%.  
 
 
Table 4-4  Inter-day Analysis of Serum QC Samples from a Clinical Study   
 


















































Accuracy a(%) 98.9 99.9 99.4 
%C.V. b 8.7 4.7 3.0 
 
a Expressed as [(mean calculated concentration)/(nominal concentration)] ×100%. 





 Selective and sensitive HPLC-MS/MS methods using in-tube LLE, 96-well plate 
LLE, and in-tip SPME with derivatization were developed and validated for the 
determination of vitamin D3 in human serum. The use of chemical derivatization was 
necessary to improve analyte ionization efficiency, detection selectivity, and assay 
sensitivity in the presence of biological matrix and in the presence of metabolites. Among 




consuming, provided better accuracy and precision than the 96-well plate LLE and in-tip 
SPME, and was chosen for the determination of vitamin D3 in human serum after dosing 
human subjects with low oral doses of 70 µg of vitamin D3. The 96-well plate LLE 
method B increased sample throughput and provided comparable assay accuracy, 
precision, and the same LLOQ (0.5 ng/mL) as Method A. Method B required lower 
sample volume (0.4 mL) in comparison with method A (1 mL). The in-tip SPME coupled 
with automated liquid handling system provided a new alternative  approach for high 
throughput routine drug analysis. For the first time, a simple, fast, and high throughput 
method was developed for preparing monolithic in-tip SPME fibers using 
photopolymerization. These disposable fiber tips completely eliminated the carryover 
effect and unnecessary pre-conditioning steps associated with the use of non-disposable 
fibers. The feasibility of using the automated SPME-HPLC-MSMS as an alternative 








Applications of In-tip SPME (Part II):  
HILIC-MS/MS for the Determination of Three Polar Compounds, 





One of the major recent fundamental advances in bioanalytical applications of 
SPME is the development of high throughput SPME using multi-well plate technology.64 
Traditionally, in bioanalytical analysis where LC is selected as the main separation 
technique due to the non-volatile and/or polar properties of the drug compounds, 
interfacing of LC and SPME has included such strategies as manual injection interface 
tees, in-tube SPME, and off-line desorption followed by a conventional liquid injection. 
Neither manual desorption interface or off-line desorption allows automated sample 
preparation as all of the SPME steps are performed manually with single or multiple 
fibers making it impractical to simultaneously process a large number of samples. In-tube 
SPME permits a high degree of automation using commercially available HPLC 
autosamplers, however, each sample is still processed serially resulting in low overall 
throughput.  An automated SPME system has been development recently by PAS 
Technology, which consists of a three-arm robotic autosampler that is fully controlled 
with Concept software and two orbital agitators. The system is capable of performing all 
sample preparation automatically including the addition of internal standard, multi-fiber 
SPME extraction and desorption with controlled agitation, solvent evaporation and 
reconstitution, as well as final sample injection. Some very promising results have been 




with method precision less than 14% and accuracy ranged from 91 to 114%;146 and more 
recently, an automated SPME-LC-MS/MS method for the analysis of four 
benzodiazepines in whole blood has been fully validated with a low limit of 
quantification (LLOQ) of 4 ng/mL.78 However, there are some major drawbacks of the 
system, large sample volume and desorption solvent (800-1000 µL) is required in order 
to achieve acceptable precision and accuracy due to the geometric design of the SPME 
multi-fiber device, the biggest advantage of solvent-less over other sample preparation 
methods is abandoned. In addition, the claimed high throughput is questionable when 
multiple plates are processed as sample extraction, desorption, and injection could not be 
performed simultaneously. A new concept of in-tip SPME has been introduced recently 
in the development of automated high throughput SPME methods in bioanalysis.142 The 
in-tip SPME technique takes the advantage of widely used commercially available 
automated liquid handling systems and couples the fiber SPME with the system in a 
unique configuration. In-tip SPME maintains the simplicity and advantages of traditional 
SPME approaches and is easily adopted for automation without introducing additional 
devices. More importantly, the approach is amenable to all fiber types possessing a wide 
range of different coating materials, which will overcome the drawback of limited 
selections of commercial available fibers and broaden its use with HPLC.      
Primaxin®, a combination of the carbapenem IMP and the renal dehydropeptidase 
inhibitor, CIL, has for many years been used as a potent antibacterial agent for the 
treatment of serious infections because of its broad spectrum of antimicrobial activity.147-
150  Unfortunately, Gram-negative pathogens that are resistant to all the beta-lactam 




emerged as an urgent problem in the hospital. One of the resistance mechanisms is the 
high-level expression of β-lactamase that inactivates β-lactam antibiotics by catalyzing 
the hydrolysis of the β-lactam amide bond to produce a ring-opened structure. MK-4698 
(BLI) is being developed as a novel, non-β-lactam, phosphonate-based β-lactamase 
inhibitor151 for combination with Primaxin to restore the activity of imipenem and 
increase coverage and efficacy against multi-drug resistant Gram-negative pathogens. 
The historical methods to analyze Primaxin® were reported as separate assays for the two 
analytes IMP and CIL, respectively. For IMP, several methods that have been reported 
are based on either microbiological assays152,153 which cannot differentiate IMP from 
other coadministered antibiotics, or HPLC with UV detection after either 
ultrafiltration154,155 using relatively large volume of samples, or, most recently, protein 
precipitation156,157 with limited dynamic ranges (≤ 100 fold). For CIL, HPLC methods 
that involved solid phase extraction using C18 cartridge, and then reversed-phase 
chromatography followed by either post-column derivatization for fluorescence 
detection158 or direct UV detection,159 have been described in determination of the 
analyte in biological fluid. The methods involved complex procedures or provided 
narrow dynamic ranges (≤ 100-fold) with ≥ 0.75 µg/mL limit of detection.  
In support of the β-lactamase inhibitor program, one of our objectives is to 
develop a fast and sensitive simultaneous assay for all three analytes – IMP, CIL, and 
BLI. Clearly, such a method is more desirable than the individual determination of each 
substance because of the low sample amount available in preclinical studies and 
timesaving analysis for fast data turn around. This paper describes a newly developed 




non-structurally related compounds – IMP, CIL, and BLI in biological fluids. In the 
meantime, the in-tip SPME assay is compared to a different sample preparation method 
using PPT in terms of assay sensitivity and selectivity, recovery and matrix effects, and 
the advantages and limitations of in-tip SPME for high throughput drug analysis in drug 
discovery environment are discussed.  
 
5.2 Experimental  
 
5.2.1 Chemicals and Materials 
 
IMP, CIL, MK-4698, and internal standards (ISa and Isb, Figure 5-1) were 
received from the Merck Research Laboratories, Merck & Co. (West Point, PA). HPLC 
grade ACN, laboratory grade formic acid (90%), and ammonium acetate were purchased 
from Fisher Scientific (Pittsburgh, PA, USA). Ethylene glycol, 2-(N-morpholino) 
ethanesulfonic (MES) acid, and MES sodium salt were obtained from Sigma-Aldrich 
(Milwaukee, WI, USA). Ethyl alcohol was purchased from Quantum Chemical 
Corporation (Tuscola, IL, USA). Control plasma (EDTA as anticoagulant) from Sprague 
Dawley rats was purchased from Bioreclamation Inc. (NY, USA). Mouse control blood 
was obtained from Merck Research laboratories. Water was purified by a Milli-Q ultra-
pure water system from Millipore (Bedford, MA, USA). PDMS-DVB fibers (60 µm) 




















































































Figure 5-1 Chemical Structures of IMP, CIL, BLI (MK-4698) and the internal 




 A HPLC micro pump (Series 200 from Perkin Elmer, Ontario, Canada) coupled 
with a 96-Well Plate Autosampler (HTS PAL System from Leap Technology, Carrboro, 
NC, USA) was used to perform the HPLC separation. A PE Sciex API 4000 triple-
quadrupole mass spectrometer (Sciex, Toronto, Canada) with a TIS interface ionization 
source operated in a positive ion mode was used to quantitate all analytes. The samples 
were analyzed on a Waters Atlantis HILIC Silica (50mm x 2.1mm, 3µ) column with a 
mobile phase composed of 15 mM ammonium formate (pH 3) in 80% ACN at a flow rate 




acquisition window which was open between 0.6 and 4 minutes after injection.  The 
column was maintained at room temperature and the autosampler was set at 5°C. The 
instrument settings were adjusted to maximize the response for the analytes and their 
internal standards, respectively, using analyte infusion in the presence of mobile phase. 
The ion pairs (precursor ion → product ion) selected for MRM, optimized declustering 
potential (DP), collision energy (CE), collision-cell exit potential (CXP), and entrance 
potential (EP) for each analyte are summarized in Table 5-1. A voltage of 4.5 kv was 
applied to the sprayer. The turbo gas temperature was 550°C and the auxiliary gas flow 
was 60 L/min. The flow settings of nebulizing gas (nitrogen), collision gas (nitrogen), 
and curtain gas (nitrogen) at the instrument were 40, 7 (CGT = 2x1015 molecules per cm2), 
and 45 L/min, respectively. The dwell time was 100 msec for each analyte and internal 
standard. Both Q1 and Q3 quadrupoles were set at unit resolution. Peak area ratios were 
calculated using Analyst software version 1.4. Calibration curves were obtained by 
weighed (1/x2) least squares linear regression of the peak area ratio of the analyte to the 
internal standard versus the nominal concentration (x) of analyte. The internal standard 
ISa was used for qualification of IMP and CIL and Isb was used for BLI. In-tip SPME 
extraction, desorption, and liquid transfer in PPT sample preparation was performed 





Table 5-1 Mass Spectrometry Conditions for IMP, CIL and BLI, Respectively 









IMP 300.2  142.0 53 36 12 10 
CIL 359.3  202.4 55 21 4 10 
BLI 570.1  236.2 91 55 6 10 
Internal Standard      
Isa 373.3  233.1 55 26 14 10 
ISb 587.2  236.0 86 55 6 10 
 
 
5.2.3 Preparation of Stabilizing Solution 
 
The stabilizing solution (traditional stabilizer) was prepared by combining 1M 
MES (pH 6.0) buffer with 50% ethylene glycol at 1:1 (v/v) ratio, while 1M MES was 
prepared by dissolving 10.88g MES acid (molecular weight = 195.2) and 9.62g MES 
sodium salt (molecular weight = 217.2) in a 100 mL mill-Q water, without pH adjustment. 
All study samples were treated with stabilizer and stored at -70°C before analysis. 
For mouse blood samples, the stabilizer was added at 1:1 (v/v) ratio to the unknown 
samples. For rat plasma samples, since an additional component, 50% acetonitrile, was 
necessary to stabilize BLI, the final treatment of sample was in the format of rat plasma 
sample: stabilizer: 50% acetonitrile at 1:1:1 (v/v/v) ratio.  
 
5.2.4 Preparation of Standards and QC Samples 
 
 Two stock solutions in ACN/water (50/50, v/v) for each of the analytes, IMP, CIL, 
and BLI, at 2 mg/mL were prepared from two separate weighing. One set of analyte stock 
solutions was used to prepare calibration standards, and the other set was used to make 




analyte, was prepared by mixing 250 µL from each primary standard stock of IMP, CIL, 
and BLI with 250 µL of Milli-Q water. Working standards were prepared by serial 
dilutions of the secondary standard stock with ACN/water (50/50, v/v), and stored in 
amber glass vials at 4°C. All solutions were used within three days after preparation, 
except for the primary stocks of MK-4698 and CIL which could be used for up to two 
weeks. An internal standard stock solution at 1 mg/mL in ACN/water (50/50, v/v) was 
prepared for ISa and Isb, respectively. The IS working solution including both ISa and 
Isb, was prepared either at 1 µg/mL in 50% ACN for in-tip SPME or at 250 ng/mL in 
100% ACN served as the protein precipitation solvent for PPT method. Due to stability 
issue, each control matrix (rat plasma and mouse blood) was mixed with an equal volume 
of stabilizer – 1 M MES (pH 6): 50% ethylene glycol = 1:1. 
 Rat plasma calibration standards were prepared daily by adding 25 μL of working 
standard and 50 μL of stabilizer-containing control plasma (equivalent to 25 µL control 
plasma and 25 µL stabilizer) to provide the final concentrations of IMP, CIL, and BLI at 
concentrations ranged from 0.5 to 100 µg/mL for in-tip SPME and 0.1 to 100 µg/mL for 
PPT. Mouse blood calibration standards were prepared daily by mixing 40 µL stabilizer-
containing control blood with 20 µL working standard solutions to provide the final 
concentrations of IMP, CIL, and BLI at concentrations ranging from 0.5 to 100 µg/mL 
for in-tip SPME and 0.1 to 100 µg/mL for PPT. 
 The QC samples for rat plasma or mouse blood were prepared and tested at each 
of the five concentrations: lowest, second lowest, mid-range, second highest, and the 
highest standards of IMP, CIL, and BLI in their corresponding matrixes containing 




and 1000 [10x upper limit of quantification (ULOQ) with <2% organic solvent in the 
final matrix] µg/mL, stored in a -70°C freezer for at least overnight, and then placed at 
room temperature for at least 4 hours before conducting stability tests. 
 
5.2.5 In-tip SPME 
 
Different types of coatings were used and compared including PDMS-DVB, C18 
and C30 phase silica-based coatings, and Oasis HLB-coated polymer monoliths. In-tip 
SPME extraction and desorption process for all experiments was fully automated using a 
Tomtec Quadra 96 workstation. The preparation of these in-tip SPME fibers and the 
detailed sample process procedures were described previously.142  
For rat plasma samples, since there is a special need for an extra stabilizer – 50% 
ACN right after sample collection, an aliquot of 75 µL stabilizer-treated rat sample 
(equivalent to 25 µL plasma with 25 µL stabilizer and 25 µL 50% acetonitrile) was 
transferred into a plate, without the addition of make-up solvent, (because the extra 
volume of 50% ACN in the sample matched the solvent volume for working standards in 
the calibration curve). The sample mixture was then vortex-mixed for about 1 minute and 
placed on the deck of a Tomtec Quadra 96 workstation for SPME preparation. The 
Tomtec Quadra 96 workstation was programmed as such that the whole process was 
running in a sequence of tip loading, extractions, washing, and desorption. The sample 
extraction and desorption process was accomplished through repeated aspiration and 
dispensing of the sample solution and desorption solvent (100% ACN), respectively. The 
total extraction time was about 40 minutes with 5 minutes desorption time. 15 µL of 




Mouse blood samples were prepared in a similar way as those of rat plasma 
samples except that 40 µL of samples (equivalent to 20 µL blood with 20 µL stabilizer) 
were transferred, due to the limited sample volume available. The blood samples were 





In PPT, for rat plasma samples, an aliquot of 75 µL stabilizer-treated rat samples 
was transferred into a plate, protein crashed with 250 µL of the IS working solution 
without making-up solvent, vortexed for ~3 minutes, and centrifuged at 10°C, 3500 rpm 
(2000 RCF, relative centrifugal force) for 5 minutes. A 10 µL supernatant was injected 
into LC-MS/MS system for analysis. For mouse blood, an aliquot of 40 µL stabilizer-
treated mouse samples was transferred and mixed with 20 µL ethanol and 20 µL 50% 
ACN (make-up volume to match standards) in each micro sample tube to allow for the 
complete dialysis of blood cells. A 250 µL of the IS working solution was then added to 
each sample mix for protein precipitation, followed by the same procedures for 
centrifugation and injection as indicated for rat plasma samples above. 
 
5.2.7 Post-column Infusion 
 
Post-column infusion experiments were conducted in this study to investigate 
matrix effects of phospholipids in rat plasma. The plasma supernatant solution was 
prepared by mixing pooled blank rat plasma with ACN in a ratio of 1:3 following 




in a 1:1 ratio. The analyte solution, prepared at a concentration of 1 µg/mL of IMP, CIL, 
and BLI in 50% ACN, was post-column infused from the syringe pump to the LC 
effluent at a flow rate of 60 µL/min. After the signals of the analyte MRM transitions 
were stable, the plasma supernatant solution (10 µL) containing phospholipids was 
injected onto the column at the same chromatographic conditions of the analytes and the 
analytes post-column infusion spectra were acquired. Phospholipids were detected with a 
positive precursor ion scan of m/z 184 which resulted in total ion chromatograms to 
qualitatively monitor all phospholipids in rat plasma. 
 
5.2.8 Method Validation (Precision, Accuracy, Stability, Recovery, and 
Matrix Effects) 
 
 The precisions of in-tip SPME and PPT methods were determined by using 
replicate analysis (n=5) of drug compounds in five different sources of rat plasma at all 
concentrations utilized for the construction of calibration curves. Due to limited sources 
of mouse blood, triplicate analysis (n=3) was performed in three pooled lots of mouse 
blood. The linearity of each calibration curve was confirmed by plotting the peak area 
ratio of the drug to internal standard versus drug concentration. The unknown sample 
concentrations were calculated from the equation y = slope*x + intercept, as determined 
by weighted (1/x2) linear regression of the standard curve. The accuracies of the methods 
were determined as the percentage between the mean concentrations observed and the 
nominal concentrations. The precision and accuracy of the methods as measured by the 
coefficient of variation (%CV) were required to be <20% at the concentrations 
determined. The intra-day accuracy and precision was determined by analyzing six 




range, second highest, and the highest standards. F-T and room temperature stabilities 
were evaluated jointly using QC samples (at low, high, and 10x high concentrations) that 
went through a freezing-and-thawing cycle with at least one overnight storage at –70°C 
and at least 4 h at room temperature. 
Extraction recovery and matrix effects were evaluated for IMP, CIL, and BLI in 
rat plasma. Recovery was determined by comparing the mean absolute peak areas of 
standards obtained from pre-spiked plasma samples prepared from different plasma 
sources to those from post-spiked plasma samples prepared in plasma from the same 
different sources. Matrix enhancement/suppression of ionization or "absolute" matrix 
effect was evaluated by comparing the absolute peak areas of the standards in post-spiked 
extraction samples to neat standards injected in the mobile phase. “Relative” matrix 
effect on ionization was evaluated with an examination of the slopes of five standard 
curves in five different lots of plasma. 
 
5.3 Results and Discussion 
 
5.3.1 Mass Spectrometry for Simultaneous Determination of Three 
Zwitterions 
 
 All three analytes, IMP, CIL, and BLI, are zwitterions that could be detected 
under either positive or negative ionization mode, while BLI and CIL have the potential 
to be doubly charged under the appropriate conditions. Establishing mass spectrometry 
conditions for the simultaneous determination of these compounds was a challenge. Since 
the charge state correlates with the buffer pH relative to the pKa of the functional groups 
in a compound structure, MS response was evaluated by infusion of each compound 




mM ammonium formate buffer, pH 3), and MP3 (50% ACN in 5 mM ammonium 
acetate, pH 5), to assess the charge state and signal intensity of the corresponding 
precursor → product mass transition under different ionization modes. The results 
showed that IMP and CIL strongly preferred positive ionization mode regardless of the 
mobile phase choices as defined above; while BLI gave similar MS response under both 
singly charged positive and negative ionization modes regardless of the pH of mobile 
phases. The doubly charged positive ionization of BLI was extremely sensitive to the 
change of mobile phase, causing dramatic signal loss when the mobile phase was 
switched from MP1 to MP2 or MP3. Considering the sensitivity and stability of 
ionization for all compounds, positive ionization mode was chosen to detect all analytes. 
The relatively stable MS response under different mobile phases (pH 3 vs. pH 5) 
provided flexibility for selecting HPLC conditions.   
The product ion scan spectra of the MH+ ions of the analytes – IMP, CIL, BIL, 
ISa, and ISa – are presented in Figure 5-2 and the final MRM transitions used for the 
three analytes and two internal standards are summarized in Table 5-1.  
Potential interferences among the five compounds due to impurities in standard 
materials and cross talk among ion channels were examined by injecting a neat solution 
containing one compound at its highest working concentration and monitoring all five 
MRM channels. Based on this assessment, no cross-talk or interference was observed.  
 
5.3.2 HILIC Chromatography Conditions 
 
IMP, CIL, and BLI are highly polar compounds. Most of the previously published 




using mobile phases containing borate or phosphate buffers.154-159 Even at as low as 10% 
acetonitrile or methanol in mobile phase, no sufficient retention was observed, especially 
for IMP. Those conditions could not be applied to a LC-MS assay because the mobile 
phases were not compatible with a mass spectrometer.  Column evaluation on Thermo 
Scientific FluroPhase PFP and Phenomenex Luna CN under different mobile phase pHs 
(3 or 5) indicated that the tested conditions worked for one or two of the three analytes, 
but not for all.  
HILIC has become a powerful technique for the retention of polar analytes 
because of its excellent mobile phase compatibility and complementary selectivity to RP 
chromatography.160-164 Evaluation of a Waters Atlantis HILIC Silica column (50mm x 2.1 
mm, 3 µ) for IMP, CIL, and BLI resulted in favorable retentions. The elution conditions 
were subsequently optimized by evaluating organic content, pH, and salt concentration in 
mobile phase. Higher percentages of ACN caused longer retention; pH 5 gave more 
retention, but a broader peak and less sensitivity in comparison to pH 3 in the presence of 
same ACN content; higher salt concentration resulted in a shaper peak, but more ion 
suppression on the mass spectrometer. To balance the retention, peak shape, and 
sensitivity among all three analytes and their corresponding internal standards, an 
isocratic elution using 15 mM ammonium formate (pH 3) in 80% ACN at 0.4 mL/minute 
flow rate was selected, and the total run time under this isocratic condition was 4 minutes 
per injection.  Figure 5-3 shows a typical chromatogram of a sample containing IMP, 
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Figure 5-3 Representative chromatograms on Waters Atlantis HILIC column using 
isocratic mobile phase for the separation of IMP, CIL, BLI and their corresponding 




5.3.3 Stability of IMP, CLI and BLI in Biological Fluids 
 
As previously described, all samples have to be stabilized immediately to avoid 
analyte loss by hydrolysis. IMP is most stable at neutral pH; the most effective stabilizing 
buffers for storage of IMP in plasma samples were the zwitterionic buffers, such as 2-(N-
morpholino)ethanesulfonic (MES) at pH 6.0, 3-morpholino-propanesulfonic acid 
(MOPS) at pH 7.2, or 4-(2-hydroxyethyl) piperazine-ethanesulfonic acid (HEPES) at pH 
7.0. Ethylene glycol is essential to the stability of imipenem for long-term storage 
because it disrupts the organized structure that leads to breakdown of β-lactams in the 
frozen state. Stabilizers using 0.5 to 1 M buffer (MES or MOPS or HEPES) in 
combination with 50% ethylene glycol at 1:1 (v/v) ratio were reported.155-158  
In this work, the traditional stabilizer for IMP plasma assay – 1 M MES (pH 6.0): 
50% ethylene glycol (1:1, v/v) – was adapted and used by mixing with equal volume of 




fluids, including rat plasma and mouse blood under -70°C. However, the data for BLI in 
rat plasma indicated an analyte loss at the low BLI concentration, while BLI in mouse 
blood was stable after storage in a -70°C freezer. To minimize analyte loss for BLI in rat 
plasma, more stabilizing conditions were investigated. Frozen QCs in rat plasma in the 
presence of the following stabilizers were compared after a F-T cycle in a -70°C freezer 
overnight: Stabilizer #1 (the traditional stabilizer) – 1 M MES (pH6.0) :50% ethylene 
glycol in water (1:1, v/v); Stabilizer #2 – stabilizer #1:10% formic acid (1:1, v/v); 
Stabilizer #3 – 1 M MES (pH6.0) :50% ethylene glycol in ACN (1:1, v/v); Stabilizer #4 – 
premixed stabilizer including stabilizer #1 :50% ACN (1:1, v/v); and Stabilizer #5 – 
stepwise addition of stabilizer #1 and 50% ACN to rat plasma sample at 1:1:1 (v/v/v) 
ratio. The results showed that ~25 – 50% BLI loss in rat plasma with Stabilizer #1, total 
IMP loss and ~25-50 % BLI loss with Stabilizer #2, ~22% IMP loss with Stabilizer #3, 
~15% BLI loss with Stabilizer #4, while Stabilizer #5 gave the best QC accuracy and 
precision for all three analytes, IMP, CIL, and BLI in rat plasma. Based on these results, 
stabilizer #5 was selected for the treatment of rat plasma samples. 
 
5.3.4 Comparison of Overall Performance of SPME Coatings 
 
 Figure 5-4 demonstrated the comparison of absolute extraction recoveries 
obtained using different types of SPME coating fibers for the extraction of IMP, CIL, and 
BLI in rat plasma. The extraction and desorption conditions were kept the same and the 
recoveries were evaluated at 100 µg/mL of each analyte. It was found that Oasis HLB 
polymer monoliths provided much better recoveries from 9 to 16% compared with other 




Although it was impossible to make direct comparisons of fiber coatings between 
polymer monoliths and other tested fibers with coating dimensions of 1 cm of length and 
10-100 µm of thickness, it was believed that the total surface area of polymer monoliths 
was much larger due to the inner surface area of the flow channel as well as outer surface 
area of the polymer monoliths. In addition, the homogeneous distribution of Oasis HLB 
particles in polymer monolithic materials enhanced the weak intermolecular interactions 
and hydrophobic interactions between analytes and extraction sorbent, which improved 
extraction efficiency of polymer monoliths over other type of SPME fibers test in the 





























Figure 5-4 Comparison of absolute extraction recoveries obtained using different 





5.3.5 Methods Validation 
 
 Both in-tip SPME and PPT assays were validated according to Merck internal 
SOPs for non-clinical validation of bioanalytical methods based on LC-MS/MS for non-
GLP studies of Preclinical Candidate Compounds (PCCs). Because the independent 
sources of the same matrix are not always available, assessment of the intraday variability 
of calibration curve is normally conducted in triplicate with minimum of six standards in 
pooled or individual sources. However, in order to evaluate matrix effects in both assays, 
five independent calibration curves were constructed in five different sources of rat 
plasma, a practice that is commonly used in clinical assay validation. The assay 
specificity was examined for interferences from endogenous components in control rat 
plasma and mouse blood as well as predose samples. In all the MRM channels, no 
interferences were observed within the retention time windows of all analytes. 
 
5.3.5.1 Intraday precision and accuracy  
 
In-tip SPME assay using Oasis HLB-coated polymer monoliths was validated in 
rat plasma and mouse blood over the concentration range of 0.5 – 100 µg/mL for each 
analyte (IMP, CIL, and BLI). The resulting method precision and accuracy data is 
presented in Tables 5-2 and 5-3. In rat plasma, the intraday precision (%CV) of the 
method was equal to or lower than 12% for all concentrations for each of the analytes, 
and the method accuracy was found to be 89.9-108.4% of the nominal concentration for 
the entire standards evaluated. The correlation coefficient for the mean calibration curves 
constructed from five different sources of rat plasma was 0.9975, 0.9982, and 0.9972 for 





prepared in single pooled blood matrix; method precision was found to be no more than 
8.0% with accuracy within ±8.4% of nominal concentration.  
The PPT assay was found linear within the range of 0.1-100 µg/mL using the 
same amount of rat plasma or mouse blood samples as those of in-tip SPME assay. Assay 
accuracy was found to be 86.6-112.1% of nominal values for IMP, CIL, and BLI across 
the tested matrices and the intraday precision (%CV) of the method was equal to or lower 
than 10.2% for all concentrations (Tables 2 and 3). The corresponding LLOQ at 0.1 
µg/mL was established based on the criteria that back calculated values ranged within 
20% of their nominal values and <20% precision (%CV) evaluated with  different 
standard curves. The correlation coefficient for the mean calibration curves constructed 
from five different sources of rat plasma was 0.9992, 0.9982, and 0.9964 for IMP, CIL, 
and BLI, respectively. 
Representative extracted ion chromatograms of LLOQ standard for the three 
analytes using in-tip SPME are displayed in Figure 5-5. 
 
5.3.5.2 Analytes Stability 
 
 For in-tip SPME, QC samples, containing all three analytes, IMP, CIL, and BLI, 
were prepared at 0.5, 1, 10, 80, and 100 µg/mL in rat plasma and mouse blood, 
respectively, with their corresponding stabilizers; while for PPT, QC samples were 
prepared at 0.1, 0.2, 5, 80, and 100 µg/mL in rat plasma and mouse blood, respectively. 
The initial QC results showed below 20% precision and 80-120% accuracy for all 
compounds in tested biological matrix for both methods. 
 
Table 5-2 Calibration Curves for the Determination of IMP, CLI and BLI in Rat Plasma Using In-tip SPME and PPT 
Accuracy % a  (n= 5, rat plasma) 
In-tip SPME PPT Nominal Conc. 
(µg/mL) 
IMP CIL BLI IMP CIL BLI 
0.1 -- -- -- 99.3 [2.5] 95.1 [2.4] 99.0 [3.1] 
0.2 -- -- -- 99.2 [4.0] 105.6 [4.3] 100.9 [4.7] 
0.5 99.5 [4.3] 108.4 [10.9] 103.4 [8.8] 105.0 [5.9] 102.9 [2.3] 99.6 [10.2] 
1 97.9 [6.5] 105.6 [4.0] 102.1 [4.3] 100.1 [4.5] 112.1 [4.0] 103.9 [9.8] 
2 98.9 [4.3] 102.2 [4.4] 100.6 [4.7] 100.1 [3.8] 105.4 5.8] 105.2 [5.7] 
5 100.7 [6.6] 105.4 [5.2] 104.2 [6.2] 99.9 [1.7] 105.4 [2.7] 104.0 [5.9] 
10 99.0 [4.3] 100.4 [3.0] 98.7 [3.6] 98.8 [1.3] 101.6 [4.8] 104.8 [1.8] 
20 99.0 [2.5] 99.9 [3.0] 97.8 [2.3] 94.0 [1.7] 98.6 2.7] 97.7 [3.7] 
50 106.1 [4.3] 96.2 [5.8] 96.7 [2.7] 100.6 [5.2] 93.9 4.1] 101.7 [8.5] 
80 102.0 [9.8] 93.1 [7.3] 98.5 [8.2] 100.1 [4.3] 86.6 [5.0] 89.7 [5.4] 
100 97.9 [10.1] 89.9 [9.3] 96.9 [12.0] 102.8 [2.4] 89.2 [5.1] 93.7 [6.3] 
r b 0.9975 0.9982 0.9972 0.9992 0.9982 0.9964 
%CV  c 10.1 8.8 10.4 3.1 5.6 6.0 
 
a    Expressed as [(back calculated concentration)/(nominal concentration)] x 100 (%) 
b    Linear regression of peak area ratio of analyte/internal standard vs. concentration (x), y= intercept + slope * x, using 1/x2 




Table 5-3 Calibration Curves for the Determination of IMP, CLI and BLI in Mouse Blood Using In-tip SPME and PPT 
Accuracy % a  (n= 3, mouse blood) 
In-tip SPME PPT Nominal Conc. 
(µg/mL) 
IMP CIL BLI IMP CIL BLI 
0.1 -- -- -- 99.6 [0.6] 96.8 [1.0] 101.1 [5.6] 
0.2 -- -- -- 101.1 [2.4] 102.7 [3.0] 99.2 [8.6] 
0.5 99.9 [2.5] 105.4 [3.1] 97.1 [7.3] 102.4 [2.6] 104.5 [6.4] 106.0 [3.0] 
1 100.4 [1.3] 106.7 [4.6] 103.0 [1.9] 100.7 [1.6] 107.9 [3.7] 109.3 [0.5] 
2 96.2 [5.0] 101.3 [3.3] 93.5 [2.9] 99.8 [2.8] 103.2 [5.7] 103.7 [1.6] 
5 100.5 [3.3] 101.5 4.9] 96.7 [6.3] 102.6 [4.9] 105.1 [2.1] 104.2 [0.6] 
10 100.5 [7.1] 101.2 [5.2] 92.7 [6.0] 103.9 [2.8] 106.2 [0.9] 106.1 [3.5] 
20 99.7 [6.9] 100.5 [4.5] 103.4 2.8] 97.2 [3.2] 99.6 [3.0] 97.6 [1.3] 
50 102.9 [0.8] 100.0 [8.0] 104.9 [7.1] 101.9 [2.4] 96.2 4.3] 95.4 [0.7] 
80 99.2 [2.1] 91.6 [2.1] 101.2 [6.7] 96.8 [2.3] 91.1 [6.2] 90.4 [1.3] 





















































Figure 5-5 Representative extracted ion chromatograms from rat plasma for IMP, 





QC freeze-and-thaw and room temperature stabilities were tested at the 
concentrations of 0.5, 50, and 1000 (10 times of ULOQ) for IMP, CIL, and BLI in rat 
plasma and mouse blood. The stability QC samples were tested after storage at -70°C for 
at least overnight and then at room temperature for at least 4 h. The results (Table 5-4) 
indicated that there was no stability issue for the assays under the specified storage 
conditions. The QC samples at 1000 µg/mL not only showed the stability at 10x ULOQ, 
but also demonstrated the ability to dilute samples above the upper limit of the standard 
curve. 
  
Table 5-4 Stability a QCs Containing IMP, CIL and BLI in Rat Plasma and Mouse 
Blood Using In-tip SPME and PPT 
Accuracy b (%) [%CV c] (n=3) 
Matrix 
Nominal Conc. 
(nM) IMP CIL BLI 
In-tip SPME 
0.5 104.0 [4.2] 105.7 [9.0] 102.5 [6.3] 
50 102.3 [9.7] 103.6 [10.3] 100.9 [10.2] Rat       
Plasma 1000 
(10xULOQ) 99.2 [3.0] 101.7 [1.0] 103.3 [0.3] 
0.5 112.1 [11.1] 113.6 [6.4] 118.0 [9.0] 
50 92.6 [6.2] 104.6 [3.2] 100.8 [1.8] Mouse   
Blood 1000 
(10xULOQ) 86.9 [4.1] 104.5 [1.7] 95.5 [1.2] 
PPT 
0.5 110.1 [1.8] 107.2 [5.1] 96.4 [1.2] 
50 107.2 [2.2] 100.9 [1.3] 92.1 [1.8] Rat       
Plasma 1000 
(10xULOQ) 109.4 [3.0] 94.5 [2.3] 90.1 [1.2] 
0.5 110.8 [11.9] 116.6 [2.5] 105.2 [8.8] 
50 104.5 [6.4] 114.6 [3.4] 100.2 [3.4] Mouse   
Blood 1000 





a  Stability covered freeze-and-thaw after storing under -70°C for at least overnight 
and room-temperature for at least 4 hours 
b   Expressed as [(mean calculated concentration)/(nominal concentration)]x100 (%) 
c   Precision expressed as coefficient of variation (%CV) 
 
5.3.5.3 Recovery and Matrix Effects 
 
  Extraction recovery and the matrix effects were evaluated for IMP, CIL, and BLI 
with standards spiked at concentrations of 1, 10, and 100 µg/mL using in-tip SPME; and 
0.5, 5, and 50 µg/mL using PPT in five different sources of rat plasma. Mouse blood was 
not investigated due to lack of enough different sources since only one pooled control 
blood was used in the study.  
 For in-tip SPME, the mean recoveries of IMP, CIL, and BLI over the 
concentration range were 10.3, 9.3, and 15.8%, respectively (Table 5-5); while for PPT, 
the corresponding values were  98.7, 98.8, and 99.2%, respectively. Recovery was found 
consistently over the entire range of the standard curve in each method which indicated 
that extraction of the analytes in each method was conducted consistently. However, 
large variations were observed in both methods for "absolute" matrix effects with %CV 
from 12.8 to 26.7% for in-tip SPME, and from 9.3 to 25.9% for PPT, which indicated that 
matrix effects on ionization at different concentrations might not be the same. Significant 
ionization suppression with more than 25% was observed for CIL in both methods. The 
“relative” matrix effects on ionization were evaluated by examination the slope data that 
was obtained using five different sources of rat plasma, with a precision of 10.1, 8.8, and 
10.4% C.V. for IMP, CIL, and BLI, respectively for in-tip SPME; and 3.1, 5.6, and 6.0% 




that the relative standard deviation should not exceed 3-4% limit for the method to be 
considered reliable and free from the relative matrix effects, further experiments should 
be conducted to investigate the causes of these matrix effects. 
 
Table 5-5  Calculated Mean Recovery and Matrix Effects for IMP, CIL and BLI 
Using In-tip SPME and PPT 
  Recovery (%) Matrix effects (%) 
Analyte PPT a In-tip SPME b PPT a In-tip SPME b 
IMP 98.7 [2.4] 10.3 [8.4] 117.3 [17.1] 101.2 [16.6] 
CIL 98.8 [2.7] 9.3 [7.5] 72.0 [25.9] 65.1 [26.7] 
BLI 99.2 [1.9] 15.8 [3.6] 126.0 [9.3] 111.9 [12.8] 
 
a   For PPT, recovery and matrix effects were evaluated at 0.5, 5, and 50 µg/mL using 
five different lots of rat plasma 
b   For in-tip SPME, recovery and matrix effects were evaluated at 1, 10, and 100 
µg/mL using five different lots of rat plasma 
 
 
Among many matrix interferences, phospholipids have been identified as the 
major source of matrix effects.165,166 Phospholipids are extremely abundant in biological 
membranes and the glycerphosphocholines (GPCho's) constitute the major phospholipids 
in plasma. The post-column infusion was performed and the post-column spectra for IMP, 
CIL, and BLI after injection of phospholipids obtained from rat plasma extract were 
captured to clearly illustrate the phospholipids suppression effects to the analytes at the 
regions where phospholipids eluted from the columns under the same chromatographic 
conditions as the analytes. Figure 5-6 displayed the post-column spectra for IMP, CIL, 
and BLI after injection of mobile phase and phospholipids extract, as well as total ion 




phospholipids. Since stabilizer was used in this study, the potential interference from the 
stabilizer solutions was also investigated. Significant ion suppression was found for CIL 
at the elution window from 0.5 to 1.5 minute from both phospholipids and stabilizer 
solutions; and slightly ion enhancement for IMP and BLI at 1.5-2.0 minute and 3.0-3.5 
minute window from the stabilizer solutions, respectively. The quantification results from 
"absolute" matrix effects measurements and the graphic illustration from post-column 
infusion were in excellent agreements. The relatively large standard deviation from the 
five curves slope data in both methods demonstrated that analytes should be separated 
from the endogenous interference as much as possible and the analog internal standard 
might not be able to compensate matrix effects even if it was co-elute with the analyte. 
Based on previous studies,123 the utilization of stable isotope-labeled internal standards 
could effectively eliminate relative matrix effect liability, the precision of standard line 
slopes in five different lots of a biological fluid was less than 2.4%, which clearly 
indicated that stable isotope-labeled internal standard should be used when available, 
especially in SPME bioanalytical analysis considering the fact of its lower recovery 











































































































Figure 5-6 Post-column infusion spectra of a solution containing imipenem (IMP), 
cilastatin (CIL), and MK-4698 (BLI) at a concentration of 1 µg/mL for each analyte after 
injection of (A) mobile phase; (B) phospholipids extracts; and (C) stabilizing solution 
under an isocratic elution of acetonitrile (ACN):15 mM ammonium formate (pH 3, 80:20, 
v/v) with a HILIC Silica column. (D) Precursor ion scan of m/z 184 monitoring all 
phospholipids using 25 µL of rat plasma prepared by PPT and in-tip SPME, respectively. 
 
5.3.6 Comparison between In-tip SPME and PPT  
 
Both in-tip SPME and PPT methods were validated in rat plasma and mouse 
blood with small sample volume, the linearity of the calibration curves, the intraday 
precision and accuracy were satisfactory in both methods. Recovery and matrix effects 
were also evaluated for IMP, CIL, and BLI using five different sources of rat plasma at 




for handling multiple analytes simultaneously regardless of their polarities, in addition, 
since a HILIC column with 80% acetonitrile in mobile phase was used, the final sample 
mix after in-tip SPME and PPT matched the mobile phase perfectly, so that the time-
consuming solvent evaporation and reconstitution steps were avoided. In the reported 
study, PPT clearly demonstrated big advantages over in-tip SPME in terms of LLOQ, 
recovery, and sample preparation time. Compared with LLOQ of 0.5 µg/mL for in-tip 
SPME, PPT was able to achieve a LLOQ of 0.1 µg/mL using the same amount of sample 
volume with less amount of sample injection. The recoveries for three compounds were 
about 100%, which was expected in PPT, while for in-tip SPME, the mean calculated 
recoveries were generally below 15%. Although "relative" matrix effects were observed 
in both methods, the relative standard deviations of the calibration curve slopes for the 
three compounds from PPT were slightly better than those obtained from in-tip SPME, 
despite the relative larger "absolute" matrix effects observed in PPT, especially for CIL. 
In terms of sample preparation time, PPT was much faster than in-tip SPME mainly due 
to the long extraction time which was the time limiting step for overall sample 
preparation time in the latter. The advantages and limitations of SPME methods in 
general were evidently shown in this study. First, the process was relatively simple with 
automated in-tip SPME approach and the organic solvent consumption was much less 
than that in PPT, which is the biggest advantage of SPME technique compared with all 
other conventional sample preparation methods. Secondly, SPME demonstrated its 
advantage of dealing with blood samples over PPT and other methods as well such as 
LLE and SPE. In PPT, one problem associated with the direct protein precipitation for the 




cells. The commonly used method – addition of formic acid to help cell lysis was not 
suitable for IMP because its β-lactam ring could be hydrolyzed much faster under acidic 
conditions. Therefore, 20 µL of ethanol was added to lysis the red blood cells in PPT, 
however, with in-tip SPME, no additional sample treatment was necessary and blood 
sample extraction was performed directly with in-tip SPME. In addition, since sample 
volume was limited to 10-20 µL of mouse blood, practically, it was impossible to repeat 
any samples in PPT. This was not an issue using in-tip SPME as samples could be 
extracted multiple times. 
In general, if sensitivity is an issue, SPME will be more troublesome than PPT 
because of the relatively lower recovery and, as it is often the case, a large amount of 
sample is introduced to the LC-MS/MS system in order to achieve the required sensitivity 
with a risk of encountering potential matrix effects. This statement is further supported by 
the validation results of smaller calibration range and larger "relative" matrix effects 
using in-tip SPME in this particular study. Moreover, it seemed that in-tip SPME was 
more sensitive to internal standards than that of PPT and the precision and accuracy of in-
tip SPME method largely depended on the selections of appropriate internal standards. 
 
5.3.7 Applications of In-tip SPME and PPT in Preclinical Sample Analysis  
 
 In reality, the validated PPT method has been used successfully to analyze more 
than 600 samples in several clinical studies, including single administration or co-
administration of IMP, CIL, and BLI in different animal species through either 
intravenous or subcutaneous dosing regimens.  In order to compare the results of 




plasma samples from rat subjects co-administration of 80 mg/kg IMP, 80 mg/kg CIL, and 
80 mg/kg BLI through 1-h IV infusion were analyzed simultaneously after sample 
extraction using in-tip SPME and PPT, respectively. For all three compounds, it was 
found that the differences between AUC0-∞, Cmax, clearance (CL), and volume of 
distribution (Vss) obtained from two methods were within all 20%, except that for CIL, 
the variation was about 30% (Table 5-6). In addition, sparse mouse blood samples from a 
mouse PK/PD model study with co-administration of 10 mg/kg of three compounds 
through 30-min IV infusion were also analyzed using both approaches. The linear 
relationship of concentrations obtained from PPT versus those from in-tip SPME clearly 
demonstrated the excellent agreement of the two methods (Figure 5-7). 
Mouse Blood Concentration (µM, PPT)






























Figure 5-7 Comparison of IMP, CIL and BLI concentrations obtained using PPT and 
in-tip SPME extraction methods in mouse blood samples co-administration of 10 mg/kg 








A LC-MS/MS method coupled with in-tip SPME has been established and validated to 
determine IMP, CIL, and BLI simultaneously in rat plasma and mouse blood. The overall 
data demonstrated that automated in-tip SPME was comparable to the PPT method in 
terms of assay accuracy and precision. Despite its lower recovery, in-tip SPME clearly 
showed big advantages over PPT in mouse blood sample preparation. Matrix effects 
should be thoroughly investigated, especially the impact of relative matrix effects to the 
performance of the SPME assay. The results of this study also indicated that a high 
degree of automation is not a limiting factor of utilizing SPME technique in routine 
preclinical sample analysis, developing selective and high extraction capacity of SPME 
coatings is essential in any SPME methods for drug analysis. Oasis HLB-coated polymer 
monoliths provided much better extraction recovery than other traditional fiber based 
SPME coatings, and have great potential for high throughput bioanalysis.  
 
  
Table 5-6 Mean Plasma Pharmacokinetic Parameters Following Coadministration of 80 mg/kg IMP, CIL and BLI Through  
1-h IV Infusion in Rats 
 
Compound Assay AUC0-∞  (hr*µM) 
Cmax  
(µM) CL (mL/min/kg) 
Vss  
(L/kg) 
PPT 191.1 (20.0) 184.3 (10.2) 0.422 (0.043) 0.080 (0.003) 
SPME 194.1 (4.4) 195.7 (9.4) 0.412 (0.009) 0.080 (0.005) IMP 
Ratio 
(PPT/SPME) 0.98 (4.55) 0.94 (1.09) 1.02 (4.66) 0.99 (0.60) 
PPT 171.3 (62.9) 142.4 (46.0) 0.521 (0.224) 0.201 (0.030) 
SPME 143.5 (47.8) 127.5 (21.8) 0.596 (0.172) 0.152 (0.037) CIL 
Ratio 
(PPT/SPME) 1.19 (1.32) 1.12 (2.11) 0.88 (1.31) 1.32 (0.80) 
PPT 282.0 (18.0) 228.1 (55.8) 0.284 (0.019) 0.128 (0.075) 
SPME 334.6 (10.8) 241.9 (63.5) 0.239 (0.008) 0.132 (0.007) BLI 
Ratio 







Evaluation of Matrix Effects in 
Bioanalysis using Automated In-tip SPME and Liquid 





Matrix effects that are defined as interference from matrix components that are 
unrelated to the analyte,167 have received more and more attention recently in 
bioanalytical analysis using LC-MS/MS detection. In many cases, even though the assays 
are claimed to be fully validated, large signal variations are observed in real clinical 
sample analysis, mainly due to the matrix components that are not detected in the MS/MS 
spectra, but co-elute with the analyte, and therefore adversely affects the analyte 
ionization process and results in either ion enhancement or ion suppression.168-173 Matrix 
effects could cause significant errors in precision and accuracy and, therefore, invalidate 
the assessment of pharmacokinetic results based on the HPLC-MS/MS assays.174  
 In order to better understand matrix effects in bioanalysis using HPLC-MS/MS, 
extensive studies have been performed to explore the possible mechanism of matrix 
effects, qualitative and quantitative assessment and measurement of matrix effects, and 
on the elimination and reduction of matrix effects. A number of papers, reviews, and 
book chapters have been published on the topics.175--178 Although the mechanism of 
matrix induced ion enhancement or ion suppression is still not fully understood, several 
different mechanisms have been proposed based on the ionization technique that was 
used. The two most common ionization techniques are APCI and ESI. APCI is known to 
be less prone to exhibiting matrix effects when compared to ESI because, in ESI, most 




APCI, neutral molecules are first vaporized into the gas phase followed by ionization via 
the corona discharge process. Therefore, ionization efficiency can be affected by matrix 
components in both solution and gas phase for ESI and only in gas phase for APCI. The 
post-column infusion method developed by Bonfiglio et al.179 provides a qualitative 
assessment of matrix effects, in which blank sample extracts are injected on the HPLC 
column under conditions chosen for the assay while a constant amount of analyte is 
infused into the HPLC stream before it enters the ion source of the mass spectrometer. 
Ion enhancement or ion suppression caused by matrix effects is shown as a change of MS 
response of the infused analyte following injection of blank sample extract. This post-
column infusion graphically indicates potential regions in the chromatograms prone to 
matrix effects. As a result, chromatographic conditions can be adjusted to minimize 
matrix effects. However, since post-column infusion is usually performed at relatively 
high concentrations, matrix effects are not investigated for samples at low concentrations. 
In addition, when a large number of compounds are analyzed in one method, each 
compound should be infused individually to evaluate matrix effects which would make 
the approach less practical. Also, a “relative” matrix effect, a difference in the matrix 
effect between biological fluids originating from different sources or subjects, a case 
commonly encountered in PK studies, cannot be assessed using this qualitative, post-
infusion experiments. A quantitative method to assess matrix effects was proposed by 
Matuszewski et al.89 using a matrix factor defined as a ratio of the analyte peak response 
in the presence of matrix ions (post-spike sample solution) to the analyte peak response in 
the absence of matrix ions (neat sample solution). A matrix factor larger or less than one 




this so called "absolute" matrix effect is not critical for a reliable bioanalytical assay. 
However, what is important is to evaluate the "relative" matrix effect, the matrix effect 
values in biofluids (for example human plasma) originating from at least five different 
sources (subjects). A good indicator of the relative matrix effect is to use the precision of 
standard line slopes constructed in at least five different sources of the biofluid and 
calculate the relative standard deviation of these slopes.123 It was suggested, that the 
precision value for these slopes should be less than 3-4% for the method to be considered 
free from “relative” matrix effect.  
Strategies to eliminate or reduce matrix effects include choosing suitable 
instruments and ionization modes, improving chromatographic conditions to have a better 
separation between endogenous components and analytes by modifying mobile phase 
composition, using ultra-performance liquid chromatography (UPLC), using a stable-
isotope labeled internal standard of analytes, selecting appropriate analogs as internal 
standards, preparing standards and quality control samples in pre-dose samples to 
eliminate the matrix difference between the calibration standards and the samples, and 
introducing a minimum amount of sample to the HPLC-MS/MS system. Above all, the 
most efficient way of reducing matrix effects is to separate analytes from endogenous 
biofluid components/impurities by an effective sample preparation method. 
  PPT, LLE, and SPE are the most commonly used sample preparation techniques 
in bioanalytical analysis. As the simplest and fastest method for sample preparation, PPT 
does not result in a very clean extract and is most likely to cause ion suppression in ESI 
as this method fails to sufficiently remove endogenous components such as lipids, 




extracts; however, analyte recovery and matrix effects should be taken into consideration. 
In recent years, SPME, a solvent-free extraction technique that combines sampling, 
sample clean-up, and pre-concentration into a single step, has been widely used in many 
areas of analytical chemistry.180,181 The technique involves exposure of the sample matrix 
to a small amount of extracting phase dispersed on a solid support. The SPME process 
involves the performance of two basic steps: (i) partitioning of analytes between the 
extraction phase and the sample matrix and (ii) desorption of concentrated extracts into 
an analytical instrument. SPME has been used routinely in combination with gas 
chromatography (GC) and gas chromatography–mass spectrometry (GC-MS) and was 
also introduced for direct coupling with LC and LC-MS in order to analyze weakly 
volatile or thermally labile compounds not amenable to GC or GC-MS. Theoretically, 
SPME could provide sample clean-up that is as effective as or better than that obtained 
by SPE since a small volume of sorbent is used and the absolute amount of analytes of 
interest and potential interferences extracted by SPME are much smaller and depend on 
the magnitude of their distribution constant. However, in comparison with headspace 
SPME in most GC or GC-MS applications, direct SPME in HPLC or HPLC-MS is 
relatively "dirty" in bioanalysis as the SPME fiber is directly immersed in the complex 
matrix, or biological fluid (blood, plasma, urine, etc). Because SPME is a non-exhaustive 
extraction method, it cannot equally compensate for changes of the composition of the 
matrix as in the case of LLE, therefore, quantification is more prone to errors due to 
changes of matrix. Hence, it is essential and important that matrix effects be extensively 




 Among many matrix interferences, phospholipids have been identified as the 
major source of matrix effects.165,166 Phospholipids are extremely abundant in biological 
membranes and the GPCho's constitute the major phospholipids in plasma. In this work, 
six representative phospholipids from SPME extracts were monitored and measured 
using commercially available and tailor-made SPME fibers and the selectivity and 
extraction efficiency of phospholipids using different SPME fibers was investigated. The 
pH and salt effects on phospholipids recovery with different fiber coatings were also 
evaluated. Overall cleanliness of sample extracts from SPME and other sample 
preparation methods such as PPT, LLE, and SPE was compared, and the matrix effects 
and recovery of various compounds using different methods were quantitatively 
compared. Based on the experimental results, general approaches of evaluating matrix 
effects and strategies of reducing or eliminating matrix effects are proposed in SPME 
methods development and validation. It should be pointed out that SPME is performed 
using in-tip SPME format to further demonstrate the feasibility of SPME automation and 
the great advantages of in-tip SPME for high throughput quantitative determination of 
drugs in the pharmaceutical industry.  This approach is simple and easy for automation 
without introducing additional devices. More importantly, in-tip SPME format is very 
flexible and amenable to all fibers types possessing a wide range of different coating 
materials, which will overcome the drawback of limited selection of commercial 
available fibers and broaden its use with HPLC-MS. To the best of our knowledge, this is 
the first comprehensive study on the evaluation of matrix effects in SPME. The 
experimental approaches and results could be used as guide and reference for future 






6.2.1 Chemicals and Materials 
 
 Diazepam, nordiazepam, oxazepam, and diazepam-d5 were purchased from 
Cerilliant (Round Rock, TX, USA) as 1 mg/mL methanolic solutions, while lorazepam 
was purchased as a 1 mg/mL solution in acetonitrile. IMP and CIL were purchased from 
Sigma Chemical Company (St. Louis, MO, USA). MK-4698 and all the analog or 
isotopic labeled internal standards used in this work were synthesized at Merck Research 
Laboratories (Rahway, NJ, USA). Glycerophospholipids were obtained from Avanti 
Polar Lipids, Inc. (Alabaster, AL, USA). Structures of selected compounds are shown in 
Figure 6-1. All other chemicals such as triacontyldimethylchorosilane, ethylene glycol 
dimethacrylate, n-octadecyldimethylorosilane, dimethoxy-α-phenylacetophenone, 
ethylene glycol, 2-(N-morpholino)ethanesulfonic (MES) acid, MES sodium salt, 
ammonium acetate, formic acid (95%), and 1-decanol were purchased from Sigma-
Aldrich (Milwaukee, WI, USA), and all HPLC grade solvents were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA). Deionized water was obtained by passing in-
house water through a Millipore Milli-Q plus system (Bedford, MA, USA). Different lots 
of drug free human and animal plasma were obtained from Biological Specialties Corp. 
(Lansdale, PA, USA) and stored at -20 oC before use. PDMS-DVB fibers (60 µm) were 
purchased from Supelco (Bellefonte, PA USA) and Oasis HLB (5 mg) µElution SPE 
plates were from Waters Corp. (Milford, MA USA). 96-Well collection plates (1.2 and 





















1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:0 LysoPC) 
 





 Tandem mass spectrometry was performed using Sciex API 3000/4000 triple 
quadruple mass spectrometers (Foster City, CA, USA) equipped with a turbo ion spray 
(TIS) source. The HPLC system included a Perkin-Elmer (Norwalk, CT, USA) LC-200 
micro pump with a CTC PAL Leap autosampler (Carrboro, NC, USA) for 96-well plates, 
and a TLX2 system from Thermo Scientific (Franklin, MA, USA). Different columns 
were used in chromatographic separation of various analytes, such as a Restek 
(Bellefonte, PA, USA) BDS Hypersil C18 column (50 × 2.1 mm, 3 μm) and a Waters 
(Milford, MA, USA) Atlantis HILIC Silica (50 × 2.1 mm, 3 µm). Mobile phase consisted 
of (1) ACN:15 mM ammonium formate (pH 3, 80:20, v/v), flow rate of 0.4 mL/min 
(isocratic); (2) ACN (0.1% formic acid): H2O (0.1% formic acid), flow rate of 0.4 
mL/min, gradient separations performed from 10% to 95% ACN; and (3) ACN (0.1% 
formic acid): H2O (0.1% formic acid) (50:50, v/v), flow rate of 0.4 mL/min (isocratic). A 
1:1 (v/v) "cocktail" of ACN/acetone/IPA (40:40:20, v/v/v) and ACN (0.1 % formic acid) 
were used as washing solvents for the autosampler. Injection volume was from 5 to 15 
µL depending on the sample loop installed and assay sensitivity. The mass spectrometer 
sources and compounds acquisition parameters were optimized by infusing a neat 
solution of a compound prepared in 50% ACN in water at a flow rate of 20 μL/min into a 
mobile phase pumped at 0.2 mL/min through the turbo ion spray interface. A summary of 
instrumental conditions used for each compound in the study is given in Table 6-1. A 
Packard MultiPROBE II liquid handling system (Meriden, CT, USA) was used for 





Table 6-1 Summary of HPLC-MS/MS Conditions 
 









Diazepam 3.4 2.82 285.0  154.2 26 39 10 10 
Lorazepam 13 2.39 321.1  275.1 21 31 14 10 
Oxazepam 12.4 2.24 287.2  241.1 26 31 18 10 
Nordiazepam 11.8 2.93 271.0  140.2 31 39 8 10 
Diazepam-d5 -- -- 290.1  154.2 31 39 10 10 
ACN (0.1% formic acid): H2O (0.1% 
formic acid), flow rate of 0.4 
mL/min, gradient separations 
performed from 10% to 95% ACN; 
Restek BDS Hypersil C18 column (5 
×2.1 mm, 3 μm), API 3000, TIS 
IMP 4.29 2.78 300.2  142.0 53 36 12 10 
CIL 2.09 2.41 359.3  202.4 55 21 4 10 
BLI (MK-4698) 1.26 1.11 570.1  236.2 91 55 6 10 
ISa for IMP, CIL 2.11 2.65 373.3  233.1 55 26 14 10 
ISb for BLI 1.23 2.24 587.2  236.0 86 55 6 10 
20% (15 mM ammonium formate, 
pH 3) : 80% ACN, isocratic, flow 
rate of 0.4 mL/min; Atlantis HILIC 







6.2.3 In-tip SPME Fibers Preparation 
 
Different types of SPME fibers were prepared and compared to evaluate the 
matrix effects: (1) PDMS-DVB, (2) C18 and C30 phase silica-based coatings, and (3) 
Oasis HLB-coated polymer monoliths.  
In-tip PDMS-DVB fibers and Oasis HLB-coated polymer monoliths were 
prepared as described previously.142 C18 and C30 phase silica-based coatings were 
prepared based on a procedure of entrapment of porous silica particles in a network of 
polymerized silicate, followed by in situ derivatization to attach the desired extraction 
phase. Briefly, stainless steel wire of 0.02" diameter was cut into 10 cm pieces. The wires 
were chemically etched for 30 min with hydrochloric acid and rinsed thoroughly with 
purified water and dried in an oven at 130oC for 1 h. The dried and cooled wires were 
dipped in potassium silicate solution such that a length of 1.5 cm was covered and then 
carefully rolled over 5 µm porous silica particles. The resulting silicate-silica coating was 
exposed to fumes of concentrated nitric acid for 10 s and allowed to dry at ambient 
temperature for at least 12 h. The coated wires were placed in vials containing 10 mL of 
the derivatization solutions consisted of 10% either n-octadecyldimethylchlorosilane for 
C18, or triacontyldimethylchorosilane for C30 in anhydrous toluene and the vials were 
immersed in a silicone oil bath at 70oC for 24 h. Following derivatization, the fibers were 
rinsed successively for 15 min with toluene, tetrahydrofuran, MeOH, 50:50 (v:v) 
MeOH:water  and water, and were allowed to dry overnight before initial use. The tailor-






6.2.4 Sample Preparation 
 
6.2.4.1 Monitoring of Phospholipids 
 
 Two MS/MS methods were used to monitor phospholipids in positive ESI mode; 
one is based on a positive precursor ion scan of m/z 184, which results in total ion 
chromatograms to qualitatively monitor all phospholipids in plasma, and the other is the 
quantitative determination of specific phospholipids using MRM. The selected 
phospholipids monitored were: 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine 
(16:0 LysoPC), 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:1 LysoPC), 1-
stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (18:0 LysoPC), 1-palmitoyl-2-
linoleoyl-sn-glycero-3-phosphocholine(16:0-18:2 PC), 1-dodecanoyl-2-(9Z-
octadecenoyl)-sn-glycero-3-phosphocholine (12:0-18:1, PC), and 1-(9Z,12Z-
octadecadienoyl)-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine 
(18:2-22:4 PC). 
Phospholipid standard solutions (16:0 LysoPC) from 1 to 500 µM were prepared 
by transferring an appropriate volume of each lipid stock solution of about 2 mg/mL and 
diluting with MeOH:water (50:50, v/v), and were used to evaluate the effect of 
phospholipids on analyte recovery in SPME. To investigate the pH effect on 
phospholipids recovery, 100 µL of plasma samples was extracted using different types of 
fibers under acidic, neutral, and basic conditions by spiking with 100 µL of 0.1 N HCl, 
PBS buffer (pH = 7), and 0.1 N NaOH, respectively. Salt effect with mixing of 100 µL of 





Phospholipids extracted from plasma using SPME were compared with those 
from other extraction methods, such as PPT, LLE, and SPE. In these comparison studies, 
the same amount of blank plasma was applied for different extraction methods and the 
extracts were dried down and reconstituted in the same amount of 50% ACN. The same 
volumes of the extract were injected for analysis. 
 
6.2.4.2 Post-column Infusion 
 
The plasma supernatant solution was obtained by mixing pooled blank plasma 
with ACN in a ratio of 1:3 following centrifugation for 5 min at 4000 rpm. The analyte 
solution, prepared at a concentration of 1 µg/mL of each studied analyte in 50% ACN, 
was post-column infused from the syringe pump to the HPLC effluent at a flow rate of 60 
µL/min. After the signals of the analyte MRM transitions were stable, the plasma 
supernatant solution (10 µL) containing various phospholipids was injected onto the 
column under the same chromatographic conditions as the analytes and analytes post-
column infusion spectra were acquired. Different chromatographic conditions were 
evaluated for studying matrix effects with different analytes. For benzodiazepines, 
including diazepam, nordiazepam, oxazepam, lorazepam, and diazepam-d5, a gradient 
elution started at 10% B (0.1% formic acid in ACN) for the first 0.5 min, and was linearly 
ramped to 95% B in 2 min, held for 1 min and returned to 10% B in 1.5 min. For IMP, 
CIL, and BLI post-column infusion experiments, an isocratic elution of 20% A (15 mM 







6.2.4.3 In-tip SPME Conditions 
 
 In-tip SPME extraction and desorption process for all experiments was fully 
automated using a Tomtec Quadra 96 workstation. The detailed sample preparation 
procedures were described previously.22 In summary, 96-well sample extraction and 
desorption plates, as well as tip washing plate, waste plate, and reservoirs containing 
desorption solvent were placed on the deck of the Tomtec Quadra 96 workstation. The 
Tomtec Quadra 96 workstation was programmed as such that the whole process ran in a 
sequence of tip loading, extractions, washing, desorption, and tip cleaning. The sample 
extraction and desorption process was accomplished through repeated aspirating and 
dispensing of sample solution and desorption solvent, respectively. After sample 
extraction and desorption, the extracts on the plate plate were either directly injected to 
the HPLC-MS/MS system or went through an evaporation/reconstitution step if enhanced 
sensitivity was required. PDMS-DVB, C18, and C30 fibers were preconditioned for 30 
minutes using 50% methanol before initial use, and in-tip polymer monoliths fibers were 
preconditioned with 2×50 µL of 50% ACN followed by 2×50 µL of water before sample 
extraction. 
 
6.2.4.4 PPT, LLE, and SPE Conditions 
 
 In PPT sample preparation, blank plasma samples or plasma samples along with 
standards were mixed well and protein precipitated with 100% ACN in a ratio of 1:3 or 
greater depending on the experiment. Samples were vortex-mixed for about 3 min, and 
centrifuged at 10oC, 3500 rpm for 5 min. The supernatant was removed, dried down and 
reconstituted in 150 µL of 50% ACN and injected into the HPLC-MS/MS system for 




system for analysis. The PPT experiments were conducted using either tube or 96-well 
plate based on the number of samples.  
 LLE was performed in 96-well plate format where organic solvent such as MTBE, 
hexane, or ethyl acetate was added in 4:1 ratio to plasma. In some cases, the organic 
solvent was acidified or basified to increase analyte recovery. The sample plate was 
sealed with mat made of molded PTFE/silicone liner and was rotor-mixed 20 min for 
LLE. The plate was then centrifuged at 10oC, 3500 rpm for 10 min and the top organic 
layer was removed, dried down, and reconstituted in 150 µL of 50% ACN in water and 
injected into the HPLC-MS/MS system for analysis. 
 In SPE extraction, the Oasis HLB (5 mg) µElution SPE plate was conditioned 
with 2×50 µL of ACN followed by equilibration with 2×50 µL of 0.1 M acetic acid. 
Blank plasma (250 µL) was diluted (1:1, v/v) with 0.1 M acetic acid and loaded onto the 
plate. The plate was washed with 200 μL of 0.1 M acetic acid followed by 200 μL of 
10% ACN in water, and eluted with 2×100 µL of ACN. The eluate was dried down and 
reconstituted in 150 µL of 50% ACN in water and injected into the HPLC-MS/MS 
system for analysis. 
 
6.2.5 Recovery and Matrix Effects 
 
 Three sets of standard samples were prepared to evaluate recovery and matrix 
effects, as recommended in reference.90 The first set of samples were prepared to evaluate 
MS/MS response for neat standards injected in the mobile phase. The second set was 
prepared in plasma extracts originating from different plasma sources and spiked after 




but plasma samples were spiked here before extraction. Recovery was determined by 
comparing the mean absolute peak areas of standards obtained from the third set to those 
from the second set. Matrix enhancement/suppression of ionization or "absolute" matrix 
effect was evaluated by comparing the absolute peak areas of the standards in post spiked 
extraction samples (second set), to neat standards (first set). In general, a concentration 
from the standard curve was selected and prepared in five different lots of plasma for 
recovery and matrix effects assessment. “Relative” matrix effect on ionization was 
evaluated by an examination of the slopes of five standard curves constructed in five 
different lots of plasma.123 
 Human control plasma was used in most of the experiments except where animal 
plasma is indicated.  
 
6.3 Results and Discussion 
 
6.3.1 Monitoring of Phospholipids 
 
 Phospholipids are composed of ester or amide derivatives of glycerol or 
sphingosine with fatty acids and phosphoric acid and, therefore, are classified into two 
different classes, GPCho's and sphingomyelins. Phospholipids are abundant in plasma 
with total concentrations of about 1.6-3.0 mg/mL, and glycerophosphocholines are 
considered the major phospholipids in plasma that could cause significant matrix effects 
during HPLC-MS/MS analysis. Several techniques are used to monitor phospholipids in 
HPLC-MS/MS; each technique has its advantages and limitations and could be used for 
different experimental purposes. Little et al.166 developed an "in-source multiple reaction 




development. The approach uses high energy in-source collision induced dissociation 
(CID) to yield characteristic product ions (m/z 184) in positive ion electrospray mode, 
which corresponds to trimethylammonium-ethyl phosphate ions that are formed from 
mono- and di-substituded GPCho's. This simple approach could simultaneously monitor 
all GPCho's using only one channel in an MRM HPLC-MS/MS experiment, however, the 
fragmentation pathway to form the m/z 184 ion reveals little information about different 
classes of GPCho's, such as phosphatidylcholine, phosphatidylethanolamine, 
phosphatidtlserines, etc, when specific classes need to be monitored and eliminated 
during sample preparation. Another technique to monitor phospholipids is to use 
precursor ion and neutral loss scans. Positive precursor ion scan of m/z 184, positive 
neutral loss scan of 141 and 185 Da, and negative precursor ion scan of m/z 153 have 
been used to monitor different classes of phospholipids. The phospholipid profiles are, in 
general, very similar to those obtained from IS-MRM, however, as pointed out by Jemal 
et al from a recent comprehensive study on phospholipids in HPLC-MS/MS 
bioanalysis,182 a very important advantage of using precursor ion scan of m/z 184 over IS-
MRM m/z 184 → m/z 184 is that the former not only detects all the phospholipids that 
have the choline polar head, but it also identifies the precursor ions corresponding to each 
chromatography peak, which is not the case with the latter. Compared with qualitative 
assessment of all classes of phospholipids from both IS-MRM and precursor ion scan, 
quantitative determination of specific phospholipids could only be obtained using 
individual multiple reaction monitoring (MRM) transitions.  
 Both precursor ion scan and individual MRM methods were applied in this work. 




precursor ion scan of m/z 184 was significantly higher than that from positive neutral loss 
or negative precursor ion scan in both human and animal plasma under the same 
chromatographic conditions, which is in agreement with that observed by Jemal et al.,182 
when supernatant of ACN-precipitated human plasma was injected to HPLC-MS/MS in 
the detection of phospholipids. In addition, more chromatographic peaks of phospholipids 
were observed from positive precursor ion scan of m/z 184 at the same retention window. 
Based on these observations, the positive precursor ion scan of m/z 184 seems to be 
sufficient to monitor overall phospholipids mass spectra for the evaluation of matrix 
effects in bioanalytical method development. This assumption was further verified from 
MRM monitoring of 16:0 Lyso PC (m/z 496→184), 18:1 Lyso PC (m/z 522→184), 18:0 
Lyso PC (m/z 524→184), 12:0-18:1 PC (m/z 703→184), 16:0-18:2 PC (m/z 758→184), 
and 18:2-22:4 PC (m/z 806→184), representative classes of GPCho's that were most 
frequently evaluated during matrix effects assessment. All mass spectra of these 
individual lipids were captured in positive precursor ion scan.  
 Due to the unique structures of GPCho's, for example, phosphatidylcholine 
consisting of both a polar head group including a negatively charged phosphate group 
and a positively charged quaternary amine group with one or two long alkyl chains, these 
long alkyl chains could make these lipids extremely hydrophobic and they could be 
retained in reversed phase columns if the percentage of organic solvent is not high 
enough for their elution. In this study, it was found that the majority of the selected 
phospholipids would not elute from the column if the mobile phase was 50% ACN in 
water under isocratic conditions, but all phospholipids were eluted with 95% ACN (0.1% 




phospholipids were eluted with ACN:15 mM ammonium formate (pH 3, 80:20, v/v) using 
a HILIC column at a retention window of 0.5 to 2 minutes. No carry-over was observed 
from previous injections in double blank samples. 
 
6.3.2 SPME Fiber Selection on Phospholipids Extraction 
 
In order to reduce or eliminate matrix effects in bioanalysis using SPME 
technique, it is very important to evaluate the SPME fiber and extraction efficiency on 
phospholipids in plasma samples. Since SPME extraction and desorption processes for all 
experiments were conducted in multiple fiber extraction format using automation, SPME 
fibers from different coating procedures were used for comparison. Two of the major 
factors affecting analyte extraction in SPME method development, the pH and salt effects 
on phospholipids extraction recovery with different types of coatings, were investigated 
in this study.  
Compared with other exhaustive extraction techniques, such as LLE and SPE, 
SPME is an equilibrium-based sample preparation technique. The extraction efficiency of 
SPME is determined by the partitioning of analyte between the sample matrix and the 
extraction phase. The higher the affinity the analyte for the extraction phase relative to 
the sample matrix, the greater amount of analyte is extracted. Partitioning is controlled by 
the physicochemical properties of the analyte, the sample matrix, and the extraction phase. 
In most SPME methods development, the determination of extraction time profile and 
equilibrium time is a prerequisite for method optimization. To minimize the errors caused 
by different sampling time and to achieve the maximum sensitivity, the extraction time 




equilibrium time could be very long which is impractical for high throughput applications.  
Therefore, SPME is often used with pre-equilibrium extraction times, provided the 
experimental conditions, such as agitation and temperature, are well controlled. To 
determine the extraction time profiles of various phospholipids in human plasma with 
different SPME fibers, 5, 10, 40, 80, 240, and 480 aspiration/dispense cycles were 
evaluated while other experimental conditions were kept constant such as 
aspiration/dispense volume and speed. Five replicates of different SPME fibers were 
simultaneously placed in a 96-well plate for extraction at each time point. The plasma 
samples were used directly without any pH or ionic strength modifications, and all the 
experiments were conducted at room temperature. Representative extraction time profiles 
of phospholipids are shown in Figure 6-2.  
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Figure 6-2 Extraction time profiles for selected phospholipids (16:0 Lyso PC, open 
symbols, and 18:0 Lyso PC, solid symbols) using four different types of SPME fibers in 
250 µL human control plasma under SPME conditions as described in the experimental 






It was found that equilibrium was achieved fairly rapidly, in less than 10 minutes, 
for all the phospholipids monitored regardless of the different fiber coatings. Overall, 
based on absolute peak areas, Oasis HLB-coated polymer monoliths exhibited higher 
extraction efficiency than other types of coatings, while PDMS-DVB, C18 and C30 phase 
silica-based coatings showed similar extraction efficiency. The absolute amount extracted 
can be calculated if calibration curves were constructed for each phospholipid monitored 
prepared in PBS. For porous polymer SPME fibers (DVB), extraction of analytes is based 
on adsorption rather than absorption, and weak intermolecular interactions and 
hydrophobic interactions play the most important role in analytes extraction. According 
to the Langmuir isothermal model, which describes equilibrium analyte extraction by 
porous polymer SPME coatings, the number of surface sites where adsorption can take 
place is limited and, therefore, porous polymer coatings of large surface area with more 
active sites will have higher extraction capacities. A 65µm PDMS/DVB commercial fiber 
with coating length of 1 cm leads to an extract volume of 0.357 mm3 and surface area 
approximately of 8 mm2; the corresponding values of volume and surface area for tailor-
made 10µm C18 and C30 phase silica-based coatings are 0.256 mm3 and 25 mm2, 
respectively. Although it is difficult to accurately calculate the extraction volume and 
surface area of Oasis HLB-coated polymer monoliths since the polymer is physically 
attached to the wall of the tip and a capillary is used to create a main channel though the 
monolithic polymer, it is believed that the surface area is much larger than that of a 
conventional SPME fiber, because both inside and outside surface areas of the polymer 
are used for extraction. In general, the recovery using Oasis HLB-coated polymer is 




silica-based coatings. In terms of selectivity, Figure 6-3 shows all four coatings provide 
better extraction recoveries for PC lipids than Lyso PC lipids with 16:0-18:2 PC as the 
predominant phospholipids detected in human plasma. The relatively large amount of PC 
lipids in human plasma compared with LysoPC lipids and the more hydrophobic 
characteristic of PC lipids could both contribute to the differences of selectivity. However, 
it should be pointed out that the extraction recovery was relatively constant for 12:0-18:1 
PC in all four different fiber coatings. 
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Figure 6-3 Comparison of fiber extraction selectivity for monitored phospholipids 
using four different types of SPME fibers under same SPME conditions as described in 
the experimental section. The monitored phospholipids including: 16:0 Lyso PC (m/z 
496), 18:1 Lyso PC (m/z 522), 18:0 Lyso PC (m/z 524), 12:0-18:1 PC (m/z 703), 16:0-
18:2 PC (m/z 758), and 18:2-22:4 PC (m/z 806). 
 
By using four different fibers of each kind (PDMS-DVB, C18, C30, and Oasis 
HLB-coated polymer monoliths) for extraction, the fiber-to-fiber coating reproducibility 




sample analysis since multiple fibers will be used simultaneously during extraction. The 
reproducibility of all types of fibers in phospholipids extraction in human plasma was 
found to be very good as indicated by R.S.D. values ranging from 3 to 20% shown in 
Figure 6-4. Many factors could affect the performance of the fiber in biological fluids 
extraction, and, therefore, the results of fiber-to-fiber reproducibility, such as uniform 
fiber fabrication during preparation, effect of extraction speed, and carry-over of analyte 
in the extraction phase, etc. are all important. It is expected that in high throughput 
multiple fibers SPME analysis, the automation of the coating procedure and sample 
extraction and desorption will improve inter-fiber reproducibility and consequently 
system performance. Disposable fibers, with their simplicity of use and low-cost, should 
be used to completely eliminate carry-over effects.         














SPME Fiber  
Figure 6-4 Dependence of %RSD (n=30) of five monitored phospholipids extracted 
using five different fibers at each aspiration/dispense cycle time point (5, 10, 40, 80, 240, 
and 480) with PDMS-DVB, C18 and C30 phase silica-based coatings, and Oasis HLB-





The pH-dependency of phospholipids recoveries from human plasma samples has 
been investigated at different pH conditions using different types of coatings. On average, 
the extraction recovery for all phospholipids monitored was about 25% higher under 
basic conditions than that of neutral conditions, while in acidic conditions, the extraction 
recovery was about 20% lower. The pH effects on recoveries of different phospholipids 
varied from 9 to 37% in acidic conditions, and from 10 to 47% in basic conditions; 
LysoPC lipids seemed more sensitive to pH changes than PC lipids.  These observations 
are in agreement with literature that phospholipids could be significantly removed from 
plasma at acidic conditions during LLE as they are more ionized and, therefore, would 
favor less non-polar phase during extraction.183 Salt effects on phospholipids recoveries 
were also investigated with different amounts of NaCl in plasma samples. It was found 
that the extraction recovery of all phospholipids increased as NaCl amount increased. 
This increase was about 24% in 1% NaCl and 37% in 10% NaCl. Contrary to the pH 
effects, it was interesting to note that the salt effects were very similar for all 
phospholipids monitored with relative standard deviation of 6% and 3%, respectively, 
under two salts conditions for the mean extraction recovery of six phospholipids.  
 
6.3.3 Comparison of SPME with PPT, LLE, and SPE 
 
Since PPT, LLE, and SPE are the most widely used sample preparation methods 
in bioanalysis, it was interesting to compare the extract cleanness of phospholipids in 
plasma samples in order to evaluate the matrix effects of using SPME technique 
compared with other approaches. Two experiments were designed to compare SPME 




chromatographic conditions selected were commonly used in bioanalysis for drug 
discovery and development.  
In the first scenario, Oasis HLB-coated polymer monoliths SPME fiber and Oasis 
HLB (5 mg) µElution SPE plate were chosen for sample preparation along with PPT 
using 250 µL human control plasma. SPME was performed at equilibrium to make sure 
that maximum phospholipids were extracted. To ensure a valid and accurate comparison 
of the results, some variables were strictly controlled such as the same dry-down, 
reconstitution step, and final solvent composition of reconstituted extracts and volume of 
plasma. A gradient separation was performed from 10% to 95% ACN (0.1% formic acid) 
on a regular C18 column to fully elute the phospholipids monitored with precursor ion 
scan of m/z 184. Figure 6-5(A) contains the representative TICs of the phospholipids 
extracted from PPT, SPE, and SPME, respectively. It is very clear that all chromatograms 
have very similar patterns in the elution window between 2 to 5 minutes; both SPE and 
SPME methods provide a significantly cleaner extract than PPT, and SPE removes more 
hydrophobic PC lipids than LysoPC lipids compared with SPME method. MeOH and 
ACN are often selected as the desorption solvent in SPME. It was found that many of the 
phospholipids were more soluble in MeOH than ACN and, therefore, using MeOH as 
desorption solvent in SPME could end up with more phospholipids interferences. In the 
second scenario, experiments were conducted on a Waters Atlantis HILIC Silica column 
with mobile phase consisting of ACN:15 mM ammonium formate (pH 3, 80:20, v/v), 
since more and more hydrophilic interaction chromatography (HILIC)-MS/MS methods 
have been developed in drug analysis for many polar compounds. A total of 25 µL of rat 




scenario one. LLE was performed by using MTBE as extraction solvent for comparison. 
Figure 6-5(B) shows that the phospholipids monitored were coming out of the HILIC 
column very early at a retention window from 0.5 to 2 minutes, and the shape of the 
chromatograms obtained from PPT, LLE, and SPME, respectively, was almost identical 
with total peak areas decreasing from PPT to SPME to LLE. This indicated that the total 
phospholipids extracted from different sample preparation methods were very similar 
under the current experimental conditions.  
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Figure 6-5 Precursor ion scan of m/z 184 monitoring all phospholipids using various 
sample extraction methods under different chromatographic conditions: (A) 250 µL 
human plasma prepared by PPT, SPE and SPME, respectively, with a gradient separation 
from 10% to 95% ACN (0.1% formic acid) on a regular C18 column; (B) 25 µL of rat 
plasma prepared by PPT, LLE, and SPME, respectively, on a HILIC Silica column with 
mobile phase consisted of acetonitrile (ACN):15 mM ammonium formate (pH 3, 80:20, 
v/v). 
 
In both scenarios, PPT was identified as the least effective method in terms of 
sample clean-up followed by SPME, then SPE or LLE.  It is believed that in SPE or LLE, 
the analyte to be extracted is partitioned between sorbent or solvent and a plasma matrix 
in a buffer with weak eluting strength. The intermolecular forces involved for the 
retention of analyte with the sorbent or solvent are hydrogen bonding, dipole-dipole 
forces, ionic interactions, and Van der Waals forces and, therefore, the endogenous 
interferences could be selectively removed by adjusting eluting solvent strength. 
Chambers et al.184 compared various sample preparation techniques including PPT, LLE, 
and SPE for plasma samples with respect to extract cleanliness, matrix effects, and 
recovery, and pointed out that both reversed-phase and cation exchange SPE resulted in 
significantly lower phospholipids levels, and that the most effective sample preparation 
technique was mix-mode strong cation exchange SPE which combined the retention 
mechanisms of reversed-phase and ion exchange. SPME is a technique that combines 
sampling, sample clean-up, and pre-concentration into a single step and on a single 
device.  In contrast to SPE, SPME is also a non-exhaustive extraction method, uses a 
much smaller volume of sorbent and, therefore, the absolute amount of analytes of 
interests as well as potential interferences extracted by SPME are much smaller. 
Theoretically, SPME should provide sample clean-up as effective as or better than SPE 




compared to SPE or LLE, it should be pointed out that in SPME experiment, no sample 
pre-treatment was performed, and the elution solvent was either 100% MeOH or ACN. 
The current study data indicated that matrix effects should be carefully investigated 
especially in those cases where SPME is used directly without any sample treatment. 
Since sample preparation is accomplished in one-step, endogenous interfering 
compounds co-extracted with the analytes will not be removed during sample preparation 
and could potentially cause matrix effects in bioanalysis. 
“Absolute” matrix effects from different biological fluids could be different. A 
complete validation is required when analytical matrix is changed, for example, from rat 
plasma to human plasma, or plasma to urine. In the current study, experiments were also 
performed to compare the relative amount of phospholipids extracted using SPME from 
different biological matrices including rat, monkey, and dog plasma, as well as human 
plasma with different anticoagulants, such as Na-heparin or EDTA. Figure 6-6 clearly 
illustrates the differences of phospholipid contents in different matrices which further 
demonstrates the necessity of performing a full validation if biological matrix is changed.  
 
6.3.4 Recovery and Matrix Effects 
 
In order to qualitatively assess matrix effects in bioanalytical analysis using 
SPME, post-column infusion experiments were conducted to graphically illustrate the 
potential regions of ion enhancement or ion suppression due to the effects of 
phospholipids on analyte ionization. Recoveries and "absolute" as well as "relative" 




and calculated under various chromatographic conditions using different sample 








































Figure 6-6 Precursor ion scan of m/z 184 monitoring all phospholipids using Oasis 
HLB-coated polymer monoliths in-tip SPME extracted from 250 µL dog, rat, monkey, 
human Na-heparin, and human EDTA plasma, respectively, with a gradient separation 
from 10% to 95% ACN (0.1% formic acid) on a regular C18 column. 
 
 
The post-column infusion was performed under two chromatographic conditions 
as described in detail in the experimental section. The post-column spectra for different 




respectively. The spectra clearly indicated the phospholipids suppression effects to the 
analytes at the regions where phospholipids eluted from the columns under corresponding 
chromatographic conditions. The matrix effects were compound dependent.  In Figure 6-
7(A), the effects of endogenous phospholipids on lorazepam and oxazepam were 
significantly larger than those on diazepam and nordiazepam; while in Figure 6-8(A), 
significant ion suppression was observed for CIL and the effects of phospholipids on IMP 
and BLI were relatively small. The recoveries and "absolute" matrix effects for diazepam, 
lorazepam, nordiazepam, and oxazepam from SPE and SPME using Oasis HLB polymer 
monoliths and PDMS-DVB are listed in Table 6-2, as well as the corresponding results 
for BLI, IMP, and CIL obtained from PPT and SPME using Oasis HLB polymer 
monoliths and 30 phase coated fibers. In order to increase benzodiazepine recoveries, 
plasma samples were diluted with an equal amount of 25 mM ammonium formate at pH 
7 during SPE and SPME sample preparation. Overall, SPE and PPT methods provided 
higher recoveries (more than 80% for all the compounds) compared with the SPME 
method. This was not surprising as both methods were exhaustive extraction methods. 
However, it was interesting to see that Oasis HLB polymer monoliths gave much better 
recoveries from 4.4 to 23.1% compared with conventional SPME fiber geometry 
recoveries of 0.9 to 3.9 %.  In terms of "absolute" matrix effects, most of the compounds 
did not show severe decrease or increase from phospholipids regardless of extraction 
methods, except that oxazepam signal was decreased (71.4%) using Oasis HLB polymer 
monoliths, and CIL signal was 74.2% and 73.2% using Oasis HLB polymer monoliths 
and C30 phase coated fibers, respectively. However, significant matrix effects were 




to note that the slope of the calibration curve constructed in PBS buffer was very similar 
to that in plasma for the four different types of coatings, which indicated that 
phospholipids in plasma samples did not alter the interactions between analytes and 
adsorption-type coatings. The "relative" matrix effects of phospholipids on analyte 
quantification were measured by determining the precision of the slopes of five standard 
curves in five different lots of plasma. It is generally accepted that the relative standard 
deviation should not exceed 3-4% for the method to be considered reliable and free from 
“relative” matrix effects issues. The results for diazepam, lorazepam, nordiazepam, and 
oxazepam quantifications using Oasis HLB polymer monoliths are summarized in Table 
6-3. The relative standard deviation of standard line slopes were less than 4% for all four 
compounds which indicated that the SPME method was free from matrix interferences in 
the calibration range from 5 to 1000 ng/mL. By scrutinizing the individual accuracy data, 
it was noticed that, in general, the relative standard deviations at each concentration were 
larger for lorazepam and oxazepam than those for diazepam and nordiazepam. The 
quantitative results agreed very well with experimental observations when endogenous 
phospholipids were monitored simultaneously for four compounds with MRM transitions. 
The chromatograms shown in Figure 6-7(B) exhibited that the four compounds were 
completely separated from the phospholipids with representative 16:0 LysoPC and 18:0 
LysoPC that were eluted earlier than other monitored lipids. It was anticipated that the 
analytes should not be affected by lipids interferences; this was verified from their more 
precise quantitative results. The larger inter subject variations for lorazepam and 
oxazepam might be due to the higher sensitivity of these two compounds to the lipid 




variations and the interference from phospholipids are shown in Table 6-4 from the 
quantitative results of BLI, IMP, and CIL determination using Oasis HLB polymer 
monoliths in rat plasma, and illustrated in Figures 6-8(A) and 6-8(B) with 
chromatographic separations. The slope standard deviations for BLI, IMP, and CIL using 
SPME method were 10.4, 10.1 and 8.8%, respectively, with a calibration range from 0.5 
to 100 µg/mL for all three compounds. The relatively large variation in the five curves 
for CIL appeared to be due to the matrix interferences despite the fact that the analog 
internal standard almost co-eluted with the analyte. It was very interesting to compare the 
%CV for absolute peak areas for different compounds and their corresponding internal 
standards to understand the behavior of internal standards and their compensation of 
absolute matrix effects. In Figure 6-9, absolute %CV differences were obtained for each 
compound by calculating the differences between %CV of absolute peak areas at each 
concentration point from five calibration curves and %CV of absolute peak areas of 
internal standards. An isotope-labeled internal standard diazepam-d5 was used for 
diazepam, nordiazepam, lorazepam, and oxazepam; while for BLI, IMP, and CIL, two 
analog internal standards were applied. It was evident that the labeled internal standard 
compensated for matrix effects as demonstrated by the high precision of slopes in five 
different lots of plasma for benzodiazepines; on the other hand, the analog internal 
standards did not behave the same way as the drug compounds during sample extraction 
for BLI, IMP, and CIL. It is generally accepted that in most cases, the utilization of stable 
isotope-labeled internal standards effectively eliminates relative matrix effect liability. In 
the case of the four benzodiazepines studied here, the absence of a “relative” matrix 




utilized. For three other diazepams, the absence of a “relative” matrix effect using as 
internal standard diazepam-d5 is clear, but probably due to chance and not the design 
since the diazepam-d5 served as any other internal standard analog. As it was clearly 
concluded in earlier bioanalytical studies123 using PPT, SPE, and LLE extraction methods, 
it is highly recommended that in SPME bioanalysis isotope-labeled internal standard be 
used for each analyte considering low recovery of analytes and potential co-extraction of 
































































































Figure 6-7 (A) Post-column infusion spectra of a solution containing diazepam, 
nordiazepam, oxazepam, and lorazepam at a concentration of 1 µg/mL for each analyte 
after injection of plasma supernatant under a gradient elution from 10% to 95% ACN 
(0.1% formic acid) with a C18 column; (B) Chromatograms of diazepam, nordiazepam, 
oxazepam, and lorazepam, as well as phospholipids, 16:0 Lyso PC and 18:0 Lyso PC, 









































































Figure 6-8 (A) Post-column infusion spectra of a solution containing imipenem 
(IMP), cilastatin (CIL), and MK-4698 (BLI) at a concentration of 1 µg/mL for each 
analyte after injection of plasma supernatant under an isocratic elution of acetonitrile 
(ACN):15 mM ammonium formate (pH 3, 80:20, v/v) with a HILIC Silica column; (B) 


































Figure 6-9 Absolute %RSD differences between %RSD of absolute peak areas for 
drug compounds at each concentration in the calibration curve and %RSD of absolute 
peak areas of internal standard in five curves validation. DIA (diazepam), NOR 
(nordiazepam) LOR (lorazepam), OXA (oxazepam), BLI (MK-4698), IMP (imipenem), 





Table 6-2 Calculated Recovery and “Absolute” Matrix Effects for Various Compounds 
using Different Sample Preparation Methods 
 
  Recovery (%) Matrix effects (%) 







Diazepam 46.5 [9.7] 12.3 [9.2] 96.2 [7.1] 91.6 [6.8] 
Lorazepam 18.6 [3.2] 3.7 [24.0] 88.1 [13.9] 111.2 [18.2] 
Nordiazepam 22.2 [7.0] 5.8 [15.5] 91.7 [13.6] 108.9 [13.6] 
Oxazepam 13.7 [8.7] 3.3 [27.0] 71.4 [11.7] 98.1 [21.7] 
Analyte b PPT Oasis HLB (SPME) PPT 
Oasis HLB 
(SPME) 
Imipenem (IMP) 98.7 [2.4] 10.3 [8.4] 117.3 [17.1] 101.2 [16.6] 
Cilastatin (CIL) 98.8 [2.7] 9.3 [7.5] 72.0 [25.9] 65.1 [26.7] 
MK-4698 (BLI) 99.2 [1.9] 15.8 [3.6] 126.0 [9.3] 111.9 [12.8] 
 
a Recovery and “absolute” matrix effects were evaluated at 0.1 µg/mL for 
benzodiazepines, and three concentrations for BLI, IMP, and CIL in five different lots of 
plasma (0.5, 5 and 50 µg/mL for PPT; 1, 10, and 100 µg/mL for SPME) 
b To avoid analyte loss because of hydrolysis in biological matrices, rat plasma samples 
were treated with a stabilizing solution prepared by combing 1 M MES (pH 6.0) buffer 





Table 6-3 Calibration Curves for the Determination of Diazepam, Lorazepam, 
Nordiazepam, and Oxazepam in Five Different Lots of Human Plasma using SPME 
 
Accuracy (%) a  [%CV] (n= 5) Nominal 
Conc. 
(ng/mL) Diazepam Lorazepam Nordiazepam Oxazepam 
5 101.1 [11.7] 99.1 [12.5] 103.2 [2.4] 101.5 [14.5] 
10 99.2 [3.8] 98.1 [5.2] 92.5 [1.9] 95.6 [10.8] 
20 95.9 [1.5] 102.7 [5.2] 98.6 [2.8] 99.4 [2.1] 
50 105.2 [3.0] 112.9 [11.5] 109.6 [5.5] 111.5 [10.1] 
100 99.9 [3.7] 98.4 [4.5] 100.4 [6.5] 96.3 [7.6] 
200 96.1 [0.6] 96.7 [7.7] 95.4 [6.3] 99.2 [10.1] 
500 102.4 [1.9] 99.8 [6.5] 101.9 [5.4] 100.8 [11.4] 
1000 100.3 [2.1] 92.4 [2.4] 98.4 [3.8] 95.6 [5.4] 
r2  b 0.9998 0.9986 0.9996 0.9993 
 %CV c  0.8 1.6 1.3 4.0 
 
a  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100% 
b Linear regression of peak area ratio of analyte/internal standard vs. concentration (x), y= 
intercept + slope * x, using 1/x2 weighing factor, with correlation of coefficient (r2) 




Table 6-4 Calibration Curves for the Determination of BLI, IMP, and CIL in Five 
Different Lots of Rat Plasma using SPME 
 
Accuracy (%) a  [%CV] (n= 5) Nominal 
Conc. 
(µg/mL) Imipenem (IMP) Cilastatin (CIL) MK-4698 (BLI) 
0.5 99.5 [4.3] 108.4 [10.9] 103.4 [8.8] 
1 97.9 [6.5] 105.6 [4.0] 102.1 [4.3] 
2 98.9 [4.3] 102.2 [4.4] 100.6 [4.7] 
5 100.7 [6.6] 105.4 [5.2] 104.2 [6.2] 
10 99.0 [4.3] 100.4 [3.0] 98.7 [3.6] 
20 99.0 [2.5] 99.9 [3.0] 97.8 [2.3] 
50 106.1 [4.3] 96.2 [5.8] 96.7 [2.7] 
80 102.0 [9.8] 93.1 [7.3] 98.5 [8.2] 
100 97.9 [10.1] 89.9 [9.3] 96.9 [12.0] 
r2  b 0.9975 0.9982 0.9972 
 %CV c  10.1 8.8 10.4 
 
a  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100% 
b Linear regression of peak area ratio of analyte/internal standard vs. concentration (x), y= 
intercept + slope * x, using 1/x2 weighing factor, with correlation of coefficient (r2) 





6.3.5 Matrix Effects Evaluation in SPME Methods Validation 
 
For MS based bioanalytical assays, matrix effects should be investigated to ensure 
that precision, selectively, and sensitivity will not be compromised.185 Although there are 
no specific guidelines from the FDA on how matrix effects should be evaluated during 
method validation, a common practice to assess matrix effects is to use post-column 
infusion with post-extraction spiked samples according to a comprehensive literature 
overview of validated HPLC-MS/MS methods for analysis of drugs in biological 
fluids.175 However, there are only a few papers using SPME in drug analysis in which 
matrix effects were evaluated.105,110 During a new SPME method development, 
researchers focus on factors such as fiber coating, extraction mode, and agitation method 
selections; extraction and desorption conditions optimization; distribution constants 
calculations and extraction time profile determinations, as well as calibration method 
selection, etc. In fact, in most cases, SPME method validation is based on a single lot of 
matrix with analysis of multiple independent standard curves.78 In recent years, one of the 
major fundamental advances in bioanalytical applications of SPME is the development of 
in vivo SPME which allows for direct immersion of the SPME fiber into a living system 
for the direct extraction of the analyte, thereby eliminating the requirement to remove a 
representative sample of biofluid or tissue from the living system. Despite the great 
potential applications of in vivo SPME in determination of drug pharmacokinetic 
properties in biological species, this very promising technique, since its first application 
was published in 2003, has not been widely accepted and all the related research work is 
limited to one laboratory.186-188 One of the reasons is due to the complexity of applying 




of solid and comprehensive validation of the assay is another major reason of preventing 
its wide utilization, especially in the pharmaceutical industry. In vivo SPME assay 
validation has to take into consideration inter- and intra-species matrix variability as in 
most preclinical and clinical studies different animal species and/or human subjects are 
involved. Last but not least, development of an in vivo SPME assay using one single fiber 
without any process automation is practically impossible.  
Based on the results of this study, it has been demonstrated that SPME did not 
provide the cleanest sample extraction method in terms of extracting endogenous 
components such as phospholipids from biological fluids.  Thus, matrix effects cannot be 
neglected in SPME assay validation. Matrix effects should be thoroughly investigated 
during assay development and evaluated throughout sample analysis by repetitive 
analysis of incurred samples. Strategies to reduce or eliminate matrix effects from 
validation of conventional sample preparation methods, such as PPT, LLE, and SPE 
should be applied in SPME methods validation. To evaluate matrix effects, post-column 
infusion experiment should be conducted initially to directly observe their impact on the 
chromatographic separation used in a MS based SPME method. Direct comparison using 
pre-spiking and post-spiking approaches provide the most efficient and straightforward 
ways to detect and determine the extent of matrix effects since the same amount of 
analyte and internal standard are prepared in matrix free solvent and different sources of 
biological fluids. Both recovery and matrix effects can be calculated from the comparison 
of analyte response between pre-spiking and post-spiking samples, and between post-
spiking and matrix-free solvent samples, respectively. It is highly recommended that 




at all concentrations within the calibration curve range, as matrix effects at low 
concentrations might be quite different compared with those at higher concentrations. In 
order to reduce or eliminate matrix effects in SPME, besides approaches such as 
separation of endogenous components from analytes, preparation of standards and QC 
samples using pre-dose samples, and selection of different MS ionization modes, efforts 
should focus on optimization of extraction efficiency to increase SPME assay sensitivity 
so that a minimum amount of extracts will be introduced into the system. More 
importantly, a stable isotope-labeled internal standard should be used for each analyte, 
and when isotope-labeled internal standard is not available, careful studies need to be 
carried out to select a suitable unlabeled analog internal standard with a matched pKa and 
logP values and an appropriate concentration level. Parallel SPME sample preparation 
using multi-well plate technology with automation will generate large amounts of data in 
SPME method development with significant reduction in sample preparation time and 
great improvement in method reproducibility and precision compared with the traditional 




Matrix effects in bioanalysis using SPME should be thoroughly investigated in 
method development and validation, as the assumption that SPME should provide sample 
clean-up as effective or better than SPE with no or minimal matrix effects due to its non-
exhaustive, equilibrium extraction characteristics is really dependent different 
experimental conditions. Generally, SPME is less effective than LLE and SPE in terms of 





pre-treatment is performed and the elution solution is 100% organic solvent, but it is 
better than the least effective method, PPT. "Absolute" and "relative" matrix effects have 
been observed in a validated SPME assay and have had direct impact on the precision 
and accuracy of the method. It has been found that extraction equilibrium was rapidly 
achieved for phospholipids monitored in all test fibers including PDMS-DVB, C18 and 
C30 phase silica-based coatings and Oasis HLB-coated polymer monoliths, and 
phospholipids extraction recovery decreased at lower pH and higher salt concentrations. 
Automated in-tip SPME provides an efficient way to evaluate matrix effects in 
bioanalysis over traditional approaches where SPME steps are normally performed 
manually. Using manual SPME, evaluation of matrix effects would be laborious making 
this important evaluation impractical and, thus, ignored in pharmaceutical and 
bioanalytical applications. Strategies to reduce or eliminate matrix effects such as 
introducing minimum amount of sample and separation of endogenous components 
should be applied in SPME methods development. The importance of selecting an 
appropriate internal standard is critical to the success of establishing reliable quantitative 






Automated In-tip SPME-LC/MSMS for High  





The limited selection of commercially available SPME coatings are always listed 
as one of the main reasons that prevent the widespread application of SPME in biological 
sample analysis.189,190 Actually, in the past decades, the development of new coatings is 
one of the most active areas of SPME studies, many fiber coating techniques191 are now 
available in the literature including sol-gel coating technology,192 electrochemical193,194 
and chemical procedures,195 and physical deposition of biocompatible materials.98 
However, compared with the rapid growth of SPE sorbents in the market, the progress of 
developing commercial available new SPME coatings is not substantial. The initially 
developed single fiber-SPME format, which remains the most widely used form of SPME 
technique, apparently, could not meet the needs for high throughput biological sample 
analysis. The lack of instrumentation to perform SPME process in automated fashion 
could be a factor for manufactures not willing to produce new SPME coatings because of 
small market return values. Recently, the automation of SPME in a 96-well plate format 
was successfully achieved with the design and development of a new SPME robotic 
station, which is capable of preparing up to 96 samples in an automated way. Some 
applications of such automated SPME technique include high throughout analysis of 
drugs in complex biofluids such as whole blood,78 automated drug-protein binding 
studies,196 and high throughput toxicological screening studies to monitor exposure to 




approach, some of the limitations of the robotic system such as using a large amount of 
biological samples make SPME less attractive in routine bioanalysis for drug discovery 
and development studies. In addition, many advantages of the unique SPME technique 
including fast sample preparation, solvent-less, and extremes of sample volumes, etc. no 
longer exist; on the contrary, some principle disadvantages such as relative low 
recoveries and carry-over effects become more notable. Thus, it is necessary to explore 
other automation approaches so that SPME can be widely accepted as an alternative 
method in bioanalytical sample analysis in the pharmaceutical industry.   
Automated in-tip SPME technique has been proposed and developed recently and 
some reviews and studies have been published on this topic.142,198 The in-tip SPME 
technique takes advantage of widely used commercially available automated liquid 
handling systems, and has coupled the fiber SPME with the system in a unique 
configuration. In-tip SPME is simple and easy for automation without introducing 
additional devices, which could be easily adopted by chemists for bioanalytical analysis. 
More importantly, in-tip SPME maintains the simplicity and advantages of conventional 
fiber SPME technique, and the approach is emendable to all fibers types possessing a 
wide range of different coating materials, which will overcome the drawback of limited 
selections of commercial available fibers and broaden its use with HPLC-MS/MS.  
The objective of this study was to systematically evaluate the performance of the 
in-tip SPME automation using tailor-made Oasis HLB polymer monoliths in-tip fibers. 
Parameters including uniformity and speed of aspiration and dispense to extraction 
efficiency, effects of in-tip SPME fibers positions, cross-contamination and carryover, 




methods were extensively investigated. Oasis polymer monolith fibers along with 
commercially available SPME fibers PDMS-DVB were compared to Varian OMIXTM 
C18 μ-SPE tips to illustrate the advantages and limitations of SPME versus SPE in drug 
analysis using benzodiazepines as model compounds. Head-to-head comparisons 
between automation in-tip SPME and other configurations of automated SPME 
approaches such as blade and thin-film geometries demonstrated that the automation 
system did not play a critical role in quantitative determination of analytes in biological 
fluids, and in-tip SPME is apparently simple to use, easy for automation, flexible in fiber 
coating selections, and cost effective. Strategies for in-tip SPME method development 
and validation were proposed which would dramatically decrease the method 
development time than that of any other manual or automated SPME approach. A 
comprehensive summary to compare SPME with other traditional sample preparation 
methods including PPT, LLE, and SPE were tried to describe the status and future 
prospects of SPME in bioanalysis. Some potential applications of in-tip SPME in 




7.2.1 Chemicals and Materials 
 
Diazepam, nordiazepam, oxazepam, and diazepam-d5 were purchased from 
Cerilliant (Round Rock, TX, USA) as 1 mg/mL methanolic solutions, while lorazepam 
was purchased as a 1 mg/mL solution in ACN. The initial stock solutions were stored at 
4oC in a refrigerator. All HPLC grade solvents, including ACN (0.1% formic acid), H2O 




Scientific (Fair Lawn, NJ, USA). Phosphate-buffered saline solution (PBS, pH 7.4) was 
prepared by dissolving 8.0 g of sodium chloride, 0.2 g of potassium chloride, 0.2 g of 
potassium phosphate, and 1.44 g of sodium phosphate in 1 L of deionized water and 
adjusting the pH to 7.4, if necessary. Deionized water was obtained by passing in-house 
water through a Millipore Milli-Q plus system (Bedford, MA, USA). Different lots of 
drug free human plasma were obtained from Biological Specialties Corp. (Lansdale, PA, 
USA) and stored at -20 oC before use. PDMS-DVB fibers (60 µm) were purchased from 
Supelco (Bellefonte, PA USA) and OMIXTM C18 μ-SPE tips were obtained from Varian 
Corp. (Walnut Creek, CA USA). Oasis HLB-coated polymer monoliths in-tip SPME 
fibers were prepared based on photo-polymerization and the detailed procedures were 
described previously.199 96-Well deep plates (1.2 and 2.4 mL) and mats were purchased 
from Marsh Biomedical (Rochester, NY, USA). PE frits (25 µM, 6.3 mm in diameter) 
purchased from Innovative Microplate (Chicopee MA, USA), and non-sterilized 
polypropylene pipette tips purchased from Tomtec Inc (Hamden, CT, USA) were used to 




 Tandem mass spectrometry was performed using a Sciex API 3000 triple 
quadruple mass spectrometers (Foster City, CA, USA) equipped with a TIS source. The 
HPLC system included a Perkin-Elmer (Norwalk, CT, USA) LC-200 micro pump with a 
CTC PAL Leap autosampler (Carrboro, NC, USA) for 96-well plates, and a TLX2 
system from Thermo Scientific (Franklin, MA, USA). Chromatographic separation was 




column (50 × 2.1 mm, 3 μm) using mobile phase consisted of ACN (0.1% formic acid): 
H2O (0.1% formic acid) at a flow rate of 0.4 mL/min. A "cocktail" of ACN/acetone/IPA 
(40:40:20, v/v/v) and 50% of ACN (0.1 % formic acid) were used as washing solvents for 
the autosampler, and the injection volume was 15 μL.  The mass spectrometer sources 
and compounds acquisition parameters were optimized by infusing a neat solution of a 
compound prepared in 50% ACN at a flow rate of 20 μL/min into a mobile phase 
pumped at 0.2 mL/min through the turbo ion spray interface in the positive mode under 
MRM conditions. The transitions monitored were 285.0 → 154.2 for diazepam, 321.1 → 
275.1 for lorazepam, 271.0 → 140.2 for nordiazepam, 287.2 → 241.1 for oxazepam, and 
290.1 → 154.2 for diazepam-d5, respectively. The source temperature and ion-spray 
voltage were set at 450oC and 5000 V, respectively. The curtain, nebulizer, and collision 
gases were set at 7, 10, and 10, respectively. A Packard MultiPROBE II liquid handling 
system (Meriden, CT, USA) was used for sample and solution pipetting. In-tip SPME 
extraction and desorption were performed using a Tomtec Quadra 96 workstation 
(Hamden, CT, USA). 
 
7.2.3 In-tip SPME Procedures 
 
The automated in-tip SPME procedures have been described in previous chapters. 
In summary, the Tomtec Quadra 96 workstation was programmed as such that the whole 
process ran in a sequence: After the tip plate was loaded, 100 µL of plasma sample was 
repeatedly aspirated and dispensed from the sample plate for about 40 minutes (320 
aspiration/dispense cycles). When extraction was completed, in-tip SPME fibers were 




(ACN with 0.1% formic acid) was aspirated from the desorption solvent reservoir with 50 
µL air gap and dispensed into an empty sample collection plate, followed by 100 µL of 
desorption solvent repeatedly aspirated and dispensed in the same plate for about 5 
minutes (40 aspiration/dispense cycles). Finally, the in-tip SPME fibers were moved to 
the cleaning plate for fiber cleaning. The sample collection plate was evaporated to 
dryness under heated N2 stream and reconstituted in 150 μL of 50% ACN, and 15 μL 
aliquots were injected into the HPLC-MS/MS system.  
 
7.2.4 Sample Preparation 
 
 A stock solution (100 μg/mL) of the four analytes, diazepam, lorazepam, 
nordiazepam, and oxazepam was prepared in 50% ACN from the initial stock solutions 
originally kept in a refrigerator at 4oC. This stock solution was further diluted with 50% 
ACN to give a series of working standards with concentrations of 25, 50, 100, 250, 500, 
1000, 2500, and 5000 ng/mL. The internal standard (IS, diazepam-d5) was also prepared 
as a stock solution (100 μg/mL) in 50% ACN. A working standard solution of 1000 
ng/mL of IS was used for plasma samples analyses. All standard solutions were stored at 
4oC. Plasma standards were prepared by adding 50 μL of each working standard to 250 
μL of human control plasma. The resulting plasma standard concentrations ranged from 5 
to 1000 ng/mL. No sample pre-treatment, such as pH adjustment or ionic strength 
modification, was performed. Working standards preparation, internal standard addition, 
as well as plasma sample transfer was all performed by a Packard MultiPROBE II liquid 
handling system to minimize labor intensive. The sample plate should be vortex-mixed 




 Three sets of standard samples were prepared to evaluate recovery and matrix 
effects. The first set of samples was prepared to evaluate MS/MS response for neat 
standards injected in the mobile phase. The second set was prepared in plasma extracts 
originating from different plasma sources and spiked after extraction, and the third set 
was prepared in plasma from the same sources as in second set. The plasma samples were 
spiked before extraction. Recovery was determined by comparing the mean absolute peak 
areas of standards obtained from the third set to those from the second set. Matrix 
enhancement/suppression of ionization or "absolute" matrix effect was evaluated by 
comparing the absolute peak areas of the standards in post-spiked extraction samples to 
neat standards.  
 The precision of the in-tip SPME method using different type of fiber coatings 
was determined by using replicate analysis (n=5) of benzodiazepines in five different lots 
of human plasma at all concentrations utilized for construction of the calibration curves. 
The accuracy of the method was determined as the percentage between the mean 
concentrations observed and the nominal concentrations. 
 
 
7.3 Results and Discussion 
 
7.3.1 Performance of In-tip SPME Automation 
 
The evaluations of the performance of the in-tip SPME automation included the 
uniformity of aspiration and dispense in all wells and impact of the aspiration/dispense 
speed to extraction efficiency, effect of position of in-tip SPME fibers within wells, 
potential cross-contamination across wells during automation processes, fiber-to-fiber 




optimal calibration methods. The performance of different SPME fiber coatings was also 
compared with commercially available Varian C18 µ-SPE tips in terms of standard curve 
validation, recovery, and matrix effects. 
 
7.3.1.1 Uniformity and Speed of Aspiration and Dispense 
 
The uniformity of agitation is critical to SPME method precision especially when 
pre-equilibrium extraction is applied. Unlike other different agitation methods such as 
magnetic stirring, sonication, orbital shaking, etc., agitation in in-tip SPME automation is 
achieved by simply utilizing aspiration and dispense functions of the automation system. 
Therefore, the uniformity of agitation largely depends on the pipetting precision of the 
system. It has been reported that for Tomtec Workstation, a %CV of 2 to 3% could be 
achieved when aspiration and dispense volumes range from 10 to 450 µL.200 Other 
factors, such as viscosity of the biological sample and/or fiber to fiber reproducibility, 
could also contribute to the overall performance of agitation. To evaluate the uniformity 
of aspiration and dispense, 12 individual Oasis HLB-coated polymer monoliths and 
PDMS-DVB fibers, as well as Varian C18 µ-SPE tips were placed randomly in a 96-tip 
plate for sample extraction. Experimental conditions including analyte and internal 
standard concentrations in each well, sample extraction time, and desorption solvent and 
time were all kept the same to avoid any differences that could contribute to the precision 
of the uniformity. 200 ng/mL of diazepam in plasma with diazepam-d5 as internal 
standard was used in the experiment, and 80 aspiration/dispense cycles were applied with 
desorption conditions described in the experimental section. It was anticipated that the 
uniformity of aspiration and dispense should be independent of various tips and the 




independent extractions using different types of tips with 2.5%, 2.8%, and 2.4% for Oasis 
HLB-coated polymer monoliths, PDMS-DVB and Varian C18 µ-SPE tips, respectively, 
despite that the amount of diazepam extracted was different with different types of 
coatings/tips. 
  The speed of aspiration and dispense is another important parameter for in-tip 
SPME process, faster aspiration allows rapid transfer of analytes from the sample 
solution to fiber coatings. The faster the speed, the shorter the equilibrium time and the 
higher the amount of analyte extracted under pre-equilibrium conditions. There are three 
types of aspiration and dispense speed available, from low, medium, to high in a typical 
Tomtec Quadra 96 workstation. It was found that there were no significant differences 
among three different types of speed in terms of the uniformity of aspiration with CV% 
values between 5.4-9.1% from five individual extractions at each speed using Oasis HLB 
polymer monoliths. High speed is recommended for in-tip SPME extraction using a 
Tomtec Quadra 96 workstation to a shorten extraction and desorption time 
 
 
7.3.1.2 Position of In-tip SPME Fibers 
 
During in-tip SPME sample extraction, 96 tips could be loaded simultaneously by 
a Tomtec workstation and placed at any position within the wells of a 96-well plate. To 
investigate the effect of position of in-tip SPME fibers to the extraction variations of intra 
and inter-wells, three different positions inside the wells were tested: the tips positioned 
immediately below the sample surface, the tips positioned in the middle of the sample 
solution, and the tips positioned near the bottom of the well. Since the analyte extraction 




on the amount of analyte extracted as long as other parameter were kept the same such as 




7.3.1.3 Cross-contamination and Carry-over 
 
Cross-contamination could be a potential issue for any high throughput methods 
using an automated liquid handling system. Since sample extraction and desorption 
processes with in-tip SPME approach are fully automated, it is important to evaluate 
cross-contamination in each step. According to the sample process procedures described 
in the experimental section, the main steps of automated in-tip SPME includes tip loading 
and conditioning, sample extraction, washing, desorption, and tip cleaning. Because 
sample extraction and desorption steps are accomplished through repeated aspiration and 
dispense cycles within the wells of the 96-well plate, cross-contamination is unlikely to 
happen in these steps. However, as the probe with 96 tips is moving from one place to 
another on the deck of the Tomtec workstation during the whole process, tip dripping 
from plasma residues or desorption solvent could occur which may cause cross-
contamination in certain wells. To eliminate these possibilities, there are two functions of 
the Tomtec workstation that could be utilized. One is to shake the tip rack to the sidewall 
of the sample plate after sample extraction to avoid dripping from plasma residues; the 
other is to apply air gap at the end of each tip during desorption solvent transfer.  
Experiments were conducted by testing random blank well locations during assay 
validation with different types of coatings, and no cross-contaminations were observed in 




In fiber SPME, carryover is inevitable due to the repeated use of a single fiber. 
Carryover is caused by the incomplete desorption of analyte from the SPME coating, 
therefore, great effort has to be put in to minimize carryover by developing additional 
steps in the method to clean the fiber between each extraction. This will definitely affect 
the overall efficiency of sample throughput even in automated SPME method. Carryover 
was investigated with different fiber coatings using automated in-tip SPME approach, 
and the highest concentration diazepam standard in plasma assay validation (1000 ng/mL) 
was used. It was found that carryover was ranged from 4 to 11% using 100 µL of ACN 
(0.1% formic acid) as desorption solvent with 20 times of aspiration and dispense cycles. 
The degree of the carryover effects was in agreement with our previous observations21 
which indicated that carryover could not be neglected. Currently, the possible strategies 
to minimize or eliminate carryover are to explore optimized desorption conditions such as 
using different solvent combinations and increasing fiber cleaning time with large 
volume of desorption solvent, or to use disposable fibers, which will be more feasible to 
apply SPME assay for routine bioanalytical analysis. In this study, carryover was 
minimized with additional 40 times of aspiration and dispense cycles using 80% MeOH 
in tip cleaning plate after plasma sample extraction and desorption.  
 
 
7.3.1.4 Fiber-to-fiber Reproducibility 
 
It is desirable to achieve excellent fiber-to-fiber reproducibility for high 
throughput sample analysis with multiple SPME fibers in parallel extraction format; 
however, fiber-to-fiber reproducibility will not impair the precision and accuracy of 




fibers, especially when stable isotopic labeled internal standard is applied. This was 
demonstrated from the uniformity of aspiration and dispenses experiment where in house 
tailor-made Oasis HLB-coated polymer monoliths, PDMS-DVB and Varian C18 µ-SPE 
tips were compared. 12 tips of each type were used for extraction in plasma matrix 
simultaneously; the %CV value from absolute peak areas was 14.9%, 18.6%, and 5.3% 
for Oasis HLB-coated polymer monoliths, PDMS-DVB and Varian C18 µ-SPE tips, 
respectively. When labeled compound was used as an internal standard, the %CV value 
was down to 2.5%, 2.8%, and 2.4% for three different tips, which were fabricated from 
completely different approaches. Many factors could affect the performance of the fiber 
in biological fluids extraction and, therefore, the results of fiber-to-fiber reproducibility, 
such as uniform fiber fabrication during preparation, effect of extraction speed, and carry-
over of analyte in the extraction phase, etc. It is expected that in high throughput multiple 
fibers SPME analysis, the automation of the coating procedure and sample extraction and 
desorption will improve inter-fiber reproducibility and,consequently, system performance. 
 
 
7.3.1.5 Multiple-extraction Reproducibility 
 
As a non-exhaustive extraction method, SPME provides very low recovery in 
comparison with other sample preparation methods such as LLE and SPE. Sensitivity is 
often a critical issue in SPME method, which may prevent its application in 
determination of target analyte at very low concentrations. This disadvantage could be 
overcome by multiple solid phase extraction (MSPME), a stepped consecutive extraction 
procedure that could result in either an increase in extraction yield or a decrease in 




extracted amount. Based on previous studies201,202 with multiple extractions under non-
equilibrium conditions, considerably less time is required to obtain an extraction amount 
that is equal to that of one extraction at equilibrium. On the other hand, the extraction 
yield can be increased if multiple extractions are performed with the same total time as is 
needed for one extraction at equilibrium time. This interesting feature is extremely useful 
in compensating the disadvantage of relatively low recovery of SPME especially when 
extraction time is very long in order to achieve equilibrium. However, MSPME has not 
been widely used, as expected, mainly because of the intensive labor and lack of 
reproducibility of using one single fiber manually. A comparison experiment was 
performed using automated in-tip SPME approach to evaluate the reproducibility and 
sensitivity between single SPME and multiple SPME. Ten individual PDMS-DVB fibers 
were used to extract benzodiazepines solutions from plasma samples at a concentration 
from 5 to 5000 ng/mL in triplicate, the aspiration and dispense cycles were 1 × 80 times 
and 4 × 20 times, respectively. For desorption, the total aspiration and dispense cycles 
was kept the same between single SPME (1 × 40 times) and multiple SPME (4 × 10 
times). It was found that the extraction amount increased consistently across the 
concentration range for each compound in multiple SPME. The mean absolute peak area 
ratios between multiple and single SPME with %CV values from 10 concentration points 
for diazepam, lorazepam, nordiazepam, oxazepam, and internal standard, d5-diazepam 






7.3.1.6 Selection of Optimal Calibration Methods 
 
Selection of an appropriate calibration method is essential in high throughput 
bioanalytical analysis. This is even more important in multiple fibers parallel extraction 
as the fiber-to-fiber reproducibility could be significantly improved with the utilization of 
stable isotopic labeled internal standard as discussed previously. Several calibration 
methods have been proposed in the literature67 for quantitative determination of analyte 
concentrations in SPME, such as external calibration, standard addition, internal standard, 
standard-in-fiber calibration, and equilibrium extraction calibration. In high throughput 
biological sample analysis using SPME, the best approach is to use internal standard 
calibration because it is simple and easy without requiring any additional experiments. 
However, stable isotopic labeled internal standard is not always available and analog 
compound has to be used which may not be able to compensate the different variations 
during sample preparation and analysis. Figure 7-1 compares the results obtained from 12 
random selected fibers of Oasis HLB-coated polymer monoliths and PDMS-DVB, as 
well as Varian C18 µ-SPE tips for the extraction of diazepam using different calibration 
methods tested (1) calibration without internal standard, (2) standard-in-fiber calibration, 
























Figure 7-1 Comparison of calibration without internal standard, standard-in-fiber 
calibration and D5-diazepam as internal standard calibration methods for the 




7.3.1.7 Overall Performance of Different SPME Fibers and Varian C18 µ-SPE 
Tips 
 
Representative extraction time profiles for diazepam using Oasis HLB-coated 
polymer monoliths, PDMS-DVB fibers, and Varian C18 µ-SPE tips are depicted in 
Figure 7-2. Equilibrium was reached quite rapidly for Varian C18 µ-SPE tips in 40 
aspirations/dispenses cycles, which were about 5 minutes; whereas for SPME fibers, 
equilibrium was not reached even after 320 aspirations/dispenses cycles in both cases. 
This clearly indicated the different extraction mechanism between exhaustive extraction 
of SPE and equilibrium extraction of SPME. The extraction recoveries from C18 µ-SPE 
tips for benzodiazepines were generally higher than those from SPME fibers (Table 7-1), 




because the elution conditions were not optimized.203 It was very promising to notice that 
Oasis HLB-coated polymer monoliths provided from13.7 to 46.5% recoveries for SPME 
where absolute recoveries were often less than 1% for many SPME fibers. The larger 
surface areas of polymer and the weak intermolecular interactions and hydrophobic 
interactions because HLB particles all played important roles in increasing analyte 
extraction efficiency. No significant matrix effects were observed for SPME fibers in 
benzodiazepines as shown in Table 7-1, the absolute matrix effects were in the range 
between 71.4 and 111.2%. It was unexpected that C18 µ-SPE tips shown relative larger 
matrix effects than SPME fibers with ion enhancement for diazepam and ion suppression 
for lorazepam, nordiazepam, and oxazepam.  
Aspiration/Dispense Cycle


















Figure 7-2  Extraction time profile of 200 ng/mL diazepam in human plasma using 
Oasis HLB-coated polymer monoliths, PDMS-DVB fibers, and Varian C18 µ-SPE tips 




Table 7-1 Calculated Recovery and Matrix Effects for Various Compounds using SPME 
Fibers and Varian C18 µ-SPE Tips a 
 
  Recovery (%) Matrix effects (%) 
Analyte Oasis HLB PDMS-DVB 
Varian C18 





Diazepam 46.5 [9.7] 12.3 [9.2] 73.9 [10.4] 96.2 [7.1] 91.6 [6.8] 110.5 [9.0] 
Lorazepam 18.6 [3.2] 3.7 [24.0] 34.6 [8.1] 88.1 [13.9] 111.2 [18.2] 69.2 [8.2] 
Nordiazepam 22.2 [7.0] 5.8 [15.5] 46.5 [14.2] 91.7 [13.6] 108.9 [13.6] 72.8 [11.2] 
Oxazepam 13.7 [8.7] 3.3 [27.0] 26.4  [7.0] 71.4 [11.7] 98.1 [21.7] 62.8 [17.1] 
 
a Recovery and “absolute” matrix effects were evaluated at 0.1 µg/mL for 
benzodiazepines in five different lots of human control plasma under conditions as 
described in the experimental section 
 
 
The selected conditions for the determination of benzodiazepines in human 
plasma were partially validated to compare the suitability of using Oasis HLB-coated 
polymer monoliths, PDMS-DVB fibers, and Varian C18 µ-SPE tips for quantitative 
bioanalytical analysis. Five standard curves were prepared in five different lots of human 
control plasma based on what was proposed by Matuszewski et al. for bioanalytical assay 
validation.89,90 Under the same LC-MSMS conditions, for Oasis HLB-coated polymer 
monoliths and Varian C18 µ-SPE tips, the calibration curves were linear in the range of 
5-1000 ng/mL using 100 µL of plasma for all benzodiazepines; and in the range of 20-
1000 ng/mL for PDMS-DVB fibers. As shown in Tables 7-2 and 7-3, for all compounds 
and all levels, accuracy of the results does not deviate more than 15% from nominal 
concentration and precision is within 20% for both Oasis HLB-coated polymer monoliths 
and Varian C18 µ-SPE tips, which demonstrates that both are suitable for high 
throughput quantitative bioanalysis. On the other hand, the accuracy results from PDMS-




assays even the calibration range is less than 4 times comparing with that of using Oasis 
HLB-coated polymer monoliths (Table 7-4). 
 
Table 7-2 Calibration Curves for the Determination of Diazepam, Lorazepam, 
Nordiazepam, and Oxazepam in Human Plasma using Varian C18 µ-SPE Tips 
 
Accuracy (%) a  [%CV] (n= 5) Nominal 
Conc. 
(ng/mL) Diazepam Lorazepam Nordiazepam Oxazepam 
5 100.7 [5.9] 93.2 [11.0] 101.0 [11.3] 95.8 [2.2] 
10 101.9 [6.6] 108.1 [9.9] 101.0 [4.0] 105.1 [6.9] 
20 94.0 [3.6] 110.1 [8.5] 96.2 [5.9] 107.8 [9.1] 
50 100.1 [1.6] 105.9 [2.6] 97.3 [9.7] 100.4 [6.5] 
100 97.1 [1.2] 101.6 [14.9] 96.8 [5.6] 98.9 [11.9] 
200 95.0 [0.4] 85.0 [11.3] 89.4 [11.3] 85.3 [10.0] 
500 103.6 [2.0] 96.5 [12.6] 103.7 [7.7] 99.3 [9.5] 
1000 107.5 [2.8] 99.6 [17.8] 114.5 [3.4] 107.4 [13.7] 
R2  b 0.9991 0.9988 0.9958 0.9969 
 
a  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100% 
b Linear regression of peak area ratio of analyte/internal standard vs. concentration (x), y= 




Table 7-3 Calibration Curves for the Determination of Diazepam, Lorazepam, 
Nordiazepam, and Oxazepam in Human Plasma using Oasis HLB SPME 
 
Accuracy (%) a  [%CV] (n= 5) Nominal 
Conc. 
(ng/mL) Diazepam Lorazepam Nordiazepam Oxazepam 
5 101.1 [11.7] 99.1 [12.5] 103.2 [2.4] 101.5 [14.5] 
10 99.2 [3.8] 98.1 [5.2] 92.5 [1.9] 95.6 [10.8] 
20 95.9 [1.5] 102.7 [5.2] 98.6 [2.8] 99.4 [2.1] 
50 105.2 [3.0] 112.9 [11.5] 109.6 [5.5] 111.5 [10.1] 
100 99.9 [3.7] 98.4 [4.5] 100.4 [6.5] 96.3 [7.6] 
200 96.1 [0.6] 96.7 [7.7] 95.4 [6.3] 99.2 [10.1] 
500 102.4 [1.9] 99.8 [6.5] 101.9 [5.4] 100.8 [11.4] 
1000 100.3 [2.1] 92.4 [2.4] 98.4 [3.8] 95.6 [5.4] 
R2  b 0.9998 0.9986 0.9996 0.9993 
 
a  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100% 
b Linear regression of peak area ratio of analyte/internal standard vs. concentration (x), y= 




 Table 7-4 Calibration Curves for the Determination of Diazepam, Lorazepam, 
Nordiazepam, and Oxazepam in Human Plasma using PDMS-DVB SPME 
 
Accuracy (%) a  [%CV] (n= 5) Nominal 
Conc. 
(ng/mL) Diazepam Lorazepam Nordiazepam Oxazepam 
20 112.2 [1.7] 113.5 [4.4] 108.6 [8.0] 114.8 [8.9] 
50 83.8 [0.8] 83.7 [1.2] 92.3 [3.7] 88.2 [4.3] 
100 98.6 [1.0] 91.2 [13.2] 95.2 [0.5] 90.8 [13.9] 
200 103.7 [1.4] 114.6 [0.5] 104.2 [3.0] 112.8 [0.3] 
500 94.6 [2.4] 106.8 [1.4] 99.4 [0.9] 103.9 [0.6] 
1000 107.4 [1.6] 90.7 [9.8] 100.7 [0.5] 90.3 [5.1] 
R2  b 0.9958 0.9888 0.9998 0.9913 
 
a  Expressed as [(mean calculated concentration)/(nominal concentration)] ×100% 
b Linear regression of peak area ratio of analyte/internal standard vs. concentration (x), y= 






In summary, the performance of Oasis HLB-coated polymer monoliths is 
comparable to that of Varian C18 µ-SPE tips in quantitative drug analysis using 
benzodiazepines as model compounds. Varian C18 µ-SPE tips provided relatively better 
extraction recovery and less extraction time to achieve required assay sensitivity, but with 
relatively larger matrix effects. In general, extraction efficiency is fairly low from fiber 
based extraction such as PDMS-DVB, which further demonstrates that SPME is more 
suitable for drug analysis in PK studies when dose levels are relatively high, unless more 
specific and selective coatings or other types of SPME fiber configuration such as Oasis 
HLB-coated polymer monoliths using photo-polymerization are developed. Carryover 
using 1000 ng/mL of diazepam extracted from 250 µL of plasma was found to be 4.1, 
10.6, and 5.8 after the initial desorption with ACN (0.1 % formic acid) as desorption 
solvent for Oasis HLB-coated polymer monoliths, PDMS-DVB and Varian C18 µ-SPE 
tips, respectively. Although Varian C18 µ-SPE tips are not designed to be used 
repeatedly, it was found that the extraction amount did not decrease up to 5 times in 
plasma samples, however, tip blocking was observed for several tips where no sample 
extraction occurred. The phenomenon was not observed in both SPME coatings and the 
tips were used more than 10 times. It can be concluded that in-tip SPME has the ability to 
handle very complex samples such as whole blood14 with no sample pretreatment, which 
results in significant timesavings, versus µ-SPE tips, which require sample pretreatment 
in general.  
 
7.3.2 Comparison of Different Automated SPME Approaches 
 




with the first commercially available SPME robotic station (Concept 96, PAS 
Technology), which is capable of preparing up to 96 samples in a fully automated way. 
Both fiber geometry and thin-film configuration was applied in the automation processes 
for high throughput parallel SPME sample preparation. A thorough evaluation of the 
Concept 96 autosampler was given to describe the advantages and limitations of the 
system in bioanalytical analysis. Head-to-head comparisons between automated in-tip 
SPME and other SPME configurations, such as blade and thin-film geometries using 
Concept 96 autosampler were performed in terms of SPME conditions, automation 
performance, and assay validation results. 
 
7.3.2.1 Evaluation of Concept 96 Autosampler 
 
The first prototype of Concept 96 consisted of a three-arm robotic auto-sampler 
that was fully controlled with Concept software and two orbital agitators.78 One XYZ arm 
of the auto-sampler was to hold, transport, and position the 96-fiber SPME device for the 
extraction and desorption steps of SPME. The second arm was equipped with a N2 
below-down device to perform solvent evaporation and analyte pre-concentration steps if 
necessary. Finally, one XYZ arm was equipped with a 250 µL syringe with dual function 
of liquid/solvent dispensing and direct injection of samples into LC-MSMS instruments. 
The initial multi-fiber SPME device was based on a commercially available pin-tool 
replicator to support different types of SPME coatings109 and the replicator was attached 
to the one of auto-sampler arms with the appropriate screws. A new custom-built multi-
fiber SPME device was later developed to accommodate 0.061" thickness of fibers in 
order to increase surface area of coatings, as well as to improve the robustness of the 




Recently, the configuration of the SPME device has been changed from commonly used 
fiber or blade geometry to thin-film geometry and 96 thin-film devices are commercially 
available from PAS technology.65,66 
It was very clear that the original idea of the Concept 96 was aimed at achieving a 
higher degree of automation and high sample throughput of SPME. However, the system 
was not designed in a way that sample preparation and injection could be performed 
simultaneously and, therefore, sample high throughput could not be achieved as the 
system claimed. In addition, since the system had to be connected to a LC-MSMS system 
for sample injection after sample preparation, it was not good laboratory practice from a 
safety point of view as the whole system was in an open environment, especially when 
biological samples and organic solvents were used in sample preparation process. In 
Concept 96, the sample plate was vibrated by the orbital agitator at a certain speed; fiber 
bending could not be avoided using the similar size of any conventional SPME fibers; 
thus, in order to immobilize multi-fibers, in either blade or thin-film geometry, the size of 
the individual fibers was much larger. The increasing of extraction phase volume and 
surface area resulted in higher extraction efficiency (higher absolute recovery) and 
enhanced extraction rate; on the other hand, large volumes of biological samples and 
desorption solvents were necessary to completely immerse the full length of the coated 
blade/thin-film in order to achieve reasonable method accuracy and precision. For 
example, 800 µL of blood sample and 800 to 1000 µL of desorption solvent were used in 
one of the reported studies,78 while in current bioanalytical analysis, sample volumes 




consumption of organic solvent less than 500 µL was quite often in PPT and SPE 
methods.  
 
7.3.2.2 Comparison of In-tip SPME, Blade SPME and Thin-film SPME 
 
The performance of automated in-tip SPME approach was compared against 
blade and thin-film geometries using Concept 96 automation system. A detailed 
comparison is summarized in Table 7-5 including (1) SPME conditions, such as fiber 
coating type, sample volumes, sample pretreatment, extraction and desorption time, etc; 
(2) LC-MSMS conditions; (3) automation performance, such as fiber position, agitation 
speed, sample throughput, and inter-fiber reproducibility, etc, and (4) validation results. 
In terms of sample throughput, all approaches are compatible with 96 samples 
prepared in about 90-100 minutes, and the main steps including fiber precondition, 
extraction, and desorption are fully automated. Inter-fiber reproducibility significantly 
improved with the utilization of an internal standard in both in-tip and blade geometries, 
which indicated that different automation systems did not play critical roles in the 
performance of various multi-fiber SPME configurations. Assay validation was 
performed independently for in-tip SPME using Oasis HLB polymer monoliths in plasma 
and for blade-geometry SPME using RP-amide C16 in blood. For in-tip SPME, the 
results of five-curve validation prepared in five different lots of plasma are very 
encouraging with linear range of 5-1000 ng/mL for all benzodiazepines, and the overall 
intraday accuracy and precision is 92-113% and 1-14%, respectively. Absolute recoveries 
are about 14-46% and the absolute matrix effects are 71-96%. For blade-geometry SPME 
using Concept 96 auto-sampler, five-curve validation was prepared in two different lots 




500 ng/mL for lorzepam and oxazepam. The overall intraday accuracy and precision is 
87-111% and 2-17%, respectively, with absolute recoveries about 10-30%, and the 
absolute matrix effects about 95-102%. The relative deviations from nominal 
concentrations of benzodiazepines in five-curve validation using different approaches are 
shown in Figure 7-3. Assay validation was not conducted with thin-film geometry using 
Concept 96 system; however, because of the increase of absolute recovery, a low limit of 
quantification (LLOQ) of 0.2 ng/mL could be achieved, and the %CV of inter-fiber 
reproducibility is about 7% without utilizing any internal standard when 96 fibers were 
extracted in PBS buffer.  
 The biggest advantages of blade or thin-film geometry using Concept 96 system 
include the dramatic increase of absolute extraction recovery compared with conventional 
SPME fibers and robustness and reusability of the fiber coatings. For example, absolute 
recovery of diazepam is about 50% using C18 thin-film which is excellent for a 
microextraction; consistence extraction efficiency and reusability of C18-PAN coated 
thin-film fibers for more than 100 extractions of diazepam from PBS and human plasma 
have been observed. In addition, blade or thin-film geometry is particularly suitable for 
complex biological matrix, such as blood, tissues, etc. without any additional sample 
pretreatment. The main limitations of the above automated approach are that a large 
volume of biological samples and desorption solvent has to be used in order to achieve 
acceptable accuracy and precision and the the automation processes are totally dependent 
on Concept 96 system which is not very well designed and is not compatible to the 






Table 7-5 Comparison of Different Automated SPME Approaches for Benzodiazepines 
Determination in Biological Fluids 
Parameter In-tip SPME Blade-geometry SPME Thin-film SPME 
     
SPME conditions    
Analyte Benzodiazepines Benzodiazepines Benzodiazepines 
Matrix Plasma PBS/Blood PBS/Urine 
Fiber coating Oasis HLB polymer monoliths RP-amide C16 C18 
Sample volume 250 µL 800 µL 1000 µL 
Fiber pre-conditioning <5 min, 50% ACN 30 min, 50% MeOH 15 min, 50%MeOH 
Sample pre-treatment No No No 
Internal standard D5-diazepam D5-diazepam -- 
Extraction time 40 min 30 min 25 min 
Desorption time 5 min 30 min 30 min 
Desorption solvent 100 µL ACN 800 µL 50% ACN 1000 µL 80% MeOH 
Evaporation/reconstitution Yes/150 µL 50%ACN No No 
LC-MSMS conditions    
Column Restek BDS Hypersil C18 (50 x 2.1 mm, 3 µm) 
Waters Shield RP18 (50 x 2.1 mm, 
5 µm) 
Waters Shield RP18 (50 x 2.1 
mm, 5 µm) 
Mobile phase A: H2O (0.1% formic acid)  B: ACN (0.1% formic acid) 
A: 90% H2O/10% ACN (0.1% 
acetic acid)  B: 90% ACN/10% 
H2O (0.1% acetic acid) 
A: 90% H2O/10% ACN (0.1% 
acetic acid)  B: 90% 
ACN/10% H2O (0.1% acetic 
acid) 
Flow rate 0.4 mL/min, gradient 0.5 mL/min, gradient 0.5 mL/min, gradient 
Injection volume 15 µL 20 µL 20 µL 
MS conditions API 3000, TIS, positive API 3000, TIS, positive API 3000, TIS, positive 
     
Automation 
performance    
Fiber position Non critical Critical Critical 
Agitation speed Aspiration/dispense cycle Orbital agitation, 850rpm Orbital agitation, 850rpm 
Sample throughput 96 samples/90 min 96 samples/100 min 96 samples/95 min 
Instrumentation 
No extra device, coupled directly 
with commercially available 
liquid handling systems 
Utilizing customer designed "The 
Concept 96 robotic station" 
Utilizing customer designed 
"The Concept 96 robotic 
station" 
Inter-Fiber reproducibility 
15% RSD (n=96, no IS, in 
plasma); 6% RSD (n=96, with IS, 
in plasma) 
12% RSD (n=96, no IS, in PBS); 
7% RSD (n=96, with IS, in PBS) 
7.1% RSD (n=96, no IS, in 
PBS) 
Validation results    
Calibration range 5-1000 ng/mL in plasma 
4-1000 ng/mL (diazepam and 
nordiazepam); 4-500 ng/mL 
(lorzepam and oxazepam) in blood 
0.2-500 ng/mL in PBS 
Intraday accuracy 92-113% 87-111% -- 
Intraday precision 1-14% 2-17% -- 
Absolute recovery 14-46% 10-30% 17-51% 
Matrix effects 71-96% 95-102% -- 
Carry-over Non, disposable <0.3% in PBS <0.3% in PBS 
 
  
In-tip SPME demonstrated its unique automated approach of directly coupling any 
SPME fibers with commercially available automation systems, such as Tomtec, without 
introducing any additional devices. More importantly, in-tip SPME maintains the 
simplicity and advantages of conventional fiber SPME technique, and the approach is 
emendable to all fibers types possessing a wide range of different coating materials, 
which will overcome the drawback of limited selections of commercial available fibers 
and broaden its use with HPLC. This feature is extremely useful in the processes of 
developing automated SPME methods because different multiple fibers could be 
evaluated simultaneously for the determination of optimal extraction efficiency which 
will dramatically reduce the total method development time. Currently, two formats are 
commonly used for in-tip SPME, one is fiber-packed in-tip, where SPME fibers are put 
inside the pipette tips; the other is sorbent-packed in-tip, such as Oasis HLB polymer 
monoliths where extraction sorbent is prepared inside the tips through photo-
polymerization. For fiber-packed in-tip SPME, low recovery is still the biggest concern in 
the determination of target analyte in a very low concentration unless very selective fiber 
coatings are developed, otherwise, it may only be applicable as an alternative approach in 
pharmaceutical biofluid sample analyses to support PK studies at higher doses of analytes. 
Sorbent-packed in-tip SPME has shown great potential in high throughput drug analysis 
because of its simplicity and easy to fabricate, with a low-cost, enhanced extraction 
recovery, and no carry-over effects if used as a disposable. In addition, the SPME method 
selectivity could be greatly improved with a wide range of chemistries for reactions and 
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Individual data (blade-geometry SPME)
Mean (in-tip SPME) 
Mean (blade-geometry SPME) 
 
 
Figure 7-3  Comparison of relative deviations from nominal concentrations in 5-curve 




 Vuckovic et al. listed detailed troubleshooting procedures for automated thin-film 
SPME for high throughput analysis of biological fluids using Concept 96 system.196 
Some of the potential problems during SPME experiment such as sample or solvent spills, 
particle loss from the coatings, and improper thin-films lineup in the center of the wells 




never be encountered with in-tip SPME approach, which is a biggest advantage because it 
is essential to have simple, reproducible, and robust methods in routine drug analysis. 
 
7.3.3 Strategies for In-tip SPME Method Development and Validation 
 
SPME is a simple, solvent-free extraction technique, which combines sampling, 
sample clean up, and pre-concentration into a single step. However, SPME method 
development is tedious and time consuming because many parameters and steps are 
usually required to be investigated when a new SPME method is developed.190 Using the 
traditional approach with one single SPME fiber, it is practically impossible to 
investigate so many parameters in a short period of time, which prevents its applications 
in routine bioanalytical analysis. Since automated in-tip SPME has demonstrated great 
potential to be used for high throughput quantitative determination of drugs in bioanalysis, 
it is necessary to develop some new strategies to minimize labor intensive and to shorten 
the time in method development and validation. These strategies will mainly focus on 
method development scheme and key experiments involved to generate different SPME 
conditions simultaneously and systematic procedures in SPME assay validation for 
quantitative drug analysis.  
Table 7-6 listed some typical parameters and steps for optimization in SPME 
method development and validation. For high throughput drug analysis using automated 
in-tip SPME-LC/MSMS, some of the parameters are usually not necessary to be 
evaluated such as extraction mode, separation and detection method, agitation method 




SPME method development and, therefore, the total method development time will be 
compatible to that of other sample preparation approaches such as LLE and SPE. 
For automated in-tip SPME methods development, the following experiments 
should be considered and performed in sequence: 
A.  Evaluate different fiber coatings and optimize fiber extraction conditions. 
In the experiments, various SPME fibers are screened in biological matrix under three 
conditions: no sample treatment, pH adjustment, and salt effects. Sample volumes should 
start with 50 or 100 µL. The preliminary information on recovery and matrix effect could 
also be obtained if sample plate layout is arranged as shown in Figure 7-4. In addition, 
analyte extraction in matrix free samples such as PBS buffer could also be evaluated. A 
combination of following parameters could be selected as the default conditions: 
extraction time (30 minutes), desorption time (10 minutes), extraction speed (high), 
desorption solvent (100 µL of ACN, 0.1% formic acid), washing step between extraction 
and desorption (50 µL of water, 0.1% formic acid). In SPME method development, 
extraction at equilibrium is not necessary as long as enough sensitivity has been achieved. 
In general, the extraction time should not exceed 60-min otherwise SPME should not be 
considered if all other options such as fiber coatings, pH adjustment, salt effects, sample 
volume, etc. have been explored. Fiber conditioning procedure should follow the 





 Fiber #1 Fiber #2 Fiber #3 
X A B C X A B C X A B C 
X A B C X A B C X A B C Pre-Spike 
X A B C X A B C X A B C 
X A B C X A B C X A B C 
X A B C X A B C X A B C Post-spike 
X A B C X A B C X A B C 
             
Neat Neat Neat Neat  Neat Neat Neat  Neat Neat Neat  
 
Note:  Treatment X: PBS buffer pH 7.4 
 Treatment A: No sample treatment 
 Treatment B: pH adjustment 
 Treatment C: Salt effect 
 Neat: neat standard solution 
 
 
Figure 7-4  96-well plate layout for evaluation of recovery and matrix effects under 
different experimental conditions with various SPME fibers using automated in-tip 
SPME 
 
B. Select one (or two) fibers with the best extraction efficiency from section 
A and perform experiments of optimization on desorption conditions and sample volume, 
as well as evaluation of carry-over effects. Different compositions of desorption solvent 
mixtures such as MeOH/water, ACN/water, ACN/water/0.1% acetic acid or any other 
combinations should be evaluated. Desorption solvent that is compatible to the mobile 
phase will be helpful to achieve acceptable peak shape and eliminate the need for an 
evaporation/reconstitution step if no pre-concentration is required. The total desorption 
time should be less than extraction time with typical 10 to 30-min. Effect of sample 
volume of extraction efficiency may not be dramatic when 25-250 µL of biological fluids 




between fiber and matrix. Carry-over should be assessed by injecting an extracted double 
blank immediately after an extracted highest standard and the analyte response in the double 
blank should not exceed 20% of the LLOQ. Disposable tips should be considered if carry-
over is difficult to minimize with too much effort. 
C. Select the fiber with the most optimized extraction and desorption 
conditions to evaluate linear curve range with an appropriate calibration method. The 
stability of quality control (QC) samples could also be evaluated in this step with one 
selected concentration point. Assay sensitivity could be increased by adding an 
evaporation/reconstitution step if all other parameters are optimized, or by increasing 
injection volume with no significant matrix effects. QC samples should be prepared as 
close as possible to real samples with the amount of organic solvent in the spiked 
biological samples kept below 1% (vol/vol). However, for calibration standard samples 
preparation, incubation time is not necessary to establish binding equilibrium between 
analyte and biological protein as pointed in many other studies105, 196 as make-up solvent 
will be added to real biological samples during sample preparation. 
D. Perform in-tip SPME method validation according to different 
requirements for discovery and development assays. Currently, there are no standard 
validation procedures for bioanalytical assays before drug development stage in industry, 
while in clinical sample analysis; assay validation should follow FDA guidelines. In 
general, selectivity, sensitivity, standard curve, intraday variation, recovery, stability, 
matrix effect, sample dilution, and carryover should be determined during assay 
validation procedures. To assess intraday precision and accuracy, at least five replicates 
of standard curves should be prepared and analyzed. The precision value for these 





“relative” matrix effect. Stable isotopic labeled internal standard is highly recommended 
if it is available. Recovery experiments should be performed at three concentrations (low, 
middle, and high), and results reported as a mean concentration at each level obtained 
from five different lots of matrix. Storage stability of the analyte in the biological matrix 
and the influence of freeze-thaw cycles should be examined by using a set of QC 
prepared by spiking biological fluids with analyte to yield low QC (within 3x the 
concentration of the LLOQ), middle QC (near the center), and high QC (near the upper 
boundary) of the standard curve. All validation procedures can be accomplished with 




Table 7-6 Typical Parameters and Steps that Require Optimization during Traditional SPME and In-tip SPME Method Development 
Procedures 
 
Typical parameters and steps for optimization in  
SPME method development and validation 
Parameters optimization for in-tip SPME 
method development and validation 
 
Comments 
o selection of fiber coating 
o selection of extraction mode 
o selection of separation and detection method 
o selection of agitation method 
o selection of derivatization reagent, if required 
o optimization of sample volume 
o optimization of extraction conditions (pH, ionic 
strength, temperature) 
o optimization of water content and organic solvent 
content 
o determination of extraction time 
o optimization of desorption conditions 
o selection of calibration method 
o method validation 
o selection of fiber coating 
o optimization of sample volume 
o optimization of extraction conditions 
(pH, ionic strength) 
o determination of extraction time 
o optimization of desorption conditions 
o selection of calibration method 
o method validation 
 
 
o in-tip SPME is normally 
performed with direct extraction 
due to polar compounds for 
majority of  drug candidates  
o HPLC/UPLC-MSMS is the best 
option in terms of column 
separation and sensitivity 
o sample aspiration and dispense is 
the only process for in-tip SPME 
sample extraction 
o temperature and derivatization are 









Run 1 Run 2 Run 3
• standard curve: 5-curve (at 
least 6 points each curve)
• selectivity: 6 DB and 6 SB 
from 6 different sources
• cross-talk: ULOQ without IS
• dilution: 10x of ULOQ (n≥3)
• carryover: DB right after 
ULOQ
• stability: 
1-FT cycle: LQC, MQC and 
HQC (n=5, each)
3-FT cycle: LQC, MQC and 
HQC ( n= 5, each)
RT: LQC, MQC and HQC 
(n=3, each)
• one standard curve
• recovery and matrix effect:
three concentrations (low, 
middle, high) prepared in pre, 
post-spiked samples and neat 
standard solutions
• autosampler stability: one 
standard curve with one set 
of QCs at the beginning and 


















Note:  DB: double blank, control blank biological sample without drug and internal 
standard (IS); 
 SB: single blank, same as DB except with IS; 
 ULOQ: upper limit of quantification; 
 FT: freeze thaw, quality control (QC) samples should be stored at -20oC or other 
temperatures adequate for long-term storage of clinical specimens for at least 24 
hr and thawed unassisted at room temperature (RT) for the first FT cycle. When 
completed thawed, the samples should be refrozen for at least 12 hrs under same 
conditions and thawed a second time. The FT cycle should be repeated and then 
analyzed on the third cycle; 
 LQC, MQC and HQC: low QC (within 3x the concentration of LLOQ, low limit 
of quantification); middle QC (near the center); HQC (near the upper boundary) 
 RT stability: QC samples should be thawed at RT and kept for at least 4 hr or 
longer before analyzed. 
 
 




7.3.4 Potential Applications and Future Directions of In-tip SPME in 
Bioanalysis 
 
To understand the advantages and limitations of SPME in bioanalysis would be 
extremely helpful for the development and application of SPME automation, especially 
compared with other commonly used sample preparation techniques, such as PPT, LLE, 
and SPE. Many reviews have been published on similar topic; however, there is no 
comprehensive summary available to compare SPME with other approaches in terms of 
method development and assay performance. In addition, many claimed advantages of 
SPME may not be applicable in routine quantitative drug analysis, and a big gap still 
exists between applications of SPME in the laboratory and in the pharmaceutical industry. 
Automated in-tip SPME demonstrated a great potential to bridge this gap and to 
overcome the challenges of applying SPME as an alterative approach for high throughput 
bioanalysis, while still maintaining the simplicity of SPME technique.  
 Table 7-7 summarized method development and assay performance based on 
PPT, LLE, SPE, and SPME, respectively. A decision tree for sample preparation method 
selection is also illustrated in Figure 7-6. Despite the facts that PPT provides very poor 
sample clean up which may results in significant matrix effects; LLE and SPE requires 
more solvent, significant method development time, and considerable sample pre-
treatment, in reality, PPT is the main sample preparation method in use, about 90% in 
drug discovery bioanalysis; and SPE is always the solution when PPT and LLE cannot 
meet the assay requirement in clinical sample analysis. Although there are many claimed 
advantages of SPME over traditional techniques for bioanalytical applications, such as 
very clean sample extracts, similar sample throughput, capable of handling complex, 





to obtain free and total concentration from a single biofluid sample, and very low cost of 
analysis per sample, up to now, SPME technique has not been accepted by the 
pharmaceutical industry. Considering the requirements and trends in high throughput 
bianalytical analysis and the principle disadvantages of SPME technique, it can be 
concluded that SPME could only be considered as an alternative sample preparation 








• No sensitivity concern
• HILIC column is selected for HPLC
• Unstable compound/metabolite
• Multiple analytes w/ different polarity
• Volatile compound with high sensitivity 
requirement
• Extremely polar compound with sensitivity 
requirement and matrix effect concerns.
• Non-volatile compound
• No multiple analytes w/different polarity




















Table 7-7 Comparison of Different Sample Preparation Approaches in Bioanalysis 
  PPT LLE SPE SPME 
       
Method Development         
Analyte 
Useful to multiple 
analytes/metabolites with 
different polarities; unstable 
compounds 
Suitable for non-volatile 
compounds 
Applicable to volatile and 
extremely polar compounds Good for volatile compounds 
Matrix 
Plasma, blood, serum, tissue 
homogenates, in vitro incubation 
mixtures 
Plasma, blood, serum, urine Plasma, serum, urine, in vitro incubation media 
Whole blood, urine, serum, plasma, 
complex heterogeneous mixtures  
Sample pretreatment Not necessary in general Requires pH modification to increase analyte recovery 
Requires dilution, centrifugation, 
pH adjustment, and filtration to 
ensure analyte retention 
Simple to no sample pretreatment 
Simplicity Simple, generic, and universal procedure Relative simple to do as a routine 
Versatile, complex, and labor 
intensive method development, 
despite generic sorbents and 
methods have been developed 
Relative simple but labor intensive 
method development 
Method development time 
No method development time: 
easy to perform, simply mix 
solvents, centrifuge/filtration 
Moderate method development 
time: multiple transfer steps and 
limited amount of non-water 
soluble extraction solvents, requires 
to examine the influence of pH, 
ionic strength, etc. 
Long method development time: 
difficult to grasp the chemistry 
of the technique duo to great 
selectivity of SPE sorbents and 
the many choices for 
manipulating pH and solvent 
conditions 
Long method development time: 
requires to examine too many 
parameters including fiber coating, 
extraction mode, agitation method, 
pH, ionic strength, extraction time 
and desorption time and solvent, 
calibration method, etc. 
Automation 
Semi-automated procedure as 
plate sealing, vortex mix and 
centrifugation steps could not be 
automated 
Semi-automated procedure as plate 
sealing, vortex mix, centrifugation, 
and evaporation steps could not be 
automated 
Fully automated and integrated 
process for on-line SPE; not a 
fully automated process for off-
line SPE 
Fully automated and integrated 
process for in-tube SPME; not a 
fully automated process for  fiber 





Assay Performance         
Selectivity Non selective Moderate selective (limited in solvent selections) Very selective 
Moderate selective (limited in 
coating selections) 
Sensitivity 
Low sensitivity method, 
typically,1-10 ng/mL from 50 
L of sample with LC/MSMS 
Low LOD's are possible Most sensitive sample preparation method 
Relatively low sensitive, suitable 
for low volatile drugs with 
concentration range from 1 to 100 
g/mL 
Recovery 
High recovery (>95%) even 
with the extent of protein 
binding exceeds 99% 
Analyte recovery depends on 
sample pH and the characteristics 
of the organic solvent 
High recovery with evaporation 
steps needed 
Considerably low recovery range 
from 0.1% to 30% 
Reproducibility 
Less reproducibility, relatively 
high chances on validation and 
analytical run failures due to 
matrix effects and potential 
recovery losses 
Good reproducibility and good 
chances on successful validation 
and analytical run 
Vey good reproducibility and 
high chances on successful 
validation and analytical run 
Less reproducibility, relatively high 
chances on validation and 
analytical run failures due to low 
recovery and potential matrix 
effects 
Matrix effects 
Poor and limited sample cleanup 
with high potential of significant 
matrix effects in LC-MSMS 
analysis 
Very clean extracts and relatively 
low matrix effects with proper 
selection of organic solvent and 
adjustment of sample pH 
Very selective sample cleanup 
with minimized matrix effects; 
most effective method to remove 
phospholipids in plasma 
Matrix effects vary with fiber 
coatings and more prone to errors 
















     
Overall     
Advantages 
Simple, low cost, fast and 
universal sample preparation 
method dominantly used in drug 
discovery bioanalysis; 
applicable to very small sample 
volume (20-50 µL); easy for 
method transfer; first choice and 
good starting point for method 
development 
Wide applicability for many drug 
compounds; clean extracts with 
good selectivity and sample 
enrichment; relatively short method 
development time besides PPT; 
easy for method transfer; one of the 
most widely used methods in drug 
development bioanalysis  
Very selective sample extracts 
with minimized matrix effects; 
wide variety of sample matrices 
accepted and applicable for 
almost all compounds; high 
recovery with good 
reproducibility; low sample and 
solvent volumes; useful for 
volatile compounds where high 
assay sensitivity is required; 
suitable for full automation; easy 
for method transfer 
Rapid and solvent-less sample 
preparation method with sampling, 
extraction and concentration in one 
step; applicable to extreme sample 
volume and complex, 
heterogeneous samples such as 
whole blood without pretreatment; 
suitable for obtaining free and total 
concentration information from a 
single biofluid sample by 
appropriate calibration strategies, 
suitable for automation with 
relatively low cost 
Disadvantages 
 Dirty extracts with potential 
significant matrix effects; LC 
column and mass interface 
fooling due to ineffective protein 
removal; sensitivity limitations 
because of no sample pre-
concentration; possible low 
recovery for heat labile 
compounds when extra dry-
down is necessary to increase 
sensitivity 
 Very labor intensive and difficult 
for fully automation; environmental 
unfriendly because of large amount 
of organic solvent required, not 
suitable for volatile and oxygen 
labile reactive analytes due to a 
must dry-down procedure; potential 
emulation formulation problem  
 Relative time-consuming in 
method development because of 
difficulty to master the theory 
and usage; potential clogging 
problems and sample pre-
treatment always necessary; by 
far, the most expensive sample 
preparation method 
 Very limited selections of SPME 
coatings; sensitivity limitation 
because of low extraction recovery; 
very time-consuming in method 
development; lack of enough data 
to demonstrate the robust and 
reproducibility of SPME in routine 
high throughput drug analysis by 






In the drug discovery process, many compounds have to pass through a series of 
stages, which represent various in vitro and in vivo tests in order to qualify to be a 
development compound. The unique environment of drug discovery requires 
bioanalytical methods to be able to analyze many samples from many discrete 
compounds in various biological matrices in a high throughput fashion and a timely 
manner, hence, it is highly desirable to have a generic sample preparation method 
regardless of compound properties. Compared with PPT which is the dominant method 
before any compound reaches development stage, in-tip SPME is not suitable for the drug 
discovery environment, but could be used in some special cases especially when 
biological sample volume is extremely small (less than 25 µL); and when complex 
heterogeneous samples are encountered such as blood and tissue samples. One successful 
study of using in-tip SPME in drug discovery has been conducted in our laboratory 
recently when mouse blood volume was only available at 20 µL, SPME demonstrated its 
advantage over PPT that samples could be repeatedly extracted which was not feasible 
for PPT method when sample re-assay was needed. However, in-tip SPME technique is 
more suitable for the drug development environment, especially in later stage clinical 
studies, where robust clinical assays have been developed and applied to analyze 
thousands of samples and higher doses are normally selected. The advantages of in-tip 
SPME such as simplicity, solvent-less, and low cost will be notable over other sample 
preparation methods.   
The capability of determining total and free drug concentrations in the same time 
is one of the most remarkable advantages that are often claimed for SPME in 




ultrafiltration, and ultracentrifugation are the widely used methods for quantification of 
the binding of small molecule drug candidates to plasma proteins in drug discovery and 
development.204 These well established methods with commercially available 96-well 
devices allow automation and rapid determination for multiple compounds in a batch, and 
the significant bottleneck of plasma protein-binding (PPB) methods due to the lack of 
automation does not exist anymore. It is impractical that SPME will be used for high 
throughput screening purposes given the fact that each compound has to be calibrated in 
both biological fluid and buffer solution in order to obtain the free drug concentration, let 
alone that SPME conditions have to be optimized for each individual compound. This 
explains the situation that up to now the free drug concentration determination using 
SPME is only limited to laboratory researches.187, 205,206 Nevertheless, SPME is very 
promising for very hydrophobic molecules that have limited water solubility because the 
free drug is never partitioned into a solution that is void of protein. In addition, for highly 
protein bound compounds, SPME may be applicable to determine free drug concentration 
more accurately with very selective fiber coatings. The success of the automation 
approaches such as in-tip SPME or any other configurations will definitely make 
microextraction technique more compatible with other widely used approaches. 
One of the most potential applications of in-tip SPME is in DBS sampling. 
Recently, there has been increasing interest in the use of DBS to support PK/TK studies 
in small molecule drug discovery and development due to low blood volume requirement 
and the potential for simplified sample collection, storage, and shipment conditions.57,58 
The standard sample preparation approach for DBS analysis consists of punching out a 




analyzing by LC-MSMS. Although this standard procedure is most likely suitable for 
most of the compounds, performing this process manually is very time consuming and 
labor intensive. Automation of the sample preparation process is very necessary and it 
could be achieved by using different format of in-tip SPME other than fiber-packed in-tip 
(Figure 7-7A) and sorbent-packed in-tip (Figure7- 7B). Extraction sorbent (disk/film) 
could be packed within pipette tips as shown in Figure 7-7C, after blood sampling, 
known aliquot of blood samples will be collected in each individual tip and desorpted 
simultaneously afterwards for analysis. The whole sample preparation procedure could be 
easily automated to increase efficiency. In addition, sample throughout could be also 
achieved by using 96 or even 384 well collection plate. A workflow of using in-tip SPME 
during DBS sample preparation and analysis is illustrated in Figure 7-7D. 
The comparison results from in-tip SPME and rod or thin-film SPME clearly 
demonstrated that the performance of various automated SPME approaches is not 
completely dependent on an automation system; on the contrary, limited selection of 
SPME fiber coatings is still the bottleneck of preventing the technique to be widely 
accepted in routine bioanalysis. Thus, for future development of in-tip SPME or any 
other types of automated SPME, commercialization of simple, flexible, low-cost, and 
reproducible procedures for the preparation of SPME coatings for use with automated 
multi-fiber SPME is the key to promote the widely applications of the technique. In 
addition, the applicability of automated SPME for high throughput bioanalytical analysis 
should not be limited to certain selected compounds and matrices and the assay validation 
procedures for quantitatively determination of drug development candidates should be 




between researchers and pharmaceutical companies are important and mutually beneficial 
to fill up the gaps between applications of SPME in the laboratory and in the 
pharmaceutical industry. Finally, development of user friendly commercial SPME kits for 







































Figure 7-7  Configurations of (A) fiber-packed in-tip SPME, (B) sorbent-packed in-tip 
SPME, (C) disk/film-packed in-tip SPME, and (D) a workflow of using in-tip SPME in 











Unlike other exhaustive extraction methods such as SPE and LLE, where the goal 
is to extract as near as possible to 100% of the analyte from a sample, SPME is an 
equilibrium extraction. The extraction efficiency is determined by the partitioning of 
analyte between the sample matrix and the extraction phase. The higher the affinity the 
analyte has for the extraction phase relative to the sample matrix, the greater the amount 
of analyte extracted. Partitioning is controlled by the physicochemical properties of the 
analyte, the sample matrix, and the extraction phase. Typically, SPME extraction is 
completed when the analyte concentration has reached the equilibrium distribution 
between sample matrix and the extraction phase, where the amount of analyte extracted is 
constant and independent of a further increase in extraction time. However, in many 
cases, the time to reach equilibrium could be more than 10 h, which is impractically long. 
Therefore, some level of sample agitation is required in order to facilitate rapid extraction 
and transport analytes from the bulk of the sample to the extraction phase, and sometimes 
SPME is performed under pre-equilibrium conditions. For fiber SPME, the mass transfer 
from the sample matrix to the fiber coating is modeled using a zone referred to as the 
Prandtl boundary layer, which is considered as a region where analyte flux is 
progressively more dependent on analyte diffusion and less on agitation, as the fiber 
coatings approached. The analyte flux in the bulk of the sample is assumed to be 




controlled by diffusion. The presence of another binding matrix or hydrophobic phase, 
such as serum protein or humic acids, besides the SPME fiber, may strongly influence the 
extraction efficiency and complicates the calibration procedure. Binding matrices may 
interact by adsorbing to the fiber surface, thus, possibly blocking the exchange of analyte 
across the fiber boundary. This may also lead to an overestimation of the concentration in 
the fiber coating as the matrix-bound analyte adsorbed to the fiber coating is measured 
along with the analyte in the fiber coating. Therefore, it would be valuable to have a 
model that can be used to analyse measured concentrations in the fiber coating in a very 
complex sample matrix as a function of time. 
In SPME, depending on the types of fiber coatings, the extraction mechanism can 
be distinguished as absorption for liquid coatings and adsorption for solid coatings. When 
liquid coatings are used, the analytes partition onto the extraction phase and the analyte 
molecules are dissolved by the coating molecules.61,180,207,208 The magnitude of the 
analyte diffusion coefficient in the liquid coating allows the molecules to penetrate the 
entire volume of the coating with a reasonable extraction time. On the other hand, solid 
coatings possess complex crystalline structures which lead to reduced analyte diffusion 
coefficients within the structure, therefore, the extraction normally occurs on the surface 
of the coating. Several approaches have been proposed to mathematically model the 
kinetics of the absorption process to SPME liquid fibers such as PDMS. Vaes et al.80 and 
Heringa et al.209 model the fiber as a classical one compartment, first-order kinetic model 
with absorption and desorption rate constants as parameters. Such a model uses abstractly 
defined mass transfer coefficients between medium and fiber which are dependent on 




simple to use, it is not explicitly based on processes like diffusion and partitioning of the 
analyte and on the experimental conditions such as medium volume and fiber geometry. 
A mechanistically_based modeling approach180 has also been developed in which the 
mass transfer of the analyte from the bulk to the fiber coating is considered to be 
controlled by the molecular diffusion in the stagnant boundary layer around the fiber 
coating. The influence of the agitation condition on the uptake kinetics can be explained 
by this model. It can also be applied to predict kinetics based on parameters such as 
distribution coefficient, diffusion coefficient, and diffusion boundary layer thickness. 
However, additional parameters, such as fluid linear speed at the fiber surface, the fluid's 
kinematic viscosity and the diffusion coefficient of the analyte in the medium, are 
required to determine the boundary layer thickness. Recently, others have introduced 
mass transfer forced by the concentration difference between bulk medium and outer 
fiber surface,81,82 instead of mass transfer from bulk medium to fiber through an explicitly 
modeled stagnant layer around fiber. In this approach, the mass transfer coefficient is 
interpreted as the ratio of the unknown intra-layer diffusion (D) of the analyte and the 
unknown effective layer thickness (δ), where it is assumed that the diffusion process is 
instantaneously at steady state. Furthermore, the model includes binding of the analyte to 
a matrix of bovine serum albumin (BSA) to investigate the possible influence of a 
binding matrix on the uptake kinetics of analytes into the fiber. In this model, since the 
fiber coating thickness and the initial concentration of the analyte are known, the model 
requires the estimation of many parameters including diffusion coefficients, boundary 
layer thickness, fiber-medium partition coefficient, and association and dissociation 




however, from a numerical point of view, the model calculation times or numerical 
stability can become prohibitive for some combinations of these parameter values.   
 An understanding of the fundamental of thermodynamics and mass transfer of 
analytes in multiphase systems will provide insight and direction when developing SPME 
methods and identifying parameters for rigorous control and optimization. For example, 
based on the dynamic model proposed by Ai,68,69 Chen et al.70,210  demonstrated the 
isotropy of absorption and desorption in the SPME liquid coating fiber and proposed a 
new concept called "in-fiber standardization technique". Later this was termed as the 
"kinetic calibration method". The method uses the desorption of standards, which are 
preloaded in the extraction phase, to calibrate the extraction of the analytes. More 
recently, the one-calibrant kinetic calibration technique was developed. This desorption 
of a single calibrant to calibrate all extracted analytes. The technique eliminates the 
requirement of several isotopical compounds or high-concentration standards, and it 
simplifies the standard loading and quantitation procedures. Despite all the efforts and 
successfull applications of SPME modeling and simulation, the need still exists to 
develop simple and accurate models both for liquid coating fibers and for solid coating 
fibers as well. The increasing computation capabilities and the advances in the 
application of numerical techniques make it possible to include all transport steps in 
kinetic modeling and simulation. The effective use of the modeling approach will 
minimize the number of experiments needed in SPME method development and, 
therefore, shorten the total cycle time. In the current work, several model approaches 
were evaluated to investigate the kinetics of SPME extraction of the target analyte in a 




coatings. Model validation was performed by comparing the predicted results to previous 
experimental data in the literature. Different applications of SPME modeling approaches, 
including estimation of boundary layer thickness, time to reach extraction equilibrium, 




When a SPME fiber is exposed to an agitated sample matrix, mass transfer from 
the sample matrix to the surface of the SPME fiber coating occurs. The analytes can 
further diffuse from the surface of the fiber coating to its inner layer if the fiber is a liquid 
coating. The mass transfer of the analytes based on diffusion is considered the rate-


















≡     Equation 8-1 
where J is the mass flux of the analyte from the sample matrix to the SPME fiber, A is the 
surface area of the fiber, and ∂n is the amount of the extracted analyte during sampling 
time ∂t. Ds and Df are diffusion coefficients of the analyte in the sample matrix and the 
fiber coating, respectively; Cs and Cf are the concentrations of the analyte in the sample 
matrix and the surface of the fiber coating, respectively. Figure 8-1 illustrates a schematic 
of the absorption and desorption processes between liquid fiber and the sample matrix; 





























Figure 8-1 Schematic of the absorption and desorption processes between the liquid fiber 
and the sample matrix.  
 





















Figure 8-2 Schematic of the adsorption and desorption processes between the solid fiber 




In the sample matrix containing dissolved organic matter, equilibrium can be 






      Equation 8-2 
where Ka is the equilibrium binding constant; Cs, Cb, and Cbs are the analyte concentration, 




8.2.1 Boundary Layer Model (Model A) 
 
Adsorption kinetics for solid-coated SPME fiber: 
According to Equation 8-1, a steady-state mass transfer for a solid fiber can be 
established when agitation is applied effectively in the sample matrix, therefore, a linear 
concentration gradient in the boundary layer is assumed: 


















)  Equation 8-3 
where δs is the thickness of the boundary layer and is the concentration of the analyte 
in the boundary layer at the interface of the fiber coating and the boundary layer. The 
mass transfer coefficient of the analyte in the fiber coating, hs, which is defined as Ds/δs, 
is a constant for a steady-state diffusion process in an effectively agitated sample matrix. 
'
sC
 At the interface of the fiber coating and the boundary layer, there is a quick 













f ==⇒= ''      Equation 8-4 
where K is the equilibrium constant of the analyte between the coating surface and the 
sample matrix, Cf is the concentration of the analyte on the surface of the fiber coating, 
and S is the concentration of unoccupied sites on the surface of the sorbent, which is 
usually a constant when the limited sites are occupied. It is assumed that the SPME 
coating has a uniform pore distribution and surface area throughout its bulk, and Cf is 
determined by a ratio of n/A where n is the extracted amount. 
 In the bulk of the sample matrix, the mass balance for the analyte in the system 




nCCC ++=0       Equation 8-5 
where  is the total concentration of the analyte in the system, and Vs is the volume of 
















=⇒=     Equation 8-6 




























































































∂        Equation 8-8 
Equation can be solved with the initial condition: t = 0, n = 0: 
 [ )exp(1 at
a
bn −−= ]      Equation 8-9 








































The extraction profile with the presence of binding matrix in the sample can be predicted 
using Equation 8-10. The parameter  in the equation is a time constant that can be used 
to describe how quickly the equilibrium can be reached. 
a
 
Desorption kinetics for solid-coated SPME fiber: 
When a solid fiber preloaded with an analyte is exposed to an agitated sample matrix, 
desorption of the analyte from the coating surface to the sample occurs. The desorption 
process can be treated as the reverse process of adsorption. Similarly, the desorption 
process can be described as: 









where ∂q is the amount of the analyte desorbed from the fiber surface during time period 
∂t. If the initial amount of analyte preloaded on the coating surface is q0, the remaining 




= 0         Equation 8-12 
At the interface of the fiber coating and the boundary layer, there is a quick equilibrium 











f −==⇒= 0''       Equation 8-13 








=        Equation 8-14 




































































































bq −+−=     Equation 8-17 
 
Absorption and Desorption kinetics for liquid-coated SPME fiber: 
The absorption and desorption processes of a liquid SPME fiber in an agitated sample 
matrix have been described previously 71 and are expressed in Equation 8-18 and 












































































         Equation 8-19 
 
where  is the distribution coefficient of the analyte between the fiber coating and the 
sample matrix; s or  and f o fs  are mass transfer coefficients in the boundary 
layer and the fiber coating, respectiv
fsK





8.2.2 Compartment Model (Model B) 
 
When considering measurements in the dynamic stages of SPME, the classical 




as parameter for SPME liquid fibers has been applied in the past. 81,209 Although the 
model is not based on processes such as diffusion and partitioning of the analyte and it 
does not take into consideration of sample matrix volume and fiber geometry, it is very 
simple to use. This feature is particular useful when limited data is available and if the 
time to reach extraction equilibrium and the total concentration of analyte in the system 
needs to be determined during SPME method development. A modified compartment 
model has been developed in a sample medium containing a binding matrix. The model 
not only considers the concentration time courses of an analyte in the sample matrix, the 
analyte absorbed or adsorbed to the fiber coating, but also the binding matrix and the 
bounded analyte in the bulk solution. In addition, the volumes of the sample matrix and 
the fiber coating are also incorporated in the calculations. A simple schematic illustration 









Figure 8-3 Simplified schematic of compartment model in a sample matrix. 
  
In this model, it is assumed that chemical equilibrium reaches rapidly between 
unbound analyte and the binding matrix, and the binding matrix and bounded analyte will 




assumed that the bulk medium is well mixed and diffusion occurs only in a small film 
close to the fiber. Similarly, the fiber volume is well mixed and the diffusion in the fiber 


















1    Equation 8-20 
where is a composite parameter that is estimated by fitting the model to the 
experimental data. K is the partitioning coefficient of the analyte between the fiber 
coating and matrix for a liquid fiber, or the equilibrium coefficient for a solid fiber. 
and refer to the rate constants of association and of dissociation the analyte to the 
binding matrix, respectively. Similarly, based on mass balance, the following equations 



















1      Equation 8-21 









∂      Equation 8-23 
 The initial concentrations of the analyte and the binding matrix are known, as well 
as the volumes of the sample matrix and the fiber coating. The amount of the analyte 
extracted or remaining on the fiber coating depending on absorption/adsorption or 
depletion processes is the model outcome and will be corrected according to the ratio of 
( )fs VVk /2 , and  is another composite parameter that is obtained from fitting the model 





8.2.3 COMSOL Multiphysics Model (Model C) 
 
Recently, the influence of the important variables on the kinetics of SPME 
including physicochemical properties of the analyte, physical dimensions of the fiber, the 
presence of binding matrix in the sample, and the flow velocity across the fiber has been 
modeled and simulated using commercial software called COMSOL Multiphysics. The 
software provides a powerful interactive environment for modeling and solving different 
type of scientific and engineering problems such as fluid flow, heat transfer, and 
chemical reactions based on partial differential equations in one or more physical 
domains simultaneously. In general, the steps followed to solve a problem using 
COMOSL Multiphysics are: 1) defining geometrical domain; 2) domain meshing; 3) 
establishing the equations in the domain and determining the boundary conditions; 4) 
simulation to solve the equations; 5) post-processing; and 6) parametric studies.  
Based on previous studies, a two-dimensional axis-symmetric geometry was built 
to simulate the extraction process of a liquid SPME fiber in an agitated sample matrix. As 
shown in a snapshot of COMSOL model setup in Figure 8-4, rectangle sub-domain R1 
represents the dimension of a liquid fiber with a coating thickness of 8 µm and a fiber 
length of 0.5 cm, while sub-domain R2 is the diffusion layer with an arbitrarily selected 







Figure 8-4  A snapshot of a model setup in COMSOL 
 
A structured mess is applied in order to yield more accurate solution as solution is 
always dependent on the grid size – resolution. The schematic diagram of meshes 







Figure 8-5  A schematic diagram of meshes generated in COMSOL 
 
The analyte is transported by diffusion and convection in the sample matrix, but 


















































    Equation 8-25 (in fiber) 
 
where , and  is the diffusion coefficient of analyte, binding matrix and bounded 
analyte in aqueous phase, respectively;  is the diffusion coefficient of the analyte in 
the fiber coating; u is the velocity vector in aqueous phase.  
sD bD bsD
fD
As shown in Figure 8-1 (A), there will be discontinuities in the concentration 
profile at the boundaries between aqueous and fiber coating phases, in order to obtain 
continuous flux over the phase boundaries, a stiff-spring method is used to apply a 
special type of boundary condition. Instead of defining Dirichlet concentration conditions 
according to the distribution coefficient  ( = / ), which would destroy the 
continuity of the flux, continuous flux conditions are defined in order to, at the same time, 
force the concentrations to the desired values. These boundary settings for sub-domains 














  Equation 8-26 
 
)()( ' fsfsff CCKMnCD −=∇    Equation 8-28 
  
where M' is set as 10000, which is sufficiently large to give continuity in flux. In the sub-
domain of sample matrix, it is assumed that there is no transport at the horizontal 
insulation/symmetry boundaries. It is also assumed that there is symmetry at the 







8.3 Experimental Section 
 
8.3.1 Chemical and Supplies 
 
[2,4,6,8-3H]18β-estradiol (2628 GBq/mmol, 38 MBq/mL) was purchased from 
New England Nuclear (Boston, MA) and used within two months to ensure 
radiochemical purity (>98%). Pyrene (98%) was obtained from Aldrich Chemie BV 
(Zwijndrecht, The Netherlands). Bovine serum albumin (BSA) was bought from Sigma 
Chemical Co. (St. Louis, MO). Polyacrylonitrile (PAN, monomer as impurity less than 
4.85 ppm) and verapamil (>98%) were bought from Sigma (ON, Canada). The C18-silica 
(5 µm), RP-amide-silica (5 µm) and HS-F5-silica (5 µm) were obtained from Supelco 
(Belefonte, PA). A length of 50 m of SPME fiber with a coating of 7 µm of polyacrylate 
(PA) was purchased from Supelco (Bellefonte, PA) and was cut into pieces ~ 1.5 cm 
before use. Glass fibers with a core diameter of 110- and 28.5-µm poly(dimethylsiloxane) 
(PDMS) coating (volume 12.4 µL/m) were obtained from Poly Micro Industries 
(Phoenix, AZ). Tailor-made PAN/C18, PAN/RP-amide and PAN/HS-F5 SPME fibers 
with coating thickness of 60 µm and length of 1.5 cm were prepared according to a 




The radioactivity of [3H]estradiol was counted on a Minaxi Tricarb 4000 
scintillation counter of Packard Bioscience Co. (Meriden, CT). All experiments were 
carried out at room temperature. Disintegration per minute (dpm) was calibrated with a 
series of the same solution that was used to prepare the samples. Analyses determining 




equipped with a Shimadzu DGU 14 A degasser, a Varian 9012 pump, a Basic Marathon 
autosampler (Middelburg, The Netherlands), a Merck Hitachi F-1050 fluorescence 
spectrophotometer (Maarssen, The Netherlands), and a 100 mm × 3 mm, 5 µm PAH 
ChromSpher 5 C18 column. All analyses were performed with a flow rate of 400 µL/min 
and an injection volume of 20 µL. The excitation and emission wavelengths of pyrene 
were set at 284/400 nm. Concentrations of verapamil were determined by LC-MS using 
an Agilent 1100 series liquid chromatography (Palo Alto, CA) equipped with a vacuum 
solvent degassing unit, a binary high-pressure gradient pump, an autosampler, a column 
thermostat, and a variable wavelength UV-vis detector coupled on-line with an Agilent 
1100 series MSD single quadrupole instrument with atmospheric pressure electrospray 
ionization. Chromatographic separations were carried out on a Discovery C18 column 
(50 mm × 2.1 mm, 5 µm). Detailed LC-MS conditions were described previously.189 For 
optimization experiments, a positive ion of verapamil was monitored at m/z 455.3. 
 
8.3.3 Absorption Experiments of [3H]estradiol 
 
To determine whether protein affects the uptake of [3H]estradiol into the fiber, 
absorption profiles of [3H]estradiol were measured at different BSA concentrations. 
Concentrations were 7.1 ×10-9 M [3H]estradiol, and 0, 6.5 ×10-6, 1.6 ×10-5, 6.4 ×10-5, and 
1.0 ×10-3 M BSA all in 50 mM Tris buffer (pH 7.4). Mixtures were left to incubate for 10 
min at 20oC. Absorption times were 2, 5, 15, 30, 60, 90, 120, 180, 300, and 420 min in 
duplicate. The 1.5 cm PA fiber was pierced through the septa of the lids of 2-mL glass 
vials with the length of fiber sticking into to the vial of 0.5 cm. Sample volumes were 1.6 




fiber was pulled out of the septum and transferred wholly into a scintillation vial. It was 
left for desorption with 3.8 mL Ultima GOLD for at least 3 hr, then vortexed before 
counting radioactivity.  
  
8.3.4 Depletion Experiments of Pyrene 
 
All PDMS fibers were cut to a length of 2.5 cm and loaded with pyrene by 
exposing them to a 30 mL sterilized 1:1 methanol-water (v/v) mixture spiked with 2 
mg/L pyrene for 24 hr on a shaker (rocking 5 cycles/min, turning 5 rpm). Five fibers were 
immediately analyzed for their pyrene concentration after dosing to determine the initial 
pyrene concentrations in the fiber. 
The loaded fibers were fully submerged in 5 mL of culture medium supplemented 
with heat-inactivated newborn calf serum (NCS) at 0, 1.4, and 23.34 µM BSA in 5-mL 
glass vials on the shaker. The experiment was carried out in triplicate. Three non-loaded 
fibers were exposed for 48 hr in bare cell culture medium to serve as negative control. 
The samples were then sampled after 0.1, 0.25, 0.5, 1, 2, 4, 24, and 48 hr. After exposure, 
each fiber was gently blotted dry with a tissue. They were put into 1.8-mL autosampler 
vials containing 250-µL glass insert with 200 µL of acetonitrile for 24 hr to extract the 
pyrene out of the fiber coating. The samples were stored at -20oC prior to analysis. 
 
8.3.5 Adsorption Experiments of Verapamil 
 
Plasma samples were thawed at room temperature and aliquots of 1.5 mL were 




by vortex mixing for 1 minute. The time required to reach equilibrium for plasma 
samples for verapamil (5 ×10-7 M) was determined by measuring the amounts extracted 
at different time points. For extraction, the samples were placed on a digital vortex 
platform and the SPME fibers were immersed in the sample for a precise period of time. 
The fiber was briefly rinsed with water and desorbed with a desorption solution prepared 
from acetonitrile/water/acetic acid (50:49:1) for analysis. 
 
8.4 Results and Discussion 
 
8.4.1 Model Performance 
 
The experimental results of absorption of [3H]estradiol and depletion of pyrene 
from the literature were used to evaluate the performance of different model approaches 
for both absorption and desorption kinetic processes using liquid SPME fibers. The 
parameters used for model validation are listed in Tables 8-1 and 8-2.  
 
Table 8-1 The Parameters Used in the Model Validation for Absorption Process of 
[3H]estradiol in a Sample Matrix 
 
Parameter Value 
Concentration of analyte (M),  0sC 7.1×10-9 
Concentration of binding matrix (M),  0bC 0, 6.5×10
-6, 1.6×10-5, 
6.4×10-5, 1.0×10-3 
Thickness of fiber coating (μm)  7 
Distribution coefficient, Kfs 5.04×103 
Binding constant (M-1), Ka 8.9×104 
Sample volume (mL), Vs 1.6 
Diffusion coefficient in sample matrix (m2/s), Ds (Ds = hs ×δs, δs, 
boundary layer thickness) 8.96×10
-10 






Table 8-2 The Parameters Used in the Model Validation for Desorption Process of 




Concentration of analyte on fiber (M) 2.8×10-9 
Concentration of binding matrix (M),  0bC 0, 1.4×10-6, 2.3×10-5 
Thickness of fiber coating (μm) 30 
Distribution coefficient, Kfs 1.95×104 
Binding constant (M-1), Ka 8.58×106 
Sample volume (mL), Vs 5 
Diffusion coefficient in sample matrix (m2/s), Ds (Ds = hs ×δs, δs, 
boundary layer thickness) 4.38×10
-10 





In Models A and B, equations are implemented in MATLAB 7.8.0 (R2009a) 
software with initial concentrations of the analyte and the binding matrix as well as other 
necessary parameters listed in Tables 8-1 and 8-2 to obtain the amount of [3H]estradiol 
extracted or the fraction of pyrene in the fiber over time. Equations in Model C are solved 
using COMOSL Multiphysics when all the sub-domains and boundary conditions are 
established. 
Figure 8-6 illustrates the comparison between experimental data and prediction 
results of the extraction profiles of [3H]estradiol under different BSA concentrations 
using three different model approaches. It can be seen that higher concentrations of 
binding matrix do not change the shape of the absorption profile, but only the maximum 
concentration of the [3H]estradiol in the fiber. This maximum is related to the free 
concentration in the solution, which is lower at the high binding matrix concentrations. 
Therefore, the presence of the binding matrix does not seem to have an effect on the 




prediction results from all three models are in good agreement with the experimental data; 
however, there are some differences among these three models. Model A predicts the 
extraction profiles very well when the concentrations of the binding matrix are low, but 
deviations increase with increasing of BSA concentrations. Model C accurately predicts 
the concentration data after the extraction reaches equilibrium; however, it appears that 
the equilibrium is reached much faster in the model than in the real situation. Overall, 
Model B gives the best results in terms of the shape of the extraction profile. The 
diagnose plots (Figure 8-7) between experimental concentrations and predicted data at all 
conditions further demonstrate the precision of each model with standard deviation of 


































Figure 8-6 Extraction profiles of [3H]estradiol at different BSA concentrations: The 
points are experimental results and the curves are obtained from models A, B, and C, 
respectively. BSA concentrations from top to bottom are: 0 ( ), 6.5×10-6(∇), 1.6×10-5 (×) 


































































Figure 8-7 Diagnose plots between experimental concentrations from extraction of 
[3H]estradiol at different BSA concentrations and predicted data obtained from models A, 
B and C, respectively. 
  
 Figure 8-8 shows the comparison between experimental data and prediction 
results of the desorption profiles of pyrene under different BSA concentrations using 
three different model approaches. Compared with previous modeling approaches for the 
extraction processes of [3H]estradiol, it is interesting to see that only Model B provides a 
reasonable simulation of the experimental data; in contrast, Model A cannot provide 
accurate prediction at binding matrix concentration of 23.24 µM, and Model C has 
difficulties in predicting the desorption profile without matrix effects. The reasons for 
these large deviations are unclear. The accuracies of the parameters used in the models 
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Figure 8-8 Desorption profiles of pyrene under different BSA concentrations: The 
points are experimental results and the curves are obtained from models A, B and C, 
respectively.  
 
 In summary, in Model A, many parameters are needed. These include mass 
transfer coefficients, distribution coefficients, binding constant and physical dimensions 
of the sample matrix, and the SPME fiber coating in order to calculate the extraction or 
desorption profiles with the presence of a binding matrix. As the thickness of the fiber 
coating is normally known, to obtain the thickness of the boundary layer is important as 
the mass transfer coefficient can be determined. The model predicts fairly well for the 
absorption profile of [3H]estradiol, but not the desorption profiles of pyrene in the 
presence of BSA, and the deviation increases with increasing concentrations of BSA. 
Model B provides a better prediction overall than the other two model approaches with 




provide detailed information about all the parameters involved in sorption processes. The 
composite parameter  is used to determine the shape of the extraction or desorption 
curves, and has a big impact to the analyte concentrations in the fiber. The advantage 
of using COMSOL Multiphysics is that mass transfer and chemical reaction processes 
can be described by one or more physical domains simultaneously based on various 
partial differential equations and boundary conditions. However, the geometry of the 
model has to be set up properly in order to provide reasonable predictions, in addition, all 
required parameters are necessary in model set up before solving the equations, although 
unknown parameters can be obtained through curve fitting of experimental data, in this 




8.4.2 Model Applications 
 
Several different model approaches have been proposed to investigate the kinetics 
of SPME extraction and desorption of the target analyte in a sample matrix containing 
dissolved organic matter. The purpose of SPME modeling and simulation is to provide a 
more fundamental understanding of the experimental data which can be used to optimize 
experimental conditions. Although all models are wrong, some are useful.211 Applications 
of various SPME kinetic models are applied to estimate boundary layer thickness, time to 
reach extraction equilibrium and total amount of analyte extracted at a given time using 
SPME solid fibers. 
8.4.2.1 Boundary Layer Thickness Estimation 
 
Boundary layer thickness is an important piece of information as it determines the 




from the sample matrix through the boundary layer to the extraction phase. In the 
mechanistically based model based on Fick's law, a boundary layer thickness can be 
estimated under the assumption that the flow around the SPME fiber is steady and 
laminar. For such conditions to be met and controlled, the sample has to be contained in a 
vertically standing vial with stirring taking place by a magnetic stirring bar during SPME 
setups. The thickness of the boundary layer can be calculated by the following semi-
empirical equation: 
( )43.050.0/64.2 ces SRb=∂       Equation 8-28 




















vS , u is the linear velocity of the sample, and v is the kinematic 
viscosity of the matrix medium.  
  The flow velocity u around the fiber can be calculated according to the following 
equation: 
( )[ ]274.0/205.1 sRrNru −= π      Equation 8-29 
where N is the magnetic stirrer speed in revolutions per second, r is the distance between 
the fiber and the center of the vial, and  is the radius of the stirring bar. sR
 Although the model with a defined film thickness layer is useful for steady, 
laminar conditions, in many cases there are other types of agitation regimes that will not 
fulfill the conditions for the estimation of a stagnant thickness. For example, ultrasound 




experiments of Heringa et al.,209 disposable fibers are exposed and mechanically agitated 
by placing the vials horizontally on a rotating plate which results in a non-steady, 
periodically accelerated movement of the fiber with the medium. As a result, flow 
velocities vary from about plus to minus 17 cm/s every 0.085 seconds. The method of 
least-squares is applied in Model A to estimate the boundary layer thickness during 
pyrene desorption process. The method of least-squares assumes that the best-fit curve of 
a given type is the curve that has the minimal sum of the deviations squared (least square 
error) from a given set of data. Suppose that the data points are ( )11 , yx
1d =
, , ..., 
 where x is the independent variable and y is the dependent variable. The fitting 
curve f(x) has the deviation (error) d from each data point, i.e., , 
, ..., . According to the method of least squares, the best 
fitting curve has the property that:  
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in xfydddd a minimum  
Equation 8-30 
In Equation 8-28, all parameters are known except , assh sss Dh δ/= ; the boundary layer 
thickness sδ can be obtained from curve fitting of the experimental data to estimate . In 
the simulation, the range of the boundary thickness layer was assumed from 1 to 100 µm 
with an interval of 2, therefore, 50 iterations were performed and the least square error 
generated an estimated value of 
sh
sδ to be 45.9 µm. Selected plots from this exercise are 
illustrated in Figure 8-9. In the mass transfer model where mass transfer is forced by the 




layer thickness was estimated from 18.5 to 41.7 µm for pyrene desorption process using 
different diffusion coefficients of bound pyrene. The current model prediction result is in 
agreement with the literature data (41.7 µm) when assuming the diffusion coefficient of 

























Figure 8-9 Selected plots for model simulation using least-squares method. 
 
 Similarly, an attempt has been made to estimate the boundary layer thickness in 
the absorption experiments of [3H]estradiol, and the estimated value of sδ  from Model A 




invalid to calculate the theoretical sδ according to Equations 8-28 and 8-29 since an 
accelerated flow regime is applied in the experiments. However, if a steady flow rate is 
assumed from 10 to 100 cm/s, a range that is often used in SPME experiments, the 
corresponding calculated boundary layer thickness using the two equations is from 1.1 to 
4.7 µm. Based on the predicated results from both processes including desorption of 
pyrene and absorption of [3H]estradiol in a sample matrix, it can be concluded that it is 
feasible to estimate the boundary layer thickness using Model A. 
 
8.4.2.2 Extraction Equilibrium Time Prediction 
 
In SPME method development, the process limiting step is to determine the time 
to reach extraction equilibrium. As SPME is a non-exhaustive extraction technique, it is 
desirable to perform extraction at equilibrium to reach maximum extraction efficiency. 
However, SPME experiments are often performed under non-equilibrium conditions as 
for more hydrophobic compounds for which equilibrium times can be very long. The 
total method development time will be greatly shortened if mechanistic models can 
accurately predict the extraction equilibrium time, which, in the meantime, will help to 
optimize the experimental conditions. 
Both Models A and B provide very close estimations on the times to reach 
equilibrium in all five uptake curves in the experiments of [3H]estradiol absorption. The 
extraction amount appears to reach steady state after about two hours. It can be seen from 
Figure 8-6 that the presence of a binding matrix does not impact the uptake kinetics of an 
analyte to the fiber coating and, therefore, the increasing concentrations of the binding 




10 and 8-18, the extract amount of analyte is proportional to the total concentration of the 
analyte, providing the sample, fiber, and the concentration of the binding matrix are held 
constant, which indicates that the equilibrium time is independent of the concentration of 
the analyte in the sample matrix. The equilibrium binding constant should also not affect 
the equilibrium time, but the amount of analyte extracted in the fiber coating, as the 
higher affinity of the analyte to the binding matrix, the more the analyte bounded by the 
binding matrix and the less free analyte present in the sample matrix. Factors that will 
change the time to reach equilibrium include agitation speed and the distribution 
coefficient of the analyte between the fiber coating and the sample matrix. By increasing 
the speed of agitation, the boundary layer thickness will decrease, as a result, the mass 
transfer rate will be increased and the time to reach equilibrium becomes much shorter. 
For an analyte with a larger distribution coefficient, the equilibrium time can last several 
hours. For example, the time to reach equilibrium is about 30 minutes for an analyte with 
a distribution coefficient of 1000; however, under the same extraction conditions, it will 
take seven hours when the distribution coefficient is above 100,000. 
It appears that Model C overestimates the equilibrium time which generates very 
quick diffusion in the fiber with respect to the reaction rates. The concentration gradient 
evens out more or less instantaneously in the fiber, but the level builds up gradually in 
time.  
 
8.4.2.3 Total Concentration Estimation 
To predict the total amount of target analyte extracted at a given time in the 




know the equilibrium or distribution constants of the analyte between the fiber coating 
surface and the sample matrix. The equilibrium constant can be calculated from the total 








=       Equation 8-31 
where is the initial concentration of a given analyte in the sample,  and  are the 
sample volume and fiber coating volume, respectively. For any new coatings, the new 
volume of coating can be estimated from the coating length (b), coating thickness (d) and 
radius of the supporting wire (r):  
0C sV sV
 [ ]22)( rdrbV f −+= π      Equation 8-32 
 As mentioned previously, since the concentration of the sample analyzed by 
SPME has no impact on the extraction time profile and equilibrium time, and the 
agitation conditions, coating thickness, equilibrium constant, and diffusion coefficient of 
the analyte play very important roles in determining the equilibrium time, it is essential to 
keep the experimental conditions constant for different fiber coatings and the extraction 
time should be equal to or longer than the equilibrium to minimize potential errors caused 
by different sampling times. The time required for verapamil to reach equilibrium was 
found to be 60 minutes in three cases, the total concentration of verapamil extracted at 
equilibrium and the calculated equilibrium constants for fiber coatings PAN/C18, 




  Because no binding matrix was involved in the experiments, Equation 8-10 from 
model A could be simplified to estimate the total amount of verapamil extracted at any 
given time. The adsorption profiles of verapamil to three different fiber coatings 
obtainted from Equation 8-10 are depicted in Figure 8-10, and the total amount of 
verapamil extracted at equilibrium are calculated in Table 8-3. It can be seen that the data 
from model prediction are in reasonable agreement with the experimental results. Model 
B was also applied to simulate the experimental results of verapamil adsorption in three 
different fiber coatings. It is interesting to see in Figure 8-10 that the model predicts the 
experimental results extremely well with differences less than 3% in total amount 
extracted at equilibrium (Table 8-3). 
 
Table 8-3 Equilibrium Constants and Total Amount Extracted at Equilibrium for 
Adsorption of Verapamil to Three Different Types of Solid Fiber Coatings 
 









PAN/C18 3.27 × 103 4.96 × 10-10 6.08 × 10-10 22.6 5.04 × 10-10 1.6 
PAN/ 
HS-F5 2.33 × 10
3 4.12 × 10-10 4.33 × 10-10 5.1 4.21 × 10-10 2.2 
PAN/ 
RP-amide 1.83 × 10










Figure 8-10 Adsorption profiles of verapamil to PAN/C18 ( ), PAN/HS-F5 (O) and 
PAN/RP-amide (Δ). The points are experimental results and the curves are obtained from 





Several mathematical models have been proposed to describe the kinetics of the 
extraction and desorption processes of different types of SPME fibers in complex sample 
matrixes. The simulation results clearly indicated that SPME modeling and simulation is 
a useful tool to provide more fundamental understanding of the experimental data which 
can be used to optimize experimental conditions. The performance of the models is 
dependent on the physicochemical properties of the target analytes and fiber coatings, 
agitation conditions, as well as sample parameters. With further improvement of the 
model setup and investigation of the causes of deviations from experimental results, and 
more implementation of the modeling approach in various SPME applications and rapid 
development of SPME database, it is believed that SPME modeling and simulation will 











Since its invention in the early 1990s, SPME has gained wide interest and has 
become one of the most active research areas in sample preparation in the past twenty 
years. The original paper published in Analytical Chemistry is among the Top 20 Most 
Cited articles published by the journal on the All Time lists. This is largely due to the 
unique characteristics of SPME technique that integrates sampling, extraction, 
concentration, and introduction of a sample to an analytical instrument into a single 
solvent-free step. SPME was originally developed in an attempt to address the need for 
rapid sampling and sample preparation in both laboratory and on-site situations and now 
has been widely applied to environmental, food, metallic, forensic, and pharmaceutical 
analysis. However, in contrast to the rapid growth and development of SPME technique 
including the development of various types of fiber coatings and new SPME formats, 
advances in the automation of SPME processes and contribution to high throuput sample 
analyses, and in spite of the many claimed advantages of SPME over traditional sample 
preparation methods such as PPT, LLE, and SPE, in reality, the goal of using SPME 
technique as an alternative approach for quantitative determination of analytes especially 
in pharmaceutical bioanalysis has not been realized. Up until now, SPME has not been 
used in any pharmaceutical companies for routine sample preparation. 
One of the major reasons that prevent widespread applications of SPME in 




technique because of the big gap between the academic research and the actual needs of 
customers from the pharmaceutical industry. The literature data has not built up enough 
confidence by the manufacturers that SPME will be generally accepted by users for 
bioanalysis because most of the research is either limited to a few compounds and 
confined to certain specialized laboratories, or because inadequate and insufficient 
validation results are provided. For example, matrix effects are rarely investigated during 
the method development; assay validation is normally performed in a single lot/source 
instead of different lots/sources of biological fluids; and QC samples freeze/thaw 
stabilities are seldom tested. All these factors are important indicators for the 
reproducibility and robustness of bioanalytical assays. One of the objectives of this thesis 
is to bridge this gap and to explore the feasibilities of bringing SPME technique from 
laboratory to industry for routine drug analysis. Based on the results from a proof-of-
concept study, in the current work, an interesting approach using in-tip SPME has been 
proposed and developed for high throughput bioanalysis. In-tip SPME fibers are prepared 
through two different formats: sorbent-packed and fiber-picked. A polymerization 
mixture consisting of ethylene glycol dimethacrylate (EDMA), dimethoxy-α-
phenylacetophenone (DMPA), and 1-decanol was used to prepare the sorbent-packed in-
tip SPME fibers, and 96 fibers were fabricated at one time using a commercially 
available automation device. Fiber reproducibility of the sorbent-packed in-tip SPME 
with immobilized Oasis HLB particles was found to be 15.4% (R.S.D.) from absolute 
peak areas of 96 fibers and the value dropped to 5.6% when an isotopic labeled internal 
standard was applied. The current study clearly showed that in-tip SPME provided 




to-head comparison experiment was conducted with a clinical development drug 
candidate. In fact, SPME was much easier to use than SPE with fewer sample preparation 
steps and less consumption of organic solvent. The remarkable advantages of in-tip 
SPME technique include that automation of sample extraction and desorption can be 
easily achieved using commercially available liquid handling systems. More importantly, 
in-tip SPME maintains the simplicity and advantages of conventional fiber SPME 
technique, and the approach is amendable to all fibers types possessing a wide range of 
different coating materials. This will overcome the drawback of limited selections of 
commercial available fibers and broaden its use with HPLC-MS/MS.  
The successful applications of in-tip SPME were further demonstrated through 
two challenging studies on quantitative determination of vitamin D3 in human serum with 
derivatization and three polar analytes, imipenem (IMP), cilastatin (CIL), and an 
investigational β-lactamase inhibitor (BLI) simultaneously in rat plasma and mouse blood, 
for 3 analytes in 2 systems. Vitamin D3 and its metabolites have no easily ionizable polar 
functional groups in their molecules and the ionization efficiency of these compounds 
using either ESI or (HN) APCI is very limited. The required sensitivity for trace 
determination of these compounds in biological fluids is difficult to achieve. In addition, 
the determination of vitamin D3 in the presence of a number of metabolites circulating in 
human biofluids exhibiting similar chemical and HPLC behavior as the parent compound 
may be highly non-selective, and an efficient separation of a large number of equimolar 
interferences, metabolites or their MS fragments, and large numbers of endogenous 
impurities from plasma, may be quite challenging. Although the desired sensitivity was 




merit in that it can be used for a complex sample preparation process in which a 
derivatization reaction was applied in order to increase sensitivity and selectivity of 
vitamin D3 determination. Furthermore, in-tip SPME required only a small volume (0.1 
mL) of biological fluid for analysis (as opposed to 1.0 and 0.4 mL required in 
conventional tube-LLE and plate-LLE methods, respectively); and the extraction 
recovery, although not high in the absolute terms, was proven to be consistent between 
different plasma lots and was unusually high (~24-29%) in comparison with other 
methods based on SPME (<1%). Historically, methods to analyze Primaxin® were 
reported as separate assays for the two analytes, IMP and CIL, respectively. It would be 
very challenging to quantitatively determine the three very polar, non-structurally related 
compounds simultaneously, without considering the stability issues of all the analytes in 
biological fluids. In addition, in drug discovery preclinical environment, sample volume 
from different animal species is often very limited. For instance, in the current study; 
sample volume from mouse blood is only 20 µL. With the help of HILIC-MS/MS, it is 
very encouraging to see that PK parameters such as AUC, Cmax, clearance (CL), and 
volume of distribution (Vss) generated from in-tip SPME approach are in excellent 
agreement with those from PPT method.  
Matrix effects have been thoroughly evaluated in this thesis. Some interesting 
findings may be useful for future SPME assay development and validation in bioanalysis. 
The hypothesis that SPME should provide sample clean-up as effective as or better than 
solid phase extraction (SPE) with no or minimal matrix effects is not supported by the 
experimental data. It was found that SPME was not as effective as LLE and SPE in terms 




The ultimate test to demonstrate the absence of a “relative” matrix effect is to determine 
slopes of standard lines constructed in at least five different lots of a biological fluid 
(plasma, for example) and confirm the coefficient of variation (%CV) of these slopes is 
less than 3-4%. The results of this thesis indicated that isotopic stable labeled internal 
standard played a critical role to minimize "relative" matrix effects in SPME bioanalysis 
assays and should be utilized as much as possible. In terms of high throughput drug 
analysis, the current study has clearly shown that in-tip SPME performed as well or better 
than other automated approaches including blade-geometry SPME and thin-film SPME, 
which both heavily relied on a Concept 96 autosampler which is specifically designed for 
SPME automation. A comprehensive comparison between SPME and other traditional 
sample preparation methods in terms of method development and assay performance 
summarized in this thesis would certainly enhance the understanding of the advantages 
and limitations of SPME in bioanalysis, and the strategies with systematic experimental 
design for in-tip SPME method development and validation would provide general 
guidelines for any potential users of this technique.  
SPME modeling and simulation provides more fundamental understanding of the 
experimental data through mechanistically-based models that describe the kinetics of the 
partition processes to SPME fibers. Several different modeling approaches introduced in 
this study gave reasonable fits of the experimental data by predicting the sorption profiles 
as a function of time in a complex sample matrix for both liquid and solid SPME fibers. 
Further improvement of these kinetic models would be highly useful in developing 





9.2 Future Directions 
 
 
The successful applications of the automated in-tip SPME technique to various 
drug compounds from preclinical and clinical studies clearly show that SPME can be a 
very useful tool in bioanalysis. However, it is important for future SPME development to 
understand that, while SPME cannot replace traditional sample preparation methods such 
as PPT, LLE, and SPE, it is an alterative approach for drug analysis. Therefore, future 
research in bioanalysis using SPME should focus on its specialized application. For 
example, because of its time consuming and compound dependent method development 
and validation process, SPME is not suitable for the drug discovery environment where 
simple, generic methods are often required for high throughput and fast sample turn 
around. Since SPME is simple and easy to use with low cost, its advantages will be more 
substantial in clinical drug development when bioanalytical assays are fully established 
and a large amount of samples need to be analyzed. To promote the SPME technique in 
bioanalysis, the areas and directions outlined below should be considered. 
 
9.2.1 SPME Fiber Coatings and Devices 
Fiber commercialization is the key for widespread acceptance of SPME technique 
by bioanalytical chemists in pharmaceutical industry. This should be accomplished 
through close collaboration between researchers, customers, and manufacturers. It is 
useful to develop a broad selection of new types of SPME fiber coatings, but it is even 
more important to have a product in the market that can be used by any customer for 
routine drug analysis. Sorbent-packed in-tip SPME has a great potential to become the 




fabricating procedure can be further improved to increase inter-fiber reproducibility and 
fiber extraction capacity and efficiency. Research on in vivo SPME sampling has been 
extensively conducted recently due to the very promising applications of the technique 
because it eliminates the need for blood withdrawal during pharmacokinetic studies and 
allows the study of various biochemical processes directly in vivo. However, for most 
SPME in vivo studies, the sample preparation process, especially the analytes desorption 
step, is done manually, this will greatly hamper the wide applications of the technique. 
The fiber-packed in-tip SPME would, potentially, be a solution to increase sample 
throughput for in vivo SPME if the fiber preparation procedure can be further modified to 
assemble a fiber easily into the individual pipette tip after in vivo sampling.   
Dried Blood Spot (DBS) and Microdosing techniques are two interesting new 
trends in drug discovery and development. Although the two techniques provide great 
benefits to pharmacokinetic studies, it has to be mentioned that some challenges in terms 
of sample preparation are enormous. For example, in DBS, the standard sample 
preparation procedure is very time consuming and labor intensive as it consists of 
punching out a disk from the card that contains the DBS followed by extraction of the 
analyte. Automation of sample preparation is an emerging need to increase efficiency and 
throughput. Currently, there are no effective sample preparation methods to obtain trace 
amounts of analytes from biological fluids when drug dose level does not exceed 100 µg 
in Microdosing studies. SPME can potentially be used in these two areas if appropriate 
SPME devices are developed with extremely selective fiber coatings. An initial study 
using C18 disk/film-packed in-tip SPME format indicated that the absolute extraction 




same extraction conditions. As shown in Figure 7-7, blood samples can potentially be 
collected directly in the film-packed in-tip SPME fibers so that sample preparation 
procedure will be fully automated. With the development of highly selective fiber 
coatings, such as molecular imprinting on SPME fibers, and the help from modern 
instrument including UPLC and API 5000 mass spectrometer, it is quite possible to detect 
analytes and metabolites at very low concentrations for microdsoing studies.  
 
9.2.2 SPME Application Kit 
One of the limitations of SPME is that each application of interest involving 
different target analytes and sample matrices requires its own separate SPME method 
development procedure and extraction conditions must be consistent for all of the 
samples analyzed in one batch. Although many guidelines have been given for general 
SPME method development, in the practical performance of SPME, there are a number 
of SPME parameters must be carefully considered and specified for the problem under 
investigation. These include fiber coating, extraction mode, agitation method, sample 
volume, pH, ionic strength, water and organic solvent, extraction time, desorption 
conditions, calibration method, etc.  For any applications that will not need high sample 
throughput, such as in vivo SPME sampling in animal tissues and cerebrospinal fluids 
(CSF), to make the technique more user friendly, SPME application kits should be 
developed with detailed information of the properties of the fiber coating, in vivo 
sampling and calibration procedures, potential target analytes/biologics (proteins and 
peptides) for best performance, desorption conditions, and sampling devices as well as 




kits will make SPME a unique tool and a specialized approach in certain areas that 
traditional methods cannot achieve. 
 
9.2.3 SPME Modeling and Simulation 
SPME modeling and simulation is an interesting area that needs to be further 
explored because it will be a useful tool to provide insight and direction when developing 
SPME methods and identifying parameters for rigorous control and optimization. 
Currently, mechanistically based models to describe the kinetics of the partition processes 
to SPME fibers mainly focus on liquid fibers such as PDMS. In addition, some important 
parameters that are necessary to the models including distribution coefficient, binding 
constant, and diffusion coefficients in sample matrix and fiber coating, etc. may not 
always be available for the interested analytes which will affect the performance of the 
models. For any unknown compound, it would be ideal for an appropriate model to 
predict the concentrations of the target analyte in the fiber as a function of time based on 
the known parameters such as the types and thickness of the fiber coatings, the chemical 
properties of the compound, the geometries of the fiber and sample matrix, and the 
agitation conditions.  To achieve this, a large SPME database needs to be built to 
determine the correlation between distribution coefficients, binding constants and 
diffusion coefficients, and the physicochemical properties including, but not limited to, 
structure, molecular weight, and polarity, of various compounds with the literature data 
and additional experimental results.  It is expected that effective use of the SPME 
modeling and simulation will minimize the number of experiments that need to be 
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